

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)


PCT

(10) International Publication Number  
**WO 01/47946 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K**
- (21) International Application Number: **PCT/US00/34852**
- (22) International Filing Date:  
21 December 2000 (21.12.2000)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
09/473,551 28 December 1999 (28.12.1999) **US**
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
**US** 09/473,551 (CON)  
Filed on 28 December 1999 (28.12.1999)
- (71) Applicant (for all designated States except US): **WASHINGTON UNIVERSITY [US/US]**; One Brookings Drive, St. Louis, MO 63130 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **MILBRANDT, Jeffrey, D.** [US/US]; 75 Aberdeen Place, St. Louis, MO 63105 (US). **BALOH, Robert, H.** [US/US]; 964 Tuxedo Boulevard, St. Louis, MO 63119 (US).
- (74) Agents: **GENDLOFF, Elie, H.** et al.; Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105-1817 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **GFR $\alpha$ 1-RET SPECIFIC AGONISTS AND METHODS THEREFOR**



(57) Abstract: Chimeric GDNF family ligands which activate a GFR $\alpha$ /RET are disclosed. Included are chimeras which activate GFR $\alpha$ 1/RET but do not activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The chimeras are useful in providing trophic support to a mammalian cell or in producing differentiation of a mammalian cell, or both, particularly when the cell is in a patient suffering from various diseases, in particular Parkinson's Disease.



**Published:**

— Without international search report and to be republished upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

GFR $\alpha$ 1-RET SPECIFIC AGONISTS AND METHODS THEREFORBackground of the Invention

This invention was made with Government support under National Institutes of Health/ National Institute on Aging Grant No. 5R01-AG13730. The Government has certain rights in the invention.

## 5 (1) Field of the Invention

This invention relates generally to trophic or growth factors and, more particularly, to chimeric GDNF family growth factors which activate GFR $\alpha$ 1-RET but do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, growth factors derived therefrom and methods therefor.

## 10 (2) Description of the Related Art

The development and maintenance of tissues in complex organisms requires precise control over the processes of cell proliferation, differentiation, survival and function. A major mechanism whereby these processes are controlled is through the  
15 actions of polypeptides known as "growth factors". These structurally diverse molecules act through specific cell surface receptors to produce these actions.

Growth factors termed "neurotrophic factors" promote differentiation, maintain a mature phenotype and provide trophic  
20 support, promoting growth, function and survival of neurons. Neurotrophic factors reside in the nervous system or in innervated tissues. Nerve growth factor (NGF) was the first neurotrophic factor to be identified and characterized (Levi-Montalcini et al., *J. Exp. Zool.* 116: 321, 1951). NGF exists as a non-covalently bound  
25 homodimer that promotes the survival and growth of sympathetic,

neural crest-derived sensory, and basal forebrain cholinergic neurons. Other effects of NGF, including effects on non-neuronal cells of the endocrine and immune systems (including inflammatory cells) are disclosed in, e.g., Levi-Montalcini and Booker, *Proc Nat'l Acad Sci* 46: 384-391, 1960; Johnson et al. *Science* 210: 916-918, 1980; Crowley et al., *Cell* 76: 1001-12, 1994; Snider and Johnson, *Ann Neurol* 26: 489-506, 1989; Hefti, *J Neurobiol* 25: 1418-35, 1994; Scully and Otten, *Cell Biol Int* 19: 459-469, 1995; Otten and Gadiant, *Int. J. Devl Neurosci* 13: 147-151, 1995; and Horigome et al. *J Biol Chem* 269: 2695-2707, 1994.

In recent years it has become apparent that growth factors fall into classes, i.e. families or superfamilies based upon the similarities in their amino acid sequences. These families include, for example, the fibroblast growth factor family, the neurotrophin family and the transforming growth factor-beta (TGF- $\beta$ ) family. As an example of family member sequence similarities, TGF- $\beta$  family members have 7 canonical framework cysteine residues which identify members of this superfamily.

The NGF family is the prototype of such a family of growth factors. Brain-derived neurotrophic factor, the second member of this family to be discovered, was shown to be related to NGF by virtue of the conservation of all six cysteines that form the three internal disulfides of the NGF monomer (Barde, *Prog Growth Factor Res* 2: 237-248, 1990 and Liebrock et al. *Nature* 341: 149-152, 1989). By utilizing the information provided by brain-derived neurotrophic factor of the highly conserved portions of two factors, additional members (NT-3, NT-4/5) of this neurotrophin family were rapidly found by several groups (Klein, *FASEB J* 8: 738-44, 1994).

Recently, a new family of neurotrophic factors has been identified whose members are not structurally related to NGF and other neurotrophins but are structurally similar to TGF- $\beta$ . As described in U.S. Patent No. 5,739,307, and U.S. patent applications 08/931,858 and 09/220,531, the known members of this subfamily of the TGF- $\beta$  superfamily include glial cell line-derived neurotrophic factor (GDNF), neurturin, persephin, and artemin. The placement of GDNF, neurturin, persephin, and artemin into the same growth factor family, also referred to as the GDNF ligand family, is based on the similarities of their physical structures and biological activities. For example, human persephin has about 40% sequence identity and



about 43% sequence conservation with human GDNF; about 49% sequence identity and about 50% sequence conservation with human neurturin; and about 45% sequence identity and about 48% sequence conservation with human artemin. In addition, these four proteins have the seven  
5 cysteine residues typical of TGF- $\beta$  family members.

The GDNF family ligands support the survival of dopaminergic ventral midbrain neurons cultured from the embryo. Additionally, GDNF, neurturin, and persephin support the survival of spinal and facial motor neurons in both *in vitro* survival and *in vivo* injury  
10 paradigms, identifying these ligands as potential therapeutic agents in the treatment of neurodegenerative diseases (Henderson et al., *Science* 266: 1062-1064, 1994; Horger et al., *J Neurosci.* 18: 4929-37, 1998; Klein et al., *Nature* 387: 717-721, 1997; Lin et al., *Science* 260: 1130-1132, 1993; Milbrandt et al., *Neuron* 20: 245-53, 1998;  
15 Oppenheim et al., *Nature* 373: 344-346, 1995), reviewed by Grondin and Gash, *J Neurol.* 245(11 Suppl 3): 35-42, 1998). However, whereas GDNF and neurturin both support the survival of peripheral sympathetic, parasympathetic, sensory, and enteric neurons (Buj-Bello et al., *Neuron* 15: 821-828, 1995; Ebendal et al., *J Neurosci Res* 40: 276-284,  
20 1995; Heuckeroth et al., *Dev Biol* 200: 116-29, 1998; Kotzbauer et al., *Nature* 384: 467-470, 1996; Trupp et al., *J of Cell Biology* 130: 137-148, 1995), persephin does not support survival in any peripheral neurons tested to date (Milbrandt et al. *supra*).

The GDNF family ligands share receptors and signal transduction  
25 pathways (Creedon et al., *Proc. Natl. Acad. Sci. USA* 94: 7018-7023, 1997; Durbec et al., *Nature* 381: 789-793, 1996; Trupp et al., *Nature* 381: 785-789, 1996; Baloh et al., *Neuron* 18: 793-802, 1997). These proteins act through a multicomponent receptor complex in which a transmembrane signal transducing component, the Ret protein-tyrosine  
30 kinase (RET), is activated upon the binding of a growth factor of the GDNF family with a member of a family of closely related co-receptors named GFR $\alpha$ . A characteristic feature of the GFR $\alpha$  co-receptor family is that its members have no transmembrane domain and are attached to the cell surface via a glycosyl-phosphatidylinositol (GPI) linkage  
35 (Durbec et al., *Nature* 381: 789-793, 1996; Jing et al., *Cell* 85: 1113-1124, 1996; Treanor et al., *Nature* 382: 80-83, 1996; Trupp et al., *Nature* 381: 785-789, 1996; Baloh et al., 1997, *supra*). The members of the GFR $\alpha$  family include GFR $\alpha$ 1 (previously known as GDNFR $\alpha$ , TrnR1 and RetL1), GFR $\alpha$ 2 (previously TrnR2, NTN $\alpha$  and RetL2), GFR $\alpha$ 3

(previously TrnR3) (GFR $\alpha$  Nomenclature Committee, *Neuron* 19: 485, 1997) and possibly GFR $\alpha$ 4, a receptor currently only identified in the chicken (cGFR $\alpha$ 4) (Enokido et al., *Current Biology* 8: 1019-1022, 1998).

5           Results from extensive *in vitro* and *in vivo* experimentation has established that for each GDNF family ligand there is a preferred GFR $\alpha$  receptor, to which the GDNF family ligand binds with highest affinity and most potently activates RET. These preferred interactions are GDNF-GFR $\alpha$ 1, neurturin-GFR $\alpha$ 2, and artemin-GFR $\alpha$ 3  
10 (Baloh et al., 1997, *supra*; Baloh et al., *Proc. Natl. Acad. Sci., USA* 95: 5801-5806, 1998; Jing et al., 1996, *supra*; Jing et al., *J Biol. Chem.* 272: 33111-33117, 1997; Klein et al., *Nature* 387: 717-721, 1997; Treanor et al., 1996, *supra*). Persephin does not bind or activate any of the known mammalian GFR $\alpha$ 's but does bind to chicken GFR $\alpha$ 4  
15 (Milbrandt et al., *supra*; Baloh et al., 1998, *supra*, Enokido et al. *supra*). However, despite these preferred interactions, there is also clear cross-talk between the different ligand-receptor pairs. The known alternative interactions are neurturin-GFR $\alpha$ 1, artemin-GFR $\alpha$ 1, and GDNF-GFR $\alpha$ 2 (Baloh et al., 1998, *supra*; Sanicola et al., *Proc.*  
20 *Natl. Acad. Sci., USA* 94: 6238-6243, 1997; Suvanto et al., *Hum. Molec. Genet.* 6: 1267-1273, 1997). Thus, there is no known naturally occurring GFR $\alpha$ 1-RET activating GDNF family ligand which does not also activate another GFR $\alpha$ -RET complex.

Some information is available about the roles of each GFR $\alpha$   
25 receptor. Recent analysis of GFR $\alpha$ 1-deficient mice indicated that GFR $\alpha$ 1 is the only physiologically critical GDNF receptor in kidney organogenesis and enteric nervous system development (Cacalano et al., *Neuron* 21: 53-62, 1998; Enomoto et al., *Neuron* 21: 317-324, 1998). However, GDNF-deficient mice have greater losses in peripheral  
30 ganglia than GFR $\alpha$ 1-deficient mice, suggesting that GDNF can utilize other receptors to support survival of peripheral neurons, likely GFR $\alpha$ 2-RET (Cacalano et al., *supra*; Enomoto et al., *supra*). Nevertheless, several lines of evidence argue that the effects of GDNF, neurturin and artemin on dopaminergic ventral midbrain neurons  
35 are mediated through the GFR $\alpha$ 1-RET receptor system. First, since GFR $\alpha$ 3 is not expressed in the ventral midbrain, and artemin cannot utilize GFR $\alpha$ 2, survival promotion of these neurons by artemin is likely through its ability to activate GFR $\alpha$ 1-RET (Baloh et al.,

*supra*). Second, GFR $\alpha$ 2 expression is diffuse and weak in the pars compacta region of the substantia nigra, and does not colocalize with tyrosine hydroxylase staining (TH) neurons, in contrast to the significantly stronger expression of GFR $\alpha$ 1, which does colocalize with TH staining neurons (Horger et al., *J. Neurosci.* 18: 4929-4937, 1998). Finally, the ability of both GDNF and neurturin to support the survival of dopaminergic ventral midbrain neurons is lost in GFR $\alpha$ 1 knockout mice, indicating that at least in the embryo the survival promotion of dopaminergic ventral midbrain neurons is only through GFR $\alpha$ 1-RET signaling (Cacalano et al., 1998).

While the *in vitro* interactions between the different GDNF family ligands and GFR $\alpha$ 's is now relatively well understood, the molecular basis of this specificity and cross-talk has been heretofore unknown. The crystal structure of GDNF reveals that it is a disulfide-bonded dimer that is significantly similar to the structure of TGF- $\beta$ 2, as predicted by the cysteine spacing of its primary sequence (Daopin et al., *Science* 257: 369-373, 1992; Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997; Schlungger and Grutter, *Nature* 358: 430-434, 1992). However, the structure itself yields only speculative information regarding receptor-binding surfaces. Furthermore, analogy to other TGF- $\beta$  superfamily members regarding receptor-binding surfaces would likely be unfounded as the receptors used by GDNF and the TGF- $\beta$ 's are drastically different and likely to have little, if any, structural similarity.

It is now generally believed that neurotrophic factors regulate many aspects of neuronal function, including survival and development in fetal life, and structural integrity, function and plasticity in adulthood. Since both acute nervous system injuries as well as chronic neurodegenerative diseases are characterized by structural damage and, possibly, by disease-induced apoptosis, it is likely that neurotrophic factors play some role in these afflictions. Indeed, a considerable body of evidence suggests that neurotrophic factors may be valuable therapeutic agents for treatment of these neurodegenerative conditions, which are perhaps the most socially and economically destructive diseases now afflicting our society. For example, GDNF has been shown to relieve disease symptoms in several animal models of Parkinson's disease (reviewed by Grondin and Gash, *supra*). Nevertheless, because there is clear cross-talk between the different ligands and receptors, it would be desirable to have growth

factors of the GDNF family which are selective for particular receptors. In particular, because there are several central and peripheral sites of GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET expression which could lead to side effects as a result of treatment of central nervous system injury or neurodegenerative diseases with GDNF, neurturin or artemin, there is a need for GDNF family ligand members which are more specific in activating GFR $\alpha$ 1-RET. The identification of a GDNF family ligand which only activates GFR $\alpha$ 1-RET, would also lead to a further elucidation of the relative roles of each GFR $\alpha$  receptor.

10 Summary of the Invention

Accordingly, the inventors have succeeded in discovering that certain growth factors can be constructed which activate GFR $\alpha$ 1-RET but which do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Reference to the term "substantially" is intended to mean that the growth factor is selective for GFR $\alpha$ 1-RET and does not activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET to an extent greater than that of persephin, which is considered to be ineffective in binding to or activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, and/or preferably, no more than 50%, more preferably, no more than 40%, still more preferably, no more than 30% and, most preferably, no more than 20% as effective as GDNF in activating GFR $\alpha$ 2-RET or artemin in activating GFR $\alpha$ 3-RET.

Thus, in one embodiment, the present invention is directed to growth factors which activate GFR $\alpha$ 1-RET but do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Such growth factors can be chimeric GDNF family ligands or derivatives thereof. The derivatives can be peptidyl derivatives or non-peptidyl derivatives. Preferred peptidyl derivatives are GDNF family growth factors having conservative amino acid substitutions. In certain aspects of this embodiment, the growth factor can be based upon persephin which does not act upon GFR $\alpha$ 1-RET. The chimeric growth factor, thus, preferably comprises a substituted persephin having different amino acids in the F2a and/or F2c regions than those in a naturally occurring persephin. F2 represents the finger 2 stretch of amino acids as determined for GDNF (Eigenbrot and Gerber, 1997, *supra*) and the F2a and F2c regions are portions of finger 2 as shown in Figure 1.

The F2a region of the substituted persephin preferably comprises from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, i.e. from one to eight amino acids can be the same and in the same position in the F2a region of the

substituted persephin as in the F2a region of GDNF, neurturin or artemin. Alternatively, the amino acid in a particular position in the F2a region of the substituted persephin can be a conservative amino acid substitution for the amino acid in that position in the F2a region of GDNF, neurturin or artemin. Persephin lacks an amino acid between position 71 and 72 which is present in the aligned F2a regions of GDNF and neurturin and, hence, reference to amino acid substitutions in the F2a region of persephin is intended to include an insertion between positions 71 and 72 with an amino acid in that aligned position from GDNF, neurturin or artemin or a conservative amino acid substitution therefor.

Additionally, the F2c region of the substituted persephin of this embodiment preferably comprises from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, i.e. from one to eight amino acids can be the same and in the same position in the F2c region of the substituted persephin as in the F2c region of GDNF, neurturin or artemin. Alternatively, the amino acid in a particular position in the F2c region of the substituted persephin can be a conservative amino acid substitution for the amino acid in that position in the F2c region of GDNF, neurturin or artemin.

Preferably, the growth factor of the present invention comprises a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having substitutions in the F2a and/or F2c regions. The persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted persephin sequences have amino acids substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), mouse artemin (SEQ ID NO:10). Preferably, the growth factor of the present invention comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or human artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

The present invention also includes compositions comprising a pharmaceutically acceptable preparation of the GFR $\alpha$ 1-RET selective growth factors of the present invention.

In another embodiment, the present invention is directed to a  
5 nucleic acid comprising a polynucleotide encoding a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The encoded growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The encoded chimeric growth factor, preferably, comprises a  
10 persephin having the F2a and/or F2c region substituted with from one to eight amino acids identical to and in the same position as the amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the encoded F2a region or F2c region amino acid substitutions can comprise a conservative amino  
15 acid substitution for the amino acid in that position in the F2a region or F2c region of GDNF, neurturin or artemin. Preferably, the encoded, substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions.  
20 The encoded persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the encoded chimeric persephin sequences have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF  
25 (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the encoded sequence comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding sequences of human GDNF,  
30 human neurturin or human artemin. More preferably, the encoded sequence comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred encoded growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

In another embodiment, the present invention comprises a vector  
35 which comprises expression regulatory elements operably linked to a polynucleotide which encodes a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET and which is, preferably, a chimeric GDNF family ligand. The present

invention also encompasses a host cell which is transformed with the vector.

In an additional embodiment, the present invention provides chimeric GDNF family ligands with an altered N-terminus. The N-terminus can be eliminated, truncated, or substituted with the N-terminus of another GDNF family member or another protein such as a member of another TGF- $\beta$  superfamily member. These chimeras retain the GFR $\alpha$ -RET activating ability of the GDNF family ligand.

The growth factors of the present invention can be used to provide trophic support or produce differentiation in a mammalian cell. Thus, in another embodiment, the present invention comprises a method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or both. The method comprises treating the cell with an effective amount of a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The chimeric growth factor, preferably, comprises a persephin having the F2a region and/or F2c region substituted with from one to eight amino acids identical to and in the same position as that amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the F2a region or F2c region amino acid substitutions can comprise a conservative amino acid substitution for the amino acid in that position in the F2a region or F2c region of a GDNF, neurturin or artemin. Preferably, the substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions. The persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted or chimeric persephin sequences preferably have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the growth factor of the present invention comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or

human artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28. The mammalian cell can be any cell which contains GFR $\alpha$ 1-RET, preferably, a neuronal cell, a hematopoietic cell or a cardiac muscle cell. The treatment can further comprise administering to the cell a GFR $\alpha$ 1 polypeptide.

In a variation of this embodiment, the cell can be treated with a nucleic acid comprising a polynucleotide which encodes for expression, a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The encoded growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. In addition the cell can also be treated with a GFR $\alpha$ 1 polypeptide or a polynucleotide encoding a GFR $\alpha$ 1 polypeptide.

In one aspect of this embodiment, the cell can be in an patient and the treatment comprises administering the growth factor to the patient. The method also encompasses administering a polynucleotide encoding the growth factor to the patient or implanting into the patient a cell which expresses the growth factor. The cell can be a neuronal cell in a patient suffering from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, a nervous system tumor such as neuroblastoma, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers. The cell can also be a non-neuronal cell such as, for example, in a patient suffering from small cell lung carcinoma. The cell can also be a hematopoietic cell in a patient suffering from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemia, thrombocytopenia, or stem-cell insufficiency or a cardiac muscle cell in a patient suffering from cardiomyopathy or congestive heart failure.

In another embodiment, the present invention comprises a method for preventing or treating cellular degeneration or insufficiency in an individual. The method comprises administering to the individual a therapeutically effective amount of a growth factor which activates



GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The growth factor is preferably, a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The chimeric growth factor, preferably, comprises a persephin having the F2a region  
5 and/or F2c regions independently substituted with from one to eight amino acids identical to and in the same position as that amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the F2a region or F2c region amino acid substitutions can comprise a conservative amino acid substitution for  
10 the amino acid in that position in the F2a region or F2c region of GDNF, neurturin or artemin. Preferably, the substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions. The persephin sequence can also  
15 include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted or chimeric persephin sequences preferably have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ  
20 ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the growth factor comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or human  
25 artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28. The mammalian cell can be any cell which contains GFR $\alpha$ 1-RET, preferably, a neuronal cell, a hematopoietic cell or a cardiac muscle cell. The  
30 treatment can further comprise administering to the individual a GFR $\alpha$ 1 polypeptide.

In a variation of this method, a polynucleotide encoding the growth factor can be administered to the individual. Moreover, a cell which expresses the growth factor can be implanted into the  
35 individual. In addition, the treatment with the growth factor can be facilitated by also administering to the individual a GFR $\alpha$ 1 polypeptide or a polynucleotide encoding a GFR $\alpha$ 1 polypeptide or a cell which expresses a GFR $\alpha$ 1 polypeptide can be implanted into the individual.

The growth factor or polynucleotide encoding the growth factor can be administered to an individual suffering from (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, chemotherapy side effects, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, (b) from small cell lung carcinoma, (c) from hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemia, thrombocytopenia, or stem-cell insufficiencies therefor, or (d) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

In an additional embodiment, mimics of neurturin are provided which activate GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET but do not substantially activate GFR $\alpha$ 3-RET. These mimics comprise persephin having amino acid substitutions in regions Ha, F2a and F2c from neurturin, or conservative amino acid substitutions therefor. Nucleic acids comprising polynucleotides encoding these mimics are also provided. These mimics can substitute for neurturin, for example in methods for providing trophic support to a mammalian cell or producing differentiation of a mammalian cell, or in methods for preventing or treating cellular degeneration or insufficiency in an individual. Similarly, mimics of artemin are also provided which activate GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET but do not substantially activate GFR $\alpha$ 2-RET. These mimics comprise persephin having amino acid substitutions in regions Ha, F2a and F2c from artemin, or conservative amino acid substitutions therefor. Nucleic acids comprising polynucleotides encoding these mimics are also provided. These mimics can substitute for artemin, for example in methods for providing trophic support to a mammalian cell or producing differentiation of a mammalian cell, or in methods for preventing or treating cellular degeneration or insufficiency in an individual.

Among the several advantages achieved by the present invention, therefore, may be noted the provision of chimeric GDNF family ligands, which can be used to prevent the atrophy, degeneration or death of certain cells, in particular, neurons in need of trophic

support; the provision of polynucleotides encoding chimeric GDNF family ligands for use in gene therapy; the provision of methods for obtaining chimeric GDNF family ligands by recombinant techniques; the provision of methods for providing trophic support to target cells, particularly neurons; and the provision of methods for treating disease conditions involving cellular degeneration, and in particular, neuronal dysfunction and degeneration.

#### Brief Description of the Drawings

Figure 1 illustrates the amino acid sequence alignment of rat GDNF (comprising SEQ ID NO:6); mouse neurturin (comprising SEQ ID NO:8); mouse artemin (comprising SEQ ID NO:10); and mouse persephin (comprising SEQ ID NO:2), where the sequences include the region N-terminal to the first canonical cysteine and C-terminal to the seventh canonical cysteine, where the canonical cysteines are indicated by a thick outline, and where secondary structure elements (' $\alpha$ ' for  $\alpha$ -helix, ' $\beta$ ' for  $\beta$ -strand and '3' for  $3_{10}$ -helix) as determined for GDNF (Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997) are indicated above the alignment and the regions delineated for homologue-scanning mutagenesis are in gray blocks, with the name of the region (Fla-Flb for finger 1, Ha-Hd for heel, F2a-F2d for finger 2) is below the given region;

Figure 2A depicts a schematic diagram of wild-type and tagged GDNF constructs, where the site of proprotein convertase cleavage of GDNF is indicated by the arrow (SS - signal sequence, PRO - pro domain, MATURE - mature processed monomer), where GDNF with a 6-histidine and FLAG<sup>®</sup> tag inserted two residues after the RXXR cleavage site is designated "G-hf-GDNF" and where GDNF with the histidine and FLAG<sup>®</sup> tag wherein the GDNF pro sequence is substituted with the neurturin pro sequence is designated "N-hf-GDNF";

Figure 2B is an image of a FLAG<sup>®</sup> immunoblot demonstrating the production of tagged GDNF proteins in COS cells, where the immunoblot indicates that N-hf-GDNF produces GDNF with the 40 amino acid N-terminal extension replaced by two amino acids and the tandem His-FLAG tags;

Figure 2C is a graph showing the ability of tagged full-length and truncated GDNF to activate the GFR $\alpha$ 1-RET receptor and the inability of tagged persephin with its own (P-hf-PSPN) or neurturin's pro region (N-hf-PSPN) to activate GFR $\alpha$ 1-RET;

Figure 3A is a schematic representation of the mature region from GDNF, persephin and the homologue-scanning mutants, where GPG signifies a chimera comprising primarily GDNF (open portions of figures) but having the portion of GDNF indicated by shading replaced by a homologous portion of persephin; further where mutant GPG-Hc is a deletion of amino acids 88-92 of mature GDNF to correspond with the lack of these residues in PSPN, and where the sequence of the replacements in these mutants are shown in Figure 1;

Figure 3B is a photograph of an anti-FLAG<sup>®</sup> immunoblot of homologue scanning mutants from transfected COS cell lysates, where the two major bands indicated by arrows represent the unprocessed (top) and mature (bottom) forms of the mutants, since the lower band corresponds in size to the secreted product as shown in Figure 2B;

Figure 4A is a graph showing relative GFR $\alpha$ 1-RET receptor activation by homologue-scanning GDNF mutants, where values are represented as a percentage of reporter activation by GDNF and the mean and standard deviation of triplicate measurements from a representative experiment are shown, along with arbitrary boundary lines at 33% and 66% of wild-type GDNF activation;

Figure 4B depicts a space-filling model of the GDNF crystal structure, where the upper representation is a side-view of the GDNF dimer, and the lower representation is from a viewpoint below the dimer, showing putative critical GFR $\alpha$ 1-RET interaction domains Hb, F2a, and F2c;

Figure 4C is a graph showing relative GFR $\alpha$ 2-RET receptor activation by homologue-scanning GDNF mutants, where values are represented as a percentage of reporter activation by GDNF and the mean and standard deviation of duplicate measurements from a representative experiment are shown, along with arbitrary boundary lines at 33% and 66% of wild-type GDNF activation;

Figure 4D depicts a space-filling model of the GDNF crystal structure, where the upper representation is a side-view of the GDNF dimer, and the lower representation is from a viewpoint below the dimer, showing putative critical GFR $\alpha$ 2-RET interaction domains Ha, F2a, and F2c;

Figure 5A is a schematic representation of G-hf-GDNF, P-hf-PSPN, and GDNF/persephin replacement chimeras (PGP) for gain-of-function analysis, where the persephin amino acid sequence in

parentheses below the schematics was replaced by the GDNF sequence shown above;

Figure 5B is a graph showing the ability of PGP-F2ac to activate the GFR $\alpha$ 1-RET receptor and the inability of other PGP  
5 chimeras and P-hf-PSPN to activate GFR $\alpha$ 1-RET;

Figure 5C is an image of a RET immunoblot of anti-FLAG<sup>®</sup>-immunoprecipitated lysate from neuro2a cells either untransfected (RET) or transfected with FLAG<sup>®</sup>-tagged GFR $\alpha$ 1 (RET + GFR $\alpha$ 1) treated with the indicated factor at 25 ng/mL, where a fraction of the total  
10 lysate shows a RET doublet, with the upper band corresponding to the mature cell-surface form;

Figure 5D is a histogram of BrdU incorporation by NBL-S neuroblastoma cells in the presence of the indicated factors purified from conditioned medium of transiently transfected COS cells, showing  
15 that mutant PGP-F2ac stimulates proliferation of NBL-S cells at a similar level to GDNF at all doses tested;

Figure 5E are photographs of SH-SY5Y neuroblastoma cells cultured in the presence of no factor (CTRL), retinoic acid (RA; 10 $\mu$ M) or conditioned medium from COS cells expressing the indicated  
20 construct, showing that GDNF and PGP-F2ac stimulates neurite outgrowth in these cells, whereas persephin does not;

Figure 6A is a schematic diagram depicting the structures of N-hf-GDNF, P-hf-PSPN, PGP-F2ac, PNP-F2ac, and PAP-F2ac;

Figure 6B is two graphs showing the ability or inability of the  
25 five molecules depicted in Figure 6A to activate GFR $\alpha$ 1-RET (left side) and GFR $\alpha$ 2-RET (right side);

Figure 7A is a schematic diagram depicting the structures of G-hf-GDNF, P-hf-PSPN, PGP-F2ac, PNP-F2ac, PNP-Ha/F2ac, and PNP-Ha;

Figure 7B is a graph showing the ability or inability of the  
30 six molecules depicted in Figure 7A to activate GFR $\alpha$ 2-RET;

Figure 7C is a schematic diagram depicting the structures of N-hf-GDNF, N-hf-artemin, PAP-F2ac, PAP-Ha/F2ac, and P-hf-PSPN;

Figure 7D is a graph showing the ability or inability of the  
five molecules depicted in Figure 7C to activate GFR $\alpha$ 3-RET;

Figure 8A is a graph showing survival of cerebellar granule cells transfected with the indicated receptor components and cultured for 3 days in the presence of high-potassium plus serum (K25+S), low potassium (K5), or low potassium plus GDNF (GDNF);

Figure 8B is a graph showing survival of cerebellar granule cells transfected with GFR $\alpha$ 1-RET or GFR $\alpha$ 2-RET cultured in the presence of the indicated factors.

Description of the Preferred Embodiments

5           The present invention is directed to growth factors which selectively activate GFR $\alpha$ 1-RET without substantially activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Such growth factors are, preferably, chimeric GDNF family ligand growth factors which have the ability to activate a GFR $\alpha$ 1-RET complex, and are thus useful for promoting the  
10 survival of peripheral and central neuronal populations *in vivo* or *in vitro*.

          In one embodiment, the present invention provides novel chimeras which vary from the previously known naturally occurring GDNF ligand family members GDNF, artemin, neurturin, and persephin by  
15 their ability to activate mammalian GFR $\alpha$ 1-RET without substantially activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET complexes. Examples of these novel chimeras are PGP-F2ac (e.g., SEQ ID NOS:12, 23, and 26), PNP-F2ac (e.g., SEQ ID NOS:14, 24, and 27), and PAP-F2ac (e.g., SEQ ID NOS:16, 25, and 28), in which the sequences are identical to human persephin  
20 (e.g., SEQ ID NO:1), mouse persephin (SEQ ID NO:2), or rat persephin (SEQ ID NO:3) except that amino acids 63-66 in the F2a region and/or amino acids 76-82 in the F2c region (corresponding to amino acids 68-71 and 81-87 of full length persephin, as depicted in Figure 1) are replaced with the corresponding amino acids from a GDNF in PGP-F2ac,  
25 a neurturin in PNP-F2ac, or an artemin in PAP-F2ac. Although persephin sequences do not bind to or activate GFR $\alpha$ 1-RET, GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, the replacement of these amino acids of persephin with amino acids in the same aligned positions from GDNF, neurturin, or artemin, confers upon the chimeric molecule the ability to bind to  
30 and activate GFR $\alpha$ 1-RET. However, even though the persephin amino acids 63-66 and 76-82 are substituted with regions from growth factors which can also activate GFR $\alpha$ 2-RET (neurturin and GDNF) and GFR $\alpha$ 3-RET (artemin), the chimeras do not activate those receptors.

          As used herein, the ability to substantially activate a GFR $\alpha$ -  
35 RET complex by a GDNF family ligand is defined as the ability of that ligand to activate the MAP kinase pathway at a level preferably at least about 40%, more preferably at least about 50%, and most preferably at least about 80% of the ability of GDNF to activate that pathway through GFR $\alpha$ 1-RET activation. This can be measured, e.g., by

measuring luciferase activity after activating RET-expressing cells transformed with expression plasmids encoding the individual GFR $\alpha$  receptor together with the Gal4-Elk/Gal4-Luc reporter system as previously described with GDNF (Worby et al., *J Biol Chem* 273: 3502-3508, 1998; Worby et al., *J. Biol. Chem.* 271:23619-23622, 1996).

As used herein, regions in other GDNF family ligands which are "corresponding" or "analogous" to persephin amino acids 65-71 (also known as the F2a region - Figure 1) and 81-87 (the F2c region), starting at the first canonical cysteine, are meant to encompass the regions of those growth factors which are aligned with those persephin regions by commonly used alignment methods which are designed to align regions according to similar predicted tertiary structures. An example is the Clustal method (Higgins et al, *Cabios* 8:189-191, 1992) of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI). In this method, multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment = 10; gap length penalty for multiple alignment = 10; k-tuple value in pairwise alignment = 1; gap penalty in pairwise alignment = 3; window value in pairwise alignment = 5; diagonals saved in pairwise alignment = 5. The residue weight table used for that alignment program is PAM250 (Dayhoff et al., in *Atlas of Protein Sequence and Structure*, Dayhoff, Ed., NBRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

When the GDNF family ligands are aligned using the Clustal method (see, e.g., Figure 1), the F2a and F2c regions consist of amino acids 60-66 and 76-83 of persephin, starting at the first canonical cysteine residue (as set forth in SEQ ID NOS:1-3). When numbered from the N-terminus of persephin, as depicted in Figure 1, these regions correspond to amino acids 65-71 and 81-88, respectively. When persephin is aligned by the Clustal method with

5 GDNF, the F2a and F2c regions correspond to amino acids 63-71 and 80-87, respectively, of GDNF as set forth in SEQ ID NOS:4-6 and amino acids 103-110 and 120-127, respectively, of full length GDNF (Figure 1), and have the sequences RPIAFDDD and YHILRKHS, respectively, in human GDNF (SEQ ID NO:4). In neurturin, F2a and F2c are amino acids 64-71 and 81-88, respectively, in SEQ ID NOS:7 and 8, and amino acids 69-76 and 86-93, respectively, of full length neurturin (Figure 1), and have the sequences RPTAYEDE and YHTVHELs in human neurturin (SEQ ID NO:7). In artemin, F2a and F2c are amino acids 67-73 and 83-90, respectively, in SEQ ID NOS:9 and 10, and amino acids 82-88 and 98-105, respectively, of full length artemin (Figure 1), and have the sequences RPTRYEA and WRTVDRLS in human artemin (SEQ ID NO:9).

15 The seven amino acids 60-66 of the persephin F2a region correspond to the eight amino acids 63-70 of GDNF or 64-71 of neurturin because Clustal analysis creates a gap between amino acid 66 and 67 in persephin when aligned with GDNF or neurturin (see, e.g., Figure 1). Thus, the eighth amino acid in this region from GDNF or neurturin is not present in persephin (and artemin).

20 As it is believed that the replacement of amino acids 60-66 and 76-83 of any persephin (as numbered in SEQ ID NOS:1-3), now known or unknown, with analogous regions from any GFR $\alpha$ 1-RET activating GDNF family ligand (now known or unknown) would create a growth factor which activates GFR $\alpha$ 1-RET without activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, the scope of this embodiment is not meant to be limited to the GDNF family members disclosed herein, but is meant to encompass any GDNF family member. The invention also encompasses chimeras wherein the persephin is from one species and each substituting amino acid within 25 60-66 and 76-83 can be that of the same or different species.

30 It is also believed that the chimeras need not comprise the exact amino acid sequence of the GDNF family ligand from which they were derived in order to retain the ability to activate GFR $\alpha$ 1-RET. Rather, conservative substitutions in the chimeras are within the scope of the present invention. Conservative amino acid substitutions refer to the interchangeability of residues having 35 similar side chains. Conservatively substituted amino acids can be grouped according to the chemical properties of their side chains. For example, one grouping of amino acids includes those amino acids have neutral and hydrophobic side chains (A, V, L, I, P, W, F, and M); another grouping is those amino acids having neutral and polar



side chains (G, S, T, Y, C, N, and Q); another grouping is those amino acids having basic side chains (K, R, and H); another grouping is those amino acids having acidic side chains (D and E); another grouping is those amino acids having aliphatic side chains (G, A, V, L, and I); another grouping is those amino acids having aliphatic-hydroxyl side chains (S and T); another grouping is those amino acids having amine-containing side chains (N, Q, K, R, and H); another grouping is those amino acids having aromatic side chains (F, Y, and W); and another grouping is those amino acids having sulfur-containing side chains (C and M). Preferred conservative amino acid substitutions groups are: R-K; E-D, Y-F, L-M; V-I, and Q-H.

As used herein, the chimeras of the present invention can also include modifications of the sequences identified herein, including sequences in which one or more amino acids have been inserted, deleted or replaced with a different amino acid or a modified or unusual amino acid, as well as modifications such as glycosylation or phosphorylation of one or more amino acids so long as the chimera containing the modified sequence retains the ability to activate GFR $\alpha$ 1-RET. Amino acid(s) can be added to or removed from the N-terminus, C-terminus or within the amino acid sequence, provided the structural Cys residues are retained, which are believed to be required for GFR $\alpha$ -RET activating activity. Thus, the sequences set forth in SEQ ID NOS:1-10, which are sequences only between the first and seventh canonical cysteines of the GDNF family members, are believed to be the minimum length required for activity of these growth factors.

It is also known that the substitution of persephin amino acids with amino acids from a GFR $\alpha$ 1-RET activating growth factor need not encompass all of amino acids 60-66 and 76-83 (numbering of SEQ ID NOS:1-3). For example, the GFR $\alpha$ 1-RET activating chimeras PGP-F2ac, PNP-F2ac, and PAP-F2ac all comprise only the substitution of F2a amino acid residues 63-66 and F2c amino acid residues 76-82 (residue 83 is an S in all known GDNF family members). Additionally, a comparison of the GDNF, neurturin, and artemin amino acids in these regions with the corresponding amino acids of persephin reveals that the only GDNF, neurturin, and artemin amino acids which do not also occur in persephin are those at position 65, 77, 78, 80, and 81, as well as the amino acid which is "missing" between amino acid 66 and 67 in persephin. The "missing" amino acid between 66 and 67 is a D

in known GDNF sequences and an E in known neurturin, which are both acidic amino acids. However, this amino acid is also missing in artemin which activates GFR $\alpha$ 1. Therefore the provision of that missing amino acid in a persephin chimera is unlikely to influence the ability of the chimera to activate GFR $\alpha$ 1. At position 65, the known persephins have an A or a T, which are both uncharged at physiological pH, whereas the GFR $\alpha$ 1-activating growth factors have an E or a D, which are both acidic. At position 77, the persephins have a Q, which is uncharged and polar, whereas known GFR $\alpha$ 1-RET activating growth factors have an R or an H, which are basic. At position 78, the persephins have a Q (uncharged and polar) or an R (basic), whereas the GFR $\alpha$ 1-RET activating growth factors have a T (uncharged and polar) or an I (nonpolar). At position 80, the persephins have P (nonpolar), whereas the GFR $\alpha$ 1-RET activating growth factors have D, H, (both acidic), R (basic), and Q (uncharged and polar). Finally, at position 81, the persephins have a Q (uncharged and polar), whereas the GFR $\alpha$ 1-RET activating growth factors have an H (basic), an E (acidic), or a K (basic). Based on this analysis, only the substitutions at residues 65 and 77 represent an unequivocal change to a particular charge or polarity from the "nonfunctional" (i.e., does not activate GFR $\alpha$ 1-RET) persephin to the "functional" (GFR $\alpha$ 1-RET activating) GDNF family ligands. Therefore, these "hot spots" may be particularly important for GFR $\alpha$ 1-RET activation. Thus, it is believed that GFR $\alpha$ 1-RET activation can be achieved with a persephin wherein (a) from 1 to 4 of amino acids 63-66 are substituted with the corresponding amino acids of a GFR $\alpha$ 1-RET activating GDNF family ligand, or a conservatively substituted variant thereof, including at least the substitution of amino acid 65 with an acidic amino acid; and (b) from 1 to 7 of amino acids 76-82 are substituted with the corresponding amino acids of a GFR $\alpha$ 1-RET activating GDNF family ligand, or a conservatively substituted variant thereof, including the substitution of amino acid 77 with a basic amino acid. Preferred substitutions at position 65 are E and D. Preferred substitutions at position 77 are K, R, or H; most preferred are R and H.

In another embodiment, the present invention provides chimeric GDNF family ligands comprising a persephin wherein all three of the F2a, the F2c, and the Ha regions are substituted with the equivalent regions of a GFR $\alpha$ -RET activating GDNF family ligand. The Ha region encompasses amino acids 33-41 of persephin SEQ ID NOS:1-3 (equivalent

to amino acids 38-46 of full length persephin - Figure 1) and equivalent regions (as determined by Clustal analysis) of other GDNF family ligands (figure 1). The addition of the Ha region provides the ability to activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, depending on the source of the Ha region. If the Ha region (along with F2a and F2c) is derived from neurturin (e.g., PNP-Ha/F2ac - figure 7A), the chimera will activate GFR $\alpha$ 2-RET; if the Ha region (along with F2a and F2c) is derived from artemin (e.g., PAP-Ha/F2ac - figure 7C) the chimera will activate GFR $\alpha$ 3-RET. It has been found that the activation of GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET by these chimeras is generally about 70% of the activation of that GFR $\alpha$ -RET by the natural (e.g., neurturin or artemin) ligand (see, e.g., figure 7). Because neurturin does not substantially bind to or activate GFR $\alpha$ 3, chimeras such as PNP-Ha/F2ac would be expected to activate only GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET and not GFR $\alpha$ 3-RET or other GFR $\alpha$ -RET complexes having similar additional binding and activation requirements. Similarly, because artemin does not substantially bind to or activate GFR $\alpha$ 2-RET, chimeras such as PAP-Ha/2ac would be expected to activate only GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET and not GFR $\alpha$ 2-RET or other GFR $\alpha$ -RET complexes having similar additional binding and activation requirements.

PNP-Ha/F2ac and PAP-Ha/F2ac thus represent mimics of neurturin and artemin, respectively. As used herein, a mimic of a GDNF family ligand is a chimera which activates the same GFR $\alpha$ -RET receptor as the GDNF family ligand but which primarily comprises a different GDNF family ligand. Because mimics such as PNP-Ha/F2ac and PAP-Ha/F2ac activate the same GFR $\alpha$ -RET receptors as neurturin and artemin, respectively, it is believed that they can substitute for those GDNF family ligands in any treatment regime, such as described in U.S. Patent No. 5,843,914 for neurturin, or U.S. Patent Application No. 09/218,698 for artemin, both of which are hereby incorporated by reference.

As with the persephin chimeras having only the F2a and F2c regions from GFR $\alpha$ 1-RET activating ligands, the persephin chimeras with the F2a, F2c, and Ha chimeric regions can encompass conservatively substituted and modified amino acids. The chimeric regions from the GFR $\alpha$ 1-RET activating ligands can also comprise only partial substitutions, as previously discussed.

In an additional embodiment, the present invention provides chimeric GDNF family ligands with an altered N-terminal region. It

has been discovered that the region N-terminal to the first cysteine residue is not necessary to activate a GFR $\alpha$ /RET (see Example 1). Thus, any GDNF family ligand with an N-terminal region from any other GDNF family ligand, or with any other sequence of about 100 amino acids or less (including a lack of an N-terminal region) would be expected to activate the GFR $\alpha$ -RET which the wild-type ligand activates. Thus, this embodiment comprises a GDNF family member with from zero to 100 amino acids N-terminal to the first cysteine residue. This N-terminal region can comprise a functional sequence, such as a signal sequence or a prepro region comprising a signal sequence. It is well known in the art that many proteins are synthesized within a cell with a signal sequence at the N-terminus of the mature protein sequence and the protein carrying such a leader sequence is referred to as a preprotein. The pre region can serve as a signal peptide which directs transport of the protein to subcellular organelles or outside of the cell. The pre- portion of the protein is cleaved during cellular processing of the protein. In addition to a pre-leader sequence, many proteins contain a distinct pro sequence that describes a region on a protein that is a stable precursor of the mature protein. In view of the processing events known to occur with other TGF- $\beta$  family members, the inventors believe that the form of the GDNF family ligands which are synthesized within a cell is the pre-pro-ligand. The GDNF family ligand pre- region is thus generally followed by a pro- domain which is believed to preferably terminate with an RXXR consensus site immediately before the N-terminal amino acid of the mature ligand. Proteins synthesized with both pre- and pro- regions are referred to as preproproteins.

Thus, within the scope of the present invention are GDNF family ligands containing a pre-pro- region from another GDNF family ligand or another protein, as well as polynucleotides encoding such polypeptides. The polypeptides can generate a mature ligand upon cleavage of the pre-pro- region and the polynucleotides can be used in an expression system to produce the polypeptide which upon cleavage of the non-artemin pre-pro- region yields mature artemin. Such non-GDNF family ligand pre-pro- region polypeptides and encoding polynucleotides are well known in the art.

Thus, chimeras of the GDNF family ligand can comprise an N-terminal region from any protein, pro-protein, or pre-pro-protein. This can be utilized, for example, to target the protein to a

particular cellular region, or outside of the cell. Alternatively, GFR $\alpha$ -RET activating, truncated GDNF family members (including chimeras) containing only a portion of, or entirely lacking an N-terminal region can be made.

5           Although it is not intended that the inventors herein be bound by any theory, it is thought that the chimeric GDNF family ligands identified herein may exist as dimers in their biologically active form in a manner consistent with what is known for other factors of the TGF- $\beta$  superfamily. The chimeras may be used in homodimers or  
10 heterodimers. It is believed that monomers of the chimeras will associate under physiological conditions into homodimers.

          A preferred chimera according to the present invention is prepared in pure form by recombinant DNA technology. By "pure form" or "purified form" or "substantially purified form" it is meant that  
15 a chimera composition is substantially free of other proteins which are not the chimera. Preferably, a substantially purified chimera composition comprises at least about 50 percent chimera on a molar basis compared to total proteins or other macromolecular species present. More preferably, a substantially purified chimera  
20 composition will comprise at least about 80 to about 90 mole percent of the total protein or other macromolecular species present and still more preferably, at least about 95 mole percent or greater.

          A recombinant chimera may be made by expressing a DNA sequence encoding the chimera in a suitable transformed host cell. Using  
25 methods well known in the art, the DNA encoding the chimera may be linked to an expression vector and transformed into a host cell, and conditions established that are suitable for expression of the chimera by the transformed cell.

          Any suitable expression vector may be employed to produce a  
30 recombinant chimera such as, for example, the mammalian expression vector pCB6 (Brewer, *Meth Cell Biol* 43: 233-245, 1994) or the *E. coli* pET expression vectors, specifically, pET-30a (Studier et al., *Methods Enzymol* 185: 60-89, 1990). Other suitable expression vectors for expression in mammalian and bacterial cells are known in the art  
35 as are expression vectors for use in yeast or insect cells. Baculovirus expression systems can also be employed.

          A number of cell types may be suitable as host cells for expression of a recombinant chimera. Mammalian host cells include, but are not limited to, monkey COS cells, Chinese Hamster Ovary (CHO)

cells, human kidney 293 cells, human epidermal A431 cells, human Colo 205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L  
5 cells, BHK, HL-60, U937, HaK and Jurkat cells. Yeast strains that may act as suitable host cells include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, and any other yeast strain capable of expressing heterologous proteins. Host bacterial strains include *Escherichia coli*, *Bacillus subtilis*,  
10 *Salmonella typhimurium* and any other bacterial strain capable of expressing heterologous proteins. If the polypeptide is made in yeast or bacteria, it may be necessary to modify the polypeptide, for example, by phosphorylation or glycosylation of the appropriate sites using known chemical or enzymatic methods, to obtain a biologically  
15 active polypeptide.

The chimeras of the present invention can also be expressed in transgenic plants (see, for example, U.S. Patent No. 5,679,880) or transgenic animals such as, for example, cows, goats, pigs, or sheep whose somatic or germ cells contain a nucleotide sequence encoding  
20 the chimera.

The expressed chimera can be purified using known purification procedures, such as gel filtration and ion exchange chromatography. Purification may also include affinity chromatography using an agent that will specifically bind the chimeric polypeptide, such as a  
25 polyclonal or monoclonal antibody raised against the mature chimera or fragment thereof. Other affinity resins typically used in protein purification may also be used such as concanavalin A-agarose, HEPARIN-TOYOPEARL® or CIBACROM BLUE 3GA SEPHAROSE®. Purification of the chimera can also include one or more steps involving hydrophobic  
30 interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether.

It is also contemplated that the chimera may be expressed as a fusion protein to facilitate purification. Such fusion proteins, for example, include the chimera amino acid sequence fused to a histidine  
35 tag, as well as the chimera amino acid sequence fused to the amino acid sequence of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Similarly, the invention chimera can be tagged with a heterologous epitope, such as a FLAG® epitope, and subsequently purified by immunoaffinity chromatography

using an antibody that specifically binds the epitope. Kits for expression and purification of such fusion proteins and tagged proteins are commercially available. A preferred fusion protein is one containing both a histidine tag and a FLAG® tag, e.g. as  
5 described in Example 1.

The recombinant chimeras may also be expressed as monomeric units or such monomeric form may be produced by preparation under reducing conditions. In such instances refolding and renaturation can be accomplished using one of the agents noted above that is known  
10 to promote dissociation/association of proteins. For example, the monomeric form can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.

The chimeras of the present invention may also be produced by  
15 chemical synthesis using methods known to those skilled in the art.

The present invention also encompasses isolated polynucleotides comprising nucleotide sequences that encode any of the chimeras described herein. As used herein, a polynucleotide includes DNA and/or RNA and thus the nucleotide sequences recited in the Sequence  
20 Listing as DNA sequences also include the identical RNA sequences with uracil substituted for thymine residues.

The present invention also encompasses vectors comprising an expression regulatory element operably linked to any of the chimera-encoding nucleotide sequences included within the scope of the  
25 invention. This invention also includes host cells, of any variety, that have been transformed with such vectors.

In yet another embodiment, a polynucleotide which specifically hybridizes to a chimera-encoding polynucleotide or to its complement is provided. Specific hybridization is defined herein as the  
30 formation of hybrids between a polynucleotide, including oligonucleotides, and a specific reference polynucleotide (e.g., a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence encoding a chimera) wherein the polynucleotide preferentially hybridizes to the specific chimera over other GDNF  
35 family ligands. Specific hybridization is preferably done under high stringency conditions which, as well understood by those skilled in the art, can readily be determined by adjusting several factors during hybridization and during the washing procedure, including temperature, ionic strength, length of hybridization or washing

times, and concentration of formamide (see for example, Sambrook, Fritsch and Maniatis., *Molecular Cloning: a Laboratory Manual*, 2d Ed., Vols. 1-3, Cold Spring Harbor Laboratory Press, Plainview N.Y. 11803, 1989)

5           The chimeras of the present invention would be expected to promote the survival and growth of neuronal as well as non-neuronal cells (see, e.g., Examples 2 and 4 herein). As discussed above, GDNF, neurturin, artemin and persephin influence a broad spectrum of neuronal populations in the peripheral and central nervous systems  
10           and the invention chimeras would be expected to also have such an effect. Moreover, all other growth factors isolated to date have been shown to act on many different cell types (for example see Scully and Otten, *Cell Biol Int* 19: 459-469, 1994; Hefti, *Neurotrophic Factor Therapy* 25: 1418-1435, 1994 which are  
15           incorporated by reference). As an example of the actions of neurotrophic factors on non-neuronal tissues, the prototypical neurotrophic factor, NGF, also acts upon mast cells to increase their number when injected into newborn rats (Aloe, *J Neuroimmunol* 18: 1-12, 1988). In addition, mast cells express the trk receptor and  
20           respond to NGF such that NGF is a mast cell secretagogue and survival promoting factor (Horigome et al., *J Biol Chem* 269: 2695-2707, 1994). Moreover, members of the TGF- $\beta$  superfamily act on many cell types of different function and embryologic origin. For example, GDNF activation of GFR $\alpha$ 1 is apparently critical in kidney organogenesis.  
25           Thus, it is likely that the invention chimeras will have trophic activity on a variety of different neuronal cells, both peripheral and central, as well as on non-neuronal cells.

          The present invention also includes therapeutic or pharmaceutical compositions comprising a chimera of the present  
30           invention in an effective amount for providing trophic support to cells in patients with cellular degeneration or dysfunction and a method comprising administering a therapeutically effective amount of the chimera to a cell *ex vivo* or *in vivo*. The term "trophic support" is used herein to mean that a growth factor such as the invention  
35           chimeras provides sufficient nourishment to a cell such that the cell maintains or recovers at least one or more of its normal functions.

          The compositions and methods of the present invention are useful for treating a number of degenerative diseases and anaplastic diseases. Where the cellular degeneration, dysfunction or anaplasia



involves neurons, the diseases include, but are not limited to peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, nervous system tumors such as neuroblastomas, multiple sclerosis, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal dysfunctions and damage caused by infectious agents or chemotherapy. In addition, compositions of the invention chimeras can be used to treat enteric diseases such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers. If the cellular degeneration or dysfunction involves nonneuronal cells such as bone marrow cells, a chimera may be useful in treating diseases including, but not limited to disorders of insufficient blood cells such as, for example, leukopenias including eosinopenia and/or basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia as well as an insufficiency of stem cells for any of the above. The cellular degeneration or dysfunction can also involve myocardial muscle cells in diseases such as cardiomyopathy and congestive heart failure. In addition small cell lung carcinoma can be treated with polypeptide or polynucleotide compositions of the invention chimeras.

Treatment of enteric diseases with the chimeras includes the treatment of enteric neuropathies. The enteric nervous system is a complex collection of nerves that control the function of the gastrointestinal system, including gastrointestinal motility. Initial clinical studies with the NT-3, have shown that this neurotrophic factor increases gastrointestinal motility in normal volunteers and in patients suffering from peripheral neuropathies. Heuckeroth et al., *Dev Biol* 200: 116-29, 1998. Similarly, it is believed that the invention chimeras as well as the other GDNF family ligands will show activity on enteric neurons. As a result, it is believed that the chimeras will be useful in treating enteric neuropathies such as in patients suffering from severe idiopathic constipation as well as patients suffering from constipation associated with Parkinson's disease, spinal cord injury, use of opiate pain-killers, and the like.

Whether the invention chimeras would be effective in the treatment of a particular cell type or tissues can be readily

determined by one skilled in the art using any of a variety of assays known in the art. For example, with respect to providing trophic support for cells, trophic factors can produce beneficial biochemical and morphological effects and, under some circumstances, will promote cell survival. With respect to neurons, it is known in the art that depriving a neuron of trophic support results in a decrease in metabolic activity, i.e., glucose uptake, RNA synthesis and protein synthesis, required for normal function and growth. Deckwerth and Johnson, *J. Cell Biol.* 123: 1207-1222, 1993. Removal of trophic support also results in a reduction in size of the cell body of the neuron. Presumably as a consequence of the loss of the metabolic effects of trophic factors, trophic factor deprivation results in a decrease or cessation of process outgrowth and may result in retraction of neuronal processes. In addition to the requirement of trophic factor for these aspects of neuronal biology, the neuron may require the neurotrophic factor to maintain survival. Thus, survival assays are a frequently used means to detect or quantitate the actions of a neurotrophic factor. However, trophic support can also be manifest as morphological, biochemical, and/or functional changes independent of neuronal number or any effect on survival.

As discussed above, growth factors can produce a cell differentiation in addition to providing trophic support for cells. Thus, it is believed that the invention chimeras and polynucleotides encoding them can be beneficially used to produce a differentiation of anaplastic cells such as cancer cells. In particular, the chimeras can be used to treat nervous system tumors such as neuroblastomas. In addition, small cell lung carcinomas are known to express RET. Hence, it is believed that the chimeras can also be used to treat small cell lung carcinomas.

It is also contemplated that the eliciting of trophic support and/or differentiation can be achieved by administering a chimera along with a GFR $\alpha$ 1 polypeptide (and/or GFR $\alpha$ 2 or GFR $\alpha$ 3, for the neurturin or artemin mimics, respectively) or by administering a polynucleotide encoding the chimera and the appropriate GFR $\alpha$  polynucleotide using the methods previously described with GDNF in Treanor et al., *Nature* 382: 80-83, 1996. Sequences for GFR $\alpha$ 1 are known in the art. See, e.g., Genbank Accession numbers NP\_005255 for a human polypeptide sequence and NM\_005264 for a polynucleotide sequence encoding human GFR $\alpha$ 1.

The invention chimeras are believed to bind to GFR $\alpha$ 1 (and GFR $\alpha$ 2 or GFR $\alpha$ 3 in the case of the neurturin or artemin mimics, respectively) in the absence of RET and it is believed that the resulting ligand/coreceptor complex is capable of binding to and activating RET receptors expressed by a target cell. Thus, treatment with a chimera and the appropriate GFR $\alpha$  would be expected to increase the sensitivity of cells normally responsive to the chimera and would also be expected to provide trophic support to cells that express RET but that are not normally responsive to the chimera. Preferably, the chimera and GFR $\alpha$  polypeptides are from the same species, i.e., human. It is also preferred that the GFR $\alpha$  polypeptide be in soluble form, i.e., that it lack the GPI linkage to avoid potential undesirable interactions with cell membranes. As used herein a GFR $\alpha$  polypeptide is intended to include the mature protein with or without the GPI anchor, as well as GFR $\alpha$  fragments, particularly soluble fragments lacking a GPI anchor, that are capable of binding to both the invention chimeras and RET with such binding leading to the activation of RET.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of a slow release formulation. For treating tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that an invention chimera be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the chimera across the blood-brain barrier.

The invention chimeras can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, a chimera can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection (See for example, Friden et al., *Science* 259:373-377, 1993). Furthermore, a chimera can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other

pharmaceutically advantageous properties. (See for example Davis et al. *Enzyme Eng* 4: 169-73, 1978; Burnham, *Am J Hosp Pharm* 51: 210-218, 1994).

5 Preferably, a chimera of the present invention is administered with a carrier such as liposomes or polymers containing a targeting moiety to limit delivery of the chimera to targeted cells. Examples of targeting moieties include but are not limited to antibodies, ligands or receptors to specific cell surface molecules.

10 For nonparenteral administration, the compositions can also include absorption enhancers which increase the pore size of the mucosal membrane. Such absorption enhancers include sodium deoxycholate, sodium glycocholate, dimethyl- $\beta$ -cyclodextrin, lauroyl-1-lysophosphatidylcholine and other substances having structural similarities to the phospholipid domains of the mucosal membrane.

15 The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as  
20 physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition  
25 of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. The invention chimeras can also be incorporated into a solid or semi-solid biologically compatible matrix which can be implanted into tissues requiring treatment.

30 The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still  
35 other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct

infusion into the cerebrospinal fluid by continuous or periodic infusion.

Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

It is also contemplated that certain formulations containing a chimera are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art based on the activity of the chimera for a particular cell type *in vitro*. The activity of invention chimeras on various peripheral and central neurons in culture is described below and its activity on a particular target cell type can be determined by routine experimentation. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and

response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

In one embodiment of this invention, an invention chimera may be therapeutically administered by implanting into patients vectors or cells capable of producing a biologically-active form of the chimera or a precursor of the chimera, i.e. a molecule that can be readily converted to a biological-active form of the chimera by the body. In one approach cells that secrete the chimera may be encapsulated into semipermeable membranes for implantation into a patient. In some embodiments, the cells are transformed to express and secrete both the chimera and the appropriate GFR $\alpha$ , preferably in a soluble form. It is preferred that the cell be of human origin and that the chimera be derived from human GDNF family ligands when the patient is human. However, the formulations and methods herein can be used for veterinary as well as human applications and the term "patient" as used herein is intended to include human and veterinary patients.

Cells can be grown *ex vivo* for use in transplantation or engraftment into patients (Muench et al., *Leuk & Lymph* 16: 1-11, 1994). In another embodiment of the present invention, an invention chimera can be used to promote the *ex vivo* survival or expansion of cells for transplantation or engraftment. Current methods have used bioreactor culture systems containing factors such as erythropoietin, colony stimulating factors, stem cell factor, and interleukins to expand hematopoietic progenitor cells for erythrocytes, monocytes, neutrophils, and lymphocytes (Verfaillie, *Stem Cells* 12: 466-476, 1994). These stem cells can be isolated from the marrow of human donors, from human peripheral blood, or from umbilical cord blood cells. The expanded blood cells are used to treat patients who lack these cells as a result of specific disease conditions or as a result of high dose chemotherapy for treatment of malignancy (George, *Stem Cells* 12(Suppl 1): 249-255, 1994). In the case of cell transplant after chemotherapy, autologous transplants can be performed by removing bone marrow cells before chemotherapy, expanding the cells *ex vivo* using methods that also function to purge malignant cells, and transplanting the expanded cells back into the patient following chemotherapy (for review see Rummel and Van Zant, *J Hematotherapy* 3: 213-218, 1994).

It is also believed that an invention chimera with or without the appropriate GFR $\alpha$  can be used for the ex vivo expansion of precursor cells in the nervous system. Transplant or engraftment of cells is currently being explored as a therapy for diseases in which certain populations of neurons are lost due to degeneration such as, for example, in Parkinson's disease (Bjorklund, *Curr Opin Neurobiol* 2: 683-689, 1992) and spinal cord injury. Neuronal precursor cells can be obtained from animal or human donors or from human fetal tissue and then expanded in culture using a chimera of the present invention. These cells can then be engrafted into patients where they would function to replace some of the cells lost due to degeneration. Because neurotrophins have been shown to be capable of stimulating the survival and proliferation of neuronal precursor cells such as, for example, NT-3 stimulation of sympathetic neuroblast cells (Birren et al., *Develop* 119: 597-610, 1993), the chimera could also function in similar ways during the development of the nervous system and could be useful in the ex vivo expansion of neuronal cells.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

The procedures disclosed herein which involve the molecular manipulation of nucleic acids are known to those skilled in the art. See generally Fredrick M. Ausubel et al. (1995), "Short Protocols in Molecular Biology", John Wiley and Sons, and Joseph Sambrook et al. (1989), "Molecular Cloning, A Laboratory Manual", second ed., Cold Spring Harbor Laboratory Press, which are both incorporated by reference.

#### Example 1

This example illustrates that the N-terminal extension of GDNF is not required for activity.

An alignment of the mature rat GDNF with mouse neurturin, artemin and persephin is shown in Figure 1. This amino acid sequence comparison and alignment was performed using the MegAlign program of

the DNASTAR software package. Rat GDNF was the basis for all mutagenesis in this example because its structure has been determined (Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997). For this and all other examples, the amino acid sequence of rat GDNF (SEQ ID NO:12) and mouse neurturin (SEQ ID NO:14) and persephin (SEQ ID NO:2), and human artemin (SEQ ID NO:15) were used for all constructs. The largest notable difference between the GDNF family ligands is the N-terminal extension before the first structural cysteine, which varies from 40 amino acids in GDNF (SEQ ID NO:18) to only 5 amino acids in neurturin (SEQ ID NO:18) and persephin (amino acids 1-5 of SEQ ID NOs 1-3), and shows little similarity between the different family members. Furthermore GDNF, neurturin and artemin have multiple RXXR consensus subtilisin-like proprotein convertase (SPC) cleavage sites (Molloy et al., *J. Biol. Chem.* 267: 16396-16402, 1992), and therefore multiple isoforms of these extensions are possible. The ones shown are consistent with N-terminal sequencing of GDNF and neurturin (Kotzbauer et al., *Nature* 384: 467-470, 1996), the single cleavage site in PSPN (Milbrandt et al., *supra*), and a cleavage site conserved between mouse and human artemin (Baloh et al., *supra*).

To determine if the large N-terminal extension of GDNF is required for its activity, the differential processing of GDNF and neurturin by mammalian cells was utilized. Chimeric constructs with the pre-pro region from neurturin attached to GDNF were generated, and both their processing and their ability to activate the GFR $\alpha$ 1-RET receptor complex was assessed (Figure 2). Tandem 6X Histidine and FLAG<sup>®</sup> tags were inserted after the RXXR cleavage site of GDNF or neurturin to allow purification and tracking of the proteins (Figure 2A). For mutant G-hf-GDNF the 6His-FLAG<sup>®</sup> tag was inserted between the third and fourth residue of mature GDNF, making the sequence

N-...RLKR<sub>A</sub>SPD-HHHHHHDYKDDDDK-  
 QAAALPRRERNRQAAAASPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCE  
 AAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDDDLSDLVYHILRKHSKRCGCI. For mutant P-hf-PSPN, the tag was inserted between the third and fourth residue of mature PSPN, resulting in N-...RLPR<sub>A</sub>ALA-HHHHHHDYKDDDDK-  
 GSCRLWSLTLPVAELGLGYASEEKVIFRYCAGSQCPEARTQHSLVLARLRGRGRAHGRPCCQPTSYADV  
 TFLDDQHHWQQLPQLSAAACGCGG. All mutants were produced by fusion PCR mutagenesis. PCR products were directly cloned into the MluI and XbaI sites of plasmid pCB6 (Brewer, *Meth Cell Biol.* 43: 233-245,



1994) and the inserts sequenced entirely. For mutant N-hf-GDNF, residues 1-38 were truncated from mature GDNF, and attached to the pre-pro region of NRTN. The resulting sequence was N-...RRAR<sub>A</sub>PGA-HHHHHHDYKDDDDK-

5 RGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCEAAETMYDKILKNLSRSRRLTSDKVGQACCRPVAF  
DDDL SFLDDSLVYHILRKHS AKRCGCI.

The mutant proteins were produced in COS cells as follows. For mutant protein production in COS cells, expression plasmids were transfected using the DEAE-dextran/Chloroquine method (Seed and  
10 Aruffo, *Proc. Natl. Acad. Sci. U.S.A.* 84: 3365-3369, 1987). COS cells were plated onto 10 cm or 15 cm dishes, transfected, and switched to Delbecco's Modified Eagle's Media containing 1% fetal calf serum. After 4-5 days, conditioned medium was collected, cleared, and either concentrated using Centriprep-10 concentrators  
15 (Amicon) or purified by nickel chromatography (Qiagen). Proteins were visualized by immunoblotting with anti-FLAG<sup>®</sup> M2 monoclonal antibody (Sigma). Relative quantities of FLAG<sup>®</sup>-tagged proteins were determined by an ELISA also using the anti-FLAG<sup>®</sup> M2 antibody. The absolute concentration of GDNF in purified and conditioned medium  
20 samples was determined for the G-hf-GDNF construct using the GDNF E-MAX ELISA kit following the manufacturer's instructions (Promega). As shown in Figure 2B, monomeric G-hf-GDNF ran at ~25 kD, and N-hf-GDNF at ~21.5 kD, consistent with processing at the predicted RXXR  
cleavage sites from GDNF and neurturin. Therefore N-hf-GDNF produces  
25 GDNF with the 40 amino acid N-terminal extension replaced by two amino acids and the tandem His-FLAG<sup>®</sup> tags. When expressed in COS cells, similar quantities of tagged GDNF with its own pro-region (G-hf-GDNF) or the neurturin pro-region (N-hf-GDNF) could be purified from conditioned medium using nickel chromatography (Figure 2B).  
30 Only species corresponding to the expected processing events were observed, indicating that the pro-domains of neurturin and GDNF are sufficient to direct proper processing of their different N-terminal extensions.

To assess the ability of these proteins to activate the high-  
35 affinity GDNF receptor, GFR $\alpha$ 1-RET, the Gal4-Elk1/Gal4-luciferase reporter system was used as described previously (Baloh et al., *supra*). This system monitors the level of RET activation of the MAP kinase pathway, which induces the Gal4-Elk1 fusion protein to activate the Gal4-luciferase reporter, giving a facile measure of

receptor activation (Worby et al., *J Biol Chem* 273: 3502-3508, 1998; York et al., *Nature* 392: 622-626, 1988). RET-3T3 cells were plated at 85,000 cells/well in 12-well plates, and transfected using Superfect (Qiagen) with the reporter plasmids (250 ng/well Gal4-Luc, 50 ng/well Gal4-Elk), CMV-lacZ (50 ng/well) for transfection normalization, CMV-GFR $\alpha$ 1 (250 ng/well) expression plasmid, the mutant GFL construct (250 ng/well) and 650 ng/well pBluescript as carrier for a total of 1.5  $\mu$ g DNA/well. Cells were switched to 0.5% serum-containing medium the morning after transfection and harvested 36 hours later. The average luciferase activity of duplicate or triplicate samples were normalized to  $\beta$ -galactosidase activity of the cotransfected lacZ reporter. As shown in Figure 2C, wild-type GDNF, G-hf-GDNF and N-hf-GDNF all showed comparable activation of GFR $\alpha$ 1-RET in this assay, whereas tagged PSPN constructs with either the PSPN or neurturin pro-region did not activate the receptor. These results are consistent with previous receptor activation and binding experiments indicating that GDNF, but not PSPN, can bind and activate RET through GFR $\alpha$ 1 (Baloh et al., *supra*; Milbrandt et al., *supra*). Furthermore, these data indicate that the N-terminal extension of GDNF is not required for its ability to activate the GFR $\alpha$ 1-RET receptor complex, and the location of the epitope tag does not interfere with the function of GDNF.

The N-terminal extension before the first structural cysteine-knot cysteine is highly variable amongst the TGF- $\beta$  superfamily members. In the case of TGF- $\beta$ 2, it exists as a short  $\alpha$ -helix and is stabilized by an additional disulfide bond relative to other members of the superfamily (Daopin et al., *supra*; Schlunegger and Grutter, *Nature* 358: 430-434, 1992). However, in GDNF and OP-1, the only other members of the TGF- $\beta$  superfamily that have been crystallized, the 35-37 residue N-terminal extension was unresolved and therefore does not adopt a consistent conformation in solution (Eigenbrot and Gerber, *supra*; Griffith et al., *Proc. Natl. Acad. Sci. U.S.A.* 93: 878-883, 1996). Truncating the N-terminal extension did not affect GDNF's ability to activate its receptors. This is consistent with experiments characterizing monoclonal antibodies against GDNF that also suggested the N-terminal extension is not required for receptor binding or bioactivity (Xu et al., *J. Neurochem.* 70: 1383-1393, 1998).

## Example 2

This example illustrates the use of homologue scanning to identify critical GDNF regions for activation of GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET.

5        Although the crystal structure of GDNF is known, the molecular determinants for GDNF-GFR $\alpha$  receptor binding and specificity are currently undefined. To identify regions of GDNF that are required for its ability to activate the GFR $\alpha$ 1-RET receptor complex, homologue-scanning mutagenesis was utilized together with the  
10        receptor activation assay described in Example 1. Ten GDNF mutants (termed "GPG" mutants) were generated by replacing blocks of non-conserved sequence from PSPN into GDNF (Figure 3; see Figure 1 for sequence changes). This method allows comprehensive mutagenesis of sites responsible for the difference in the ability of GDNF and PSPN  
15        to activate GFR $\alpha$ 1-RET, and is highly likely to maintain structural integrity of the mutants because the replacements are from a homologous (and likely structurally similar) protein. Expression plasmids for these mutants were produced as described in Example 1 using fusion PCR, and all were based on the N-hf-GDNF construct. All  
20        mutants were produced at similar quantities when transfected into COS cells, and processing of each appeared normal (Figure 3B).

Comparison of the GPG mutants with GDNF revealed that although many mutants showed slightly decreased activity, only one (GPG-F2a) completely lost the ability to activate the GFR $\alpha$ 1-RET receptor  
25        (Figure 4A). This region was identified in a molecular model of GDNF. Molecular modeling and analysis was done using the SwissPDB viewer (Guex and Peitsch, *Electrophoresis* 18: 2714-2723, 1997), and models were rendered using Mole software (Applied Thermodynamics). The GDNF structure was modeled after entry 1AGQ (Eigenbrot and  
30        Gerber, *supra*) of the Protein Data Bank. The 'C/D' dimer from 1AGQ is shown, with the missing segment of monomer 'C' built as determined for monomer 'D'. The F2a region maps to the bottom of the GDNF molecule along the second finger (Figure 4B; Eigenbrot and Gerber, *supra*). The only other notable mutant that consistently showed  
35        activity 60% or lower than full-length GDNF was GPG-F2c, which maps to the strand adjacent to region F2a along the bottom of the molecule.

It is well established that GDNF is also capable of activating the GFR $\alpha$ 2-RET receptor, albeit with a lower affinity than neurturin

(Baloh et al., *Neuron* 18: 793-802, 1997 Sanicola et al., *Proc. Natl. Acad. Sci., USA* 94: 6238-6243, 1997; Suvanto et al., *Hum. Molec. Genet.* 6: 1267-1273, 1997), whereas persephin cannot (Baloh et al., 1998, *supra*; Milbrandt et al., 1998, *supra*). Therefore, to compare  
5 the molecular determinants of GDNF required for GFR $\alpha$ 1 vs. GFR $\alpha$ 2 interaction, we tested the ability of this same panel of mutants to activate the GFR $\alpha$ 2-RET receptor complex. Several of the GPG mutants were significantly more attenuated in their ability to activate RET through GFR $\alpha$ 2 than they were through GFR $\alpha$ 1 (Figure 4C). As before,  
10 mutant GPG-F2a was unable to activate the receptor. Interestingly, mutant GPG-F2c, which was the second most affected mutant in activating GFR $\alpha$ 1-RET, showed essentially no activation of GFR $\alpha$ 2-RET. Finally, the mutant that showed the most contrast in its ability to activate GFR $\alpha$ 1-RET vs. GFR $\alpha$ 2-RET was mutant GPG-Ha, which was  
15 severely affected only in its ability to activate GFR $\alpha$ 2-RET. Interestingly, mapping these three regions to the GDNF crystal structure reveals that they form a continuous surface, with residues from F2a and F2c from one monomer directly adjacent to region Ha from the heel of the other monomer, suggesting a possible receptor-ligand  
20 interaction surface (Figure 4D).

To summarize, the above mutagenesis data suggest that two adjacent regions of GDNF located along the second finger are necessary for interaction with both GFR $\alpha$ 1 and GFR $\alpha$ 2 (regions F2a and F2c), and that additional regions appear required for GDNF  
25 interaction with GFR $\alpha$ 2.

### Example 3

This example illustrates that regions F2a and F2c from GDNF, neurturin, or artemin are sufficient for activating GFR $\alpha$ 1-RET.

The homologue-scanning screen disclosed in Example 2 suggests  
30 several regions that are necessary for the full ability of GDNF to activate the GFR $\alpha$ 1-RET receptor. However, using only loss of function analysis it is difficult to assess whether critical receptor-contact residues are being altered directly, or if the mutations induce structural changes that alter receptor contact  
35 surfaces elsewhere on the molecule. To identify if any of the critical regions identified above (either alone or in combination) are sufficient to allow binding and activation of the GFR $\alpha$ 1-RET receptor complex, persephin mutants were generated with the putative critical regions from GDNF replacing the corresponding regions of

persephin. It was then determined if these "PGP" mutants had gained the ability to activate the GFR $\alpha$ 1-RET receptor complex (Figure 5).

Two candidate regions, F2a and F2c, were initially evaluated along the second finger of GDNF, because mutant GPG-F2a was entirely  
5 inactive, and mutant GPG-F2c was the only other mutant that consistently showed decreased activation of GFR $\alpha$ 1-RET. Replacement of either region F2a or F2c alone from GDNF into persephin was not sufficient to allow the resulting mutants (PGP-F2a or PGP-F2c) to activate GFR $\alpha$ 1-RET. However, when both regions were placed into  
10 persephin the resulting mutant (PGP-F2ac) gained the ability to activate the GFR $\alpha$ 1-RET receptor at a level comparable to full-length GDNF (Figure 5B).

GFR $\alpha$ 1-transfected Neuro2a cells (which endogenously express RET) were then treated with either GDNF or mutant PGP-F2ac as  
15 follows. Neuro2a cells were transiently transfected using Superfect with an expression plasmid for rat GFR $\alpha$ 1 with a FLAG<sup>®</sup> tag inserted by PCR mutagenesis at after the signal sequence. Cells were treated with 25 ng/mL of the indicated factor for 6 hours, the cells were washed once with cold PBS, lysed, and immunoprecipitated using an  
20 anti-FLAG<sup>®</sup> M2 monoclonal antibody conjugated to agarose (Sigma). After washing, the immunoprecipitated samples were visualized by immunoblotting with an anti-RET antibody (C-9; Santa Cruz). Both GDNF and PGP-F2ac induced comparable receptor complex formation, demonstrating that PGP-F2ac had gained the ability to bind and induce  
25 GFR $\alpha$ 1-RET complex formation (Figure 5C).

To determine if mutant PGP-F2ac was also able to elicit biological responses comparable to GDNF, its ability to induce proliferation in the NBL-S neuroblastoma cell line was determined. This cell line expresses GFR $\alpha$ 1 and RET and responds to GFR $\alpha$ 1-RET  
30 agonists (GDNF, neurturin, artemin) by proliferation. The NBL-S proliferation assay was performed as described in Baloh et al., 1998, *supra*. Mutant PGP-F2ac purified from transiently transfected COS cell conditioned medium induced robust proliferation of NBL-S cells, similar to GDNF at all doses, whereas persephin did not (Figure 5D).  
35 Furthermore, PGP-F2ac was also able to induce neurite outgrowth in the GFR $\alpha$ 1-RET expressing neuroblastoma line SH-SY5Y (as evaluated according to the method of Baloh et al., 1998, *supra*) similar to GDNF (Figure 5E).

Neurturin and artemin are also able to activate GFR $\alpha$ 1-RET (Baloh et al., 1998, *supra*; Creedon et al., *Proc. Natl. Acad. Sci. US* 94: 7018-7023, 1997), and therefore it was determined if the same regions (F2a and F2c) from these two additional GFR $\alpha$ 1 agonists are also sufficient to activate the GFR $\alpha$ 1-RET receptor (Figure 6). Interestingly, the corresponding persephin mutants with regions F2a and F2c from neurturin and artemin were also capable of activating the GFR $\alpha$ 1-RET receptor complex, at levels comparable to GDNF and PGP-F2ac (Figure 6B). This indicates that elements of regions F2a and F2c from all the known GFR $\alpha$ 1 agonists are sufficient to activate GFR $\alpha$ 1-RET when placed in the context of persephin. Furthermore, these regions appear to be sufficient only for GFR $\alpha$ 1-RET activation, as the same mutants did not activate GFR $\alpha$ 2-RET comparably to GDNF (Figure 6C). Mutants PNP-F2ac and PGP-F2ac did elicit low-level activation (less than 30% of GDNF) of GFR $\alpha$ 2-RET, whereas PAP-F2ac did not. This is consistent with the ability of GDNF and neurturin, but not artemin to activate GFR $\alpha$ 2-RET, and indicates that regions F2a and F2c are also involved in binding and activating GFR $\alpha$ 2-RET, but that additional regions are required for full activation.

The mutagenesis reported here indicates that critical residues for GFR $\alpha$  receptor interaction and specificity are located in the second finger region of the GDNF molecule. However, while the use of homologue-scanning mutagenesis is ideally suited for identifying sites involved in differential receptor specificity, it cannot delineate all residues involved in receptor binding, as some of these are identical in GDNF and persephin. The fact that residues from region F2a and F2c are sufficient when placed in the context of persephin to activate GFR $\alpha$ 1-RET indicates that residues in these regions are likely to be directly involved in binding to GFR $\alpha$ 's.

Although it is possible that the GDNF family ligands also contact RET in the active receptor complex, the fact that all members of the GDNF family ligands, including persephin, appear to signal through RET makes it doubtful that the regions identified by this mutagenesis scheme are involved in RET-interaction directly. However, because this analysis focused on functional activation of the GFR $\alpha$ -RET receptor complex rather than receptor binding assays, the possibility cannot be excluded that some of the non-functional mutants produced here may still be capable of binding to the GFR $\alpha$  coreceptors, and potentially even function as receptor antagonists.

Current evidence suggests that the stoichiometry of the active receptor complex for GDNF is  $(\text{GDNF})_1(\text{GFR}\alpha)_2(\text{RET})_2$  (Jing et al., *Cell* 85: 1113-1124, 1996). Residues from regions F2a and F2c project essentially from the bottom the GDNF structure, and form symmetric sites on both monomers of the molecule (see Figure 4B).

Interestingly, residues from region Ha (which is critical for GDNF-GFR $\alpha$ 2, and ARTN-GFR $\alpha$ 3 interaction) lie directly adjacent to regions F2a and F2c from the finger 2 region of the opposing monomer, and form continuous surfaces along the side and bottom of the molecule (see Figure 4C). Because these regions are all critical for GFR $\alpha$  specificity, it appears that the molecular surface formed by the heel of one monomer and the second finger of the adjacent monomer form GFR $\alpha$  binding surfaces on GDNF.

Comparison of structure/function studies from other TGF- $\beta$  and cystine-knot superfamily members reveals common themes in the location of receptor binding surfaces. The best characterized of these is the binding of vascular endothelial growth factor (VEGF) with its receptors KDR and Flt-1, where extensive mutagenesis and co-crystallization have been performed (Muller et al., *Proc. Natl. Acad. Sci. U.S.A.* 94: 7192-7197, 1997; Wiesmann et al., *Cell* 91: 695-704, 1997). Mutagenesis of VEGF identified a cluster of residues critical for KDR binding, several of which were along the adjacent  $\beta$ -strands of the second finger, similar to regions F2a and F2c identified here for GDNF. Furthermore, even though the orientation of the monomers in the VEGF dimer is different from GDNF, the receptor binding site on VEGF involves residues from finger 2 and the analogous heel region of the opposing monomer. Finally, mutagenesis of TGF- $\beta$  indicates that the binding affinity of the different TGF- $\beta$  isoforms for the TGF- $\beta$  type II receptor is also determined by residues along the second finger of the molecule, analogous in location to region F2c (Burmester et al., *Growth Factors* 15: 231-242, 1998; Qian et al., *J. Biol. Chem.* 271: 30656-30662, 1996). Therefore it is possible that although the receptor systems and dimerization modes are strikingly different for these different cystine-knot superfamily proteins, the location of their receptor interaction surfaces may be quite similar.

#### Example 4

This example illustrates that additional determinants are critical for neurturin to activate GFR $\alpha$ 2-RET and artemin to activate GFR $\alpha$ 3-RET.

The observation that mutants PGP-F2ac and PNP-F2ac cannot activate GFR $\alpha$ 2-RET is consistent with the homologue-scanning mutagenesis in Example 2 (Figure 4), which suggested that regions in addition to F2a and F2c are required for GDNF to activate GFR $\alpha$ 2-RET.

5 In particular, mutant PGP-Ha was significantly attenuated in its ability to activate GFR $\alpha$ 2-RET (~27%), whereas it showed a minor loss in the ability to activate GFR $\alpha$ 1-RET (~80%; Figure 4). To address whether region Ha contains additional molecular determinants required for activating GFR $\alpha$ 2-RET, a persephin mutant was generated with

10 regions F2a, F2c and Ha replaced by the corresponding regions from neurturin, the highest affinity GFR $\alpha$ 2 agonist (PNP-Ha/F2ac; Figure 7A). While mutant PNP-F2ac elicited only a minor increase in GFR $\alpha$ 2-RET activation as before, mutant PNP-Ha/F2ac was significantly better at activating GFR $\alpha$ 2-RET, however it did not restore full activity

15 (usually 70-80% of GDNF; Figure 7B). Therefore, consistent with the homologue-scanning mutagenesis above, these data indicate that regions F2a and F2c of GDNF and NRTN are only sufficient to activate GFR $\alpha$ 1-RET, and additional regions are required for full activation of GFR $\alpha$ 2-RET (region Ha and perhaps others).

20 Artemin is a recently identified member of the GDNF family ligands that can activate GFR $\alpha$ 1-RET, and the only member of the family that can activate GFR $\alpha$ 3-RET. As shown in example 3, regions F2a and F2c from artemin are sufficient to activate GFR $\alpha$ 1-RET. In an

25 initial attempt to characterize the molecular determinants of the artemin-GFR $\alpha$ 3 interaction, the ability of persephin-artemin chimeras to activate the GFR $\alpha$ 3-RET receptor complex was examined (Figure 7C and D). To this end, the chimera N-hf-ARTN was prepared by the fusion PCR mutagenesis procedure as in example 1, where residues 1-13 were truncated from mature human ARTN and attached to the pre-pro

30 region of NRTN, with the resulting sequence (N-...RRAR $\Delta$ PGA-HHHHHHDYKDDDDK-RGCR...-C). As expected, N-hf-ARTN gave robust activation of GFR $\alpha$ 3-RET, whereas N-hf-GDNF showed no activity. Mutant PAP-F2ac, which is capable of activating GFR $\alpha$ 1-RET (see Figure 6), was also unable to activate GFR $\alpha$ 3-RET, indicating that like the

35 neurturin-GFR $\alpha$ 2 interaction, the artemin-GFR $\alpha$ 3 interaction requires regions in addition to F2a and F2c. To determine if region Ha was also involved in the artemin-GFR $\alpha$ 3 interaction, a persephin mutant was generated with regions Ha, F2a and F2c from artemin (Figure 7C). Interestingly, whereas mutant PAP-F2ac was entirely inactive, mutant



PAP-Ha/F2ac regained significant activity (ca. 70-80% of full length artemin; Figure 7D). Therefore, similar to the neurturin-GFR $\alpha$ 2 interaction, the artemin-GFR $\alpha$ 3 interaction requires molecular determinants from both the heel and finger 2 regions of the molecule, whereas interaction of GDNF, neurturin or artemin with GFR $\alpha$ 1 only requires regions F2a and F2c from finger 2.

In this analysis, it was observed that regions F2a and F2c were minimal requirements for interaction with GFR $\alpha$ 1-RET, but that additional regions (including region Ha) were required for activating GFR $\alpha$ 2-RET. GFR $\alpha$ 1-RET is the most promiscuous of the GFL receptors, able to interact with three of the four known ligands. This is consistent with GFR $\alpha$ 1-RET having the most minimal requirements for being activated (regions F2a and F2c), and additional regions being required for activating GFR $\alpha$ 2-RET and GFR $\alpha$ 3-RET. Although region Ha is critical for the neurturin-GFR $\alpha$ 2 and artemin-GFR $\alpha$ 3 interactions, persephin mutants containing regions Ha, F2a and F2c were not fully active, suggesting either additional regions are necessary, or the binding determinants from neurturin and artemin are not presented properly in the context of the persephin molecule.

#### Example 5

This example illustrates that persephin chimeras which activate GFR $\alpha$ 1-RET function as GFR $\alpha$ 1-specific agonists *in vitro*.

The homologue-scanning mutagenesis and gain of function experiments in previous examples demonstrate that for the GFR $\alpha$ 1-RET agonists (GDNF, neurturin and artemin), regions F2a and F2c are sufficient for interaction with GFR $\alpha$ 1, but that additional regions are required for interaction with GFR $\alpha$ 2 and GFR $\alpha$ 3 (Figures 6 and 7). This suggests that the persephin mutants containing only regions F2a and F2c from GDNF, neurturin or artemin may function as GFR $\alpha$ 1-RET specific agonists.

To test the above idea, a cell survival assay using rat cerebellar granule cells in culture was developed. These cells do not express endogenous RET or GFR $\alpha$  coreceptors and can be transfected efficiently, therefore providing a model system of cell survival with defined receptor components. Rat cerebellar granule cell dissection and culture was performed as described previously Miller and Johnson, *J. Neurosci.* 16: 7487-7495, 1996. Timed-pregnant Sprague-Dawley rats were purchased from Harlan Sprague-Dawley (Indianapolis, IN). At postnatal day 7 (P7), cerebella were dissected, cut into 1 mm pieces,

and incubated for 15 min in 0.3 g/ml trypsin (Worthington, Freehold, NJ) at 37°C. The pieces were triturated with a fire-polished Pasteur pipette in the presence of trypsin and the resulting cell suspension was passed through a Nitex filter (size 3-20/14; Tetko, Elmsford, NY). Cells were plated at a density of  $2.3 \times 10^5$  cells/cm<sup>2</sup> in four-well dishes (Nunc) coated with 0.1 mg/ml poly-L-lysine. Plating medium (K25 +S) consisted of Basal Medium Eagle (Life Tech, Gaithersburg, MD) containing 10% dialyzed fetal bovine serum, 20 mM KCl, 100 U/ml penicillin and 100 ug/ml streptomycin. To reduce the number of non-neuronal cells, 3.3 µg/ml aphidocholine was added to the medium 24 hrs after plating.

Granule cell transfections were performed using a modified calcium phosphate protocol as described previously (Moulder et al., *J. Neurosci.* 19: 705-715, 1999). Expression plasmids for GFRα1, GFRα2 and RET are described elsewhere (Baloh et al., 1997, *supra*). At 5 days in vitro (DIV), medium was replaced with Dulbecco's Modified Eagle's Medium (Life Tech) for 1 hr. During this time, an equal volume of solution containing 0.25M CaCl and 67 µg/ml DNA was added to a 2XHEPES-buffered saline [274 mM NaCl, 10 mM KCl, 1.4 mM Na<sub>2</sub>HPO<sub>4</sub>-7H<sub>2</sub>O (Fisher Scientific, Houston, TX), 15 mM dextrose, and 42 mM HEPES (free acid), pH 7.07] and incubated in the dark at room temperature for 25 min. 30 µL of the precipitate (1 µg DNA) were added to each of a four-well dish and incubated at 37°C for 1 hr. Cells were washed twice with Dulbecco's Modified Eagle's Medium and then returned to plating medium. Transfection efficiency was approximately 0.2-0.5%.

To quantify transfection results, the number of initial EGFP-positive cells in a defined area (minimum of 150 cells) of two to four wells (of a four-well dish) per condition were counted 24 hrs after transfection, then rinsed the cultures twice in Dulbecco's Modified Eagle's Medium and switched them to high-potassium/serum (K25+S); low potassium/no serum (K5-S) medium alone; or K5-S supplemented with the indicated factors for 48 hrs. After this period, the number of EGFP-positive cells remaining in the originally defined area of the well was counted again to obtain the percentage neuronal survival.

Cerebellar granule cells transfected with RET or GFRα1 alone do not survive in the absence of high potassium or in the presence of GDNF, however cells cotransfected with GFRα1 and RET survive in the

presence of GDNF at levels comparable to the control condition of high potassium plus serum (Figure 8A; Miller and Johnson, *supra*). Consistent with other assays, cerebellar granule cells transfected with GFR $\alpha$ 1-RET or GFR $\alpha$ 2-RET survive in the presence of either GDNF or neurturin, but not persephin (Figure 8B). However, mutant PGP-F2ac was only capable of supporting the survival of GFR $\alpha$ 1-RET transfected, but not GFR $\alpha$ 2-RET transfected cells. This is consistent with its minimal ability to activate the GFR $\alpha$ 2-RET receptor in fibroblasts (Figure 6C), and indicates that unlike GDNF and neurturin, mutant PGP-F2ac functions as a GFR $\alpha$ 1-RET specific agonist in this in vitro cell survival paradigm.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification, including patents and patent applications, are hereby incorporated by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

#### Summary of SEQ ID NOS

##### SEQ ID NO:1 - Human Persephin - C1-C7

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRYTDVAF  
LDDRHRWQRLPQLSAAACGC

##### SEQ ID NO:2 - Mouse Persephin - C1-C7

CRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTSADVT  
LDDQHHWQQLPQLSAAACGC

##### SEQ ID NO:3 - Rat Persephin - C1-C7

CRLWSLTLPVAELGLGYASEEKIIFRYCAGSCPQEVRTQHSLVLARLRGQGRAHGRPCCQPTSADVT  
LDDHHHWQQLPQLSAAACGC

SEQ ID NO:4 - Human GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFDD  
DLSFLDDNLVYHILRKHS AKRCGC

5

SEQ ID NO:5 - Mouse GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCESAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFFD  
DLSFLDDNLVYHILRKHS AKRCGC

10

SEQ ID NO:6 - Rat GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETMYDKILKNLSRNRRLTSDKVGQACCRPVAFFD  
DLSFLDDSLVYHILRKHS AKRCGC

SEQ ID NO:7 - Human Neurturin - C1-C7

15

CGLRELEVRVSELGLGYASDETVLFRYCSGSCDAAETMYDKILKNLSRNRRLTSDKVGQACCRPVAFFD  
DEVSFLDAHSRYHTVHEL SARECAC

SEQ ID NO:8 - Mouse Neurturin - C1-C7

20

CGLRELEVRVSELGLGYTSDETVLFYCSGSCDAAETMYDKILKNLSRNRRLTSDKVGQACCRPVAFFD  
DEVSFLDVHSRYHTLQEL SARECAC

SEQ ID NO:9 - Human Artemin - C1-C7

25

CRLRSQLVFVRA LGLGHRSDLVFRFCSGSCRRARSPHDL SLASLLGAGALRPPPGSRPVSQPCCRPT  
RYEAVSFMDVNSTWRTVDRLS ATACGC

SEQ ID NO:10 - Mouse Artemin - C1-C7

CRLRSQLVFVSALGLGHSSDELIRFRFCSGSCRRARSQHDL SLASLLGAGALRSPPGSRPISQPCCRPT  
RYEAVSFMDVNSTWRTVDHLS ATACGC

30

SEQ ID NO:11 - His-Flag®-PGP-F2ac (from mouse persephin and rat GDNF): GDNF sequences are underlined

ALAHHHHHHDYKDDDDKGSCRLWSLTPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
GRAHGRPCCQPTAFDDDDVTFLDDQH<sup>HH</sup>YHILRKHSAAACGC

35

SEQ ID NO:12 - PGP-F2ac (from mouse persephin and rat GDNF) C1-C7: GDNF sequences are underlined

CRLWSLTPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTAFDDDDVT  
FLDDQH<sup>HH</sup>YHILRKHSAAACGC

SEQ ID NO:13 - His-Flag®-PNP-F2ac (from mouse sequences): Neurturin  
sequences are underlined

ALAHHHHHHDYKDDDDKGSCRLWSLTLPPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
GRAHGRPCCQPTAYEDEVTFLLDDQHHYHTLQELSAACGC

5

SEQ ID NO:14 - PNP-F2ac (from mouse sequences) C1-C7: Neurturin  
sequences are underlined

CRLWSLTLPPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTAYEDEVTF  
LLDDQHHYHTLQELSAACGC

10

SEQ ID NO:15 - His-Flag®-PAP-F2ac (from mouse sequences): Artemin  
sequences are underlined

ALAHHHHHHDYKDDDDKGSCRLWSLTLPPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
GRAHGRPCCQPTRYEAVTFLLDDQHHWRTVDHLSAACGC

15

SEQ ID NO:16 - PAP-F2ac (from mouse sequences) C1-C7: Artemin  
sequences are underlined

CRLWSLTLPPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTRYEAVTF  
LDDQHHWRTVDHLSAACGC

20

SEQ ID NO:17 - human GDNF F2a 5-mer

AFDDD

SEQ ID NO:18 - human neurturin F2a 5-mer

25

AYEDE

SEQ ID NO:19 - human artemin F2a 4-mer

RYEA

30

SEQ ID NO:20 - human GDNF F2c 7-mer

YHILRKH

SEQ ID NO:21 - human neurturin F2c 7-mer

YHTVHEL

35

SEQ ID NO:22 - human artemin F2c 7-mer

WRTVDRL

SEQ ID NO:23 - PGP-F2ac (from human sequences) C1-C7: GDNF sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAFDDDDVA  
FLDDRHRYHILRKHSAACGC

5

SEQ ID NO:24 - PNP-F2ac (from human sequences) C1-C7: Neurturin sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAYEDEVA  
FLDDRHRYHTVHELSAAACGC

10

SEQ ID NO:25 - PAP-F2ac (from human sequences) C1-C7: Artemin sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRYEAVAF  
LDDRHRWRTVDRLSAAACGC

15

SEQ ID NO:26 - full length PGP-F2ac (from human sequences): GDNF sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAF  
20 DDDVAFLDDRHRYHILRKHSAACGCGG

SEQ ID NO:27 - full length PNP-F2ac (from human sequences): Neurturin sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAY  
25 EDEVAFLDDRHRYHTVHELSAAACGCGG

SEQ ID NO:28 - full length PAP-F2ac (from human sequences): Artemin sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRY  
30 EAVAFLDDRHRWRTVDRLSAAACGCGG

What is claimed is:

1. A growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET.
2. The growth factor of claim 1, comprising a chimeric GDNF family ligand or a derivative thereof.
3. The growth factor of claim 2, comprising a persephin having substitutions in regions F2a and F2c wherein the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, or conservative amino acid  
5 substitutions therefor, and wherein the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor.
4. The growth factor of claim 3, wherein the substituted persephin comprises persephin as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 with substitutions in regions F2a and F2c independently selected from corresponding regions of SEQ ID NO:4, SEQ  
5 ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
5. The growth factor of claim 4, comprising SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.
6. The growth factor of claim 4, wherein the substituted persephin comprises a human persephin as set forth in SEQ ID NO:1 with substitutions for amino acid residues 63-66 selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, and  
5 substitutions for amino acid residues 76-82 selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.
7. The growth factor of claim 6, comprising SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25.
8. The growth factor of claim 6, consisting of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.
9. A composition comprising the growth factor of claim 1 in a pharmaceutically acceptable preparation.
10. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 1.
11. The nucleic acid of claim 10, wherein the encoded growth factor is a chimeric GDNF family ligand or a conservatively substituted derivative thereof.

12. The nucleic acid of claim 11, wherein the encoded growth factor comprises a persephin having substitutions in regions F2a and F2c wherein the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor, and wherein the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor.

13. The nucleic acid of claim 12, wherein the encoded substituted persephin comprises persephin as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 with substitutions in regions F2a and F2c independently selected from corresponding regions of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

14. The nucleic acid of claim 13, wherein the encoded growth factor comprises SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.

15. The nucleic acid of claim 13, wherein the encoded growth factor comprises a human persephin as set forth in SEQ ID NO: 1 with substitutions for amino acid residues 63-66 selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, and substitutions for amino acid residues 76-82 selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.

16. The nucleic acid of claim 15, wherein the encoded growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25.

17. The nucleic acid of claim 15, wherein the encoded growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

18. A vector comprising expression regulatory elements operably linked to the polynucleotide of claim 10.

19. A host cell comprising the vector of claim 18.

20. The host cell of claim 19 which is a bacterial cell, a yeast cell, a plant cell, an insect cell or a mammalian cell.

21. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the growth factor of claim 1 or a polynucleotide which encodes for expression of the growth factor.

22. The method of claim 21, wherein the treating step further comprises administering to the cell a GFR $\alpha$ 1 polypeptide.



23. The method of claim 21, wherein the cell is in a patient and the treating comprises administering the growth factor to the patient.

24. The method of claim 23, wherein the administering comprises implanting into the patient a cell which expresses the growth factor.

25. The method of claim 24, wherein the cell is a neuronal cell in a patient suffering from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal chord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, or the cell is a non-neuronal cell in a patient suffering from small cell lung carcinoma.

26. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 1 or a polynucleotide encodes for expression of the growth factor.

27. The method of claim 26 wherein the administering comprises implanting into the individual a cell which expresses the growth factor.

28. The method of claim 25 wherein the individual suffers from (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal chord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, (b) from small cell lung carcinoma, (c) from hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia, or stem-cell insufficiencies therefor, or (d) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

29. A growth factor which activates GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET but does not substantially activate GFR $\alpha$ 3-RET comprising a persephin having substitutions in regions Ha, F2a and F2c wherein:

5 (a) the substitutions in region Ha comprise from one to nine amino acids identical to region Ha of neurturin, or conservative amino acid substitutions therefor;

(b) the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of neurturin, or conservative amino acid substitutions therefor; and

10 (c) the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of neurturin.

30. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 29.

31. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the growth factor of claim 29 or a polynucleotide which encodes for  
5 expression of the growth factor.

32. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 29 or a polynucleotide which encodes for expression of the  
5 growth factor.

33. A growth factor which activates GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET but does not substantially activate GFR $\alpha$ 2-RET comprising a persephin having substitutions in regions Ha, F2a and F2c wherein:

5 (a) the substitutions in region Ha comprise from one to nine amino acids identical to region Ha of artemin, or conservative amino acid substitutions therefor;

(b) the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of artemin, or conservative amino acid substitutions therefor; and

10 (c) the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of artemin.

34. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 33.

35. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the

growth factor of claim 33 or a polynucleotide which encodes for  
5 expression of the growth factor.

36. A method for preventing or treating cellular degeneration  
or insufficiency in an individual comprising administering to the  
individual a therapeutically effective amount of the growth factor of  
claim 33 or a polynucleotide which encodes for expression of the  
5 growth factor.


**PCT/US00/34852**

**PCT/US00/34852**



**PCT/US00/34852**

**PCT/US00/34852**

**FIGURE 1**



**FIGURE 2**



### FIGURE 3




FIGURE 4







FIGURE 5





**FIGURE 6**



**FIGURE 8**

## SEQUENCE LISTING

<110> MILBRANDT, Jeffrey D.  
BALOH, Robert H.

<120> GFR-alpha-1-RET Specific Agonists and Methods Therefor

<130> 6029-6940

<140>

<141>

<150> 09/473,551

<151> 28 December 1999

<160> 28

&lt;170&gt; PatentIn Ver. 2.0

 $\langle 210 \rangle$  1

<211> 89

<212> PRT

<213> Homo sapiens

<400> 1

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
1 5 10 15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30

Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
35 40 45

Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr  
50 55 60

Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu Pro  
65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 2

<211> 89

&lt;212&gt; PRT

<213> Mouse

<400> 2

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
1 5 10 15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30

Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
35 40 45

Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
50 55 60

Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu Pro  
65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 3  
<211> 89  
<212> PRT  
<213> RAT

<400> 3  
Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
1 5 10 15  
Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30  
Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
35 40 45  
Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
50 55 60  
Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro  
65 70 75 80  
Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 4  
<211> 93  
<212> PRT  
<213> Homo sapiens

<400> 4  
Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
1 5 10 15  
Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
20 25 30  
Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
35 40 45  
Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
50 55 60  
Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
65 70 75 80  
His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
85 90

<210> 5  
<211> 93  
<212> PRT  
<213> Mouse

<400> 5  
Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
1 5 10 15  
Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
20 25 30

Glu Ser Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
                   35                  40                  45  
 Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
                   50                  55                  60  
 Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
                   65                  70                  75                  80  
 His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
                                   85                                  90

<210> 6  
 <211> 93  
 <212> PRT  
 <213> RAT

<400> 6  
 Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
           1                  5                  10                  15  
 Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
                   20                  25                  30  
 Glu Ala Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
                   35                  40                  45  
 Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
                   50                  55                  60  
 Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Ser Leu Val Tyr  
                   65                  70                  75                  80  
 His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
                                   85                                  90

<210> 7  
 <211> 94  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly  
           1                  5                  10                  15  
 Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
                   20                  25                  30  
 Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
                   35                  40                  45  
 Arg Arg Arg Leu Arg Arg Glu Arg Val Arg Ala Gln Pro Cys Cys Arg  
                   50                  55                  60  
 Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Ala His Ser Arg  
                   65                  70                  75                  80  
 Tyr His Thr Val His Glu Leu Ser Ala Arg Glu Cys Ala Cys  
                                   85                                  90

<210> 8  
 <211> 94  
 <212> PRT

&lt;213&gt; Mouse

&lt;400&gt; 8

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
 20 25 30  
 Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
 35 40 45  
 Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His Pro Cys Cys Arg  
 50 55 60  
 Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg  
 65 70 75 80  
 Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys  
 85 90

&lt;210&gt; 9

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly  
 1 5 10 15  
 His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys  
 20 25 30  
 Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly  
 35 40 45  
 Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro  
 50 55 60  
 Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn  
 65 70 75 80  
 Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys  
 85 90 95

&lt;210&gt; 10

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 10

Cys Arg Leu Arg Ser Gln Leu Val Pro Val Ser Ala Leu Gly Leu Gly  
 1 5 10 15  
 His Ser Ser Asp Glu Leu Ile Arg Phe Arg Phe Cys Ser Gly Ser Cys  
 20 25 30  
 Arg Arg Ala Arg Ser Gln His Asp Leu Ser Leu Ala Ser Leu Leu Gly  
 35 40 45

```

<400> 11
Ala Leu Ala His His His His His His Asp Tyr Lys Asp Asp Asp Asp
  1                    5                10              15

Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu
      20                25              30

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala
      35                40              45

Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala
      50                55              60

Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro
  65                70                75              80

Thr Ala Phe Asp Asp Asp Val Thr Phe Leu Asp Asp Gln His His Tyr
      85                90              95

His Ile Leu Arg Lys His Ser Ala Ala Ala Cys Gly Cys
      100                105

```

```

<400> 12
Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly
  1              5              10              15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys
      20              25              30

Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg
      35              40              45

Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ala Phe
      50              55              60

Asp Asp Asp Val Thr Phe Leu Asp Asp Gln His His Tyr His Ile Leu
  65              70              75              80

Arg Lys His Ser Ala Ala Ala Cys Gly Cys
      85              90

```



<210> 13  
 <211> 109  
 <212> PRT  
 <213> Mouse

<400> 13  
 Ala Leu Ala His His His His His His Asp Tyr Lys Asp Asp Asp Asp  
   1                  5                  10                  15  
 Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
                   20                  25                  30  
 Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
           35                  40                  45  
 Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
       50                  55                  60  
 Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
   65                  70                  75                  80  
 Thr Ala Tyr Glu Asp Glu Val Thr Phe Leu Asp Asp Gln His His Tyr  
                   85                  90                  95  
 His Thr Leu Gln Glu Leu Ser Ala Ala Ala Cys Gly Cys  
           100                  105

<210> 14  
 <211> 90  
 <212> PRT  
 <213> Mouse

<400> 14  
 Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
   1                  5                  10                  15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
           20                  25                  30  
 Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
       35                  40                  45  
 Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ala Tyr  
       50                  55                  60  
 Glu Asp Glu Val Thr Phe Leu Asp Asp Gln His His Tyr His Thr Leu  
   65                  70                  75                  80  
 Gln Glu Leu Ser Ala Ala Ala Cys Gly Cys  
           85                  90

<210> 15  
 <211> 108  
 <212> PRT  
 <213> Mouse

<400> 15  
 Ala Leu Ala His His His His His His Asp Tyr Lys Asp Asp Asp Asp  
   1                  5                  10                  15  
 Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
           20                  25                  30

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
                   35                                  40                                  45  
 Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
                   50                                  55                                  60  
 Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
                   65                                  70                                  75                                  80  
 Thr Arg Tyr Glu Ala Val Thr Phe Leu Asp Asp Gln His His Trp Arg  
                                   85                                  90                                  95  
 Thr Val Asp His Leu Ser Ala Ala Ala Cys Gly Cys  
                                   100                                  105

<210> 16  
 <211> 89  
 <212> PRT  
 <213> Mouse

<400> 16  
 Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
                   1                                  5                                  10                                  15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
                                   20                                  25                                  30  
 Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
                                   35                                  40                                  45  
 Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Arg Tyr  
                   50                                  55                                  60  
 Glu Ala Val Thr Phe Leu Asp Asp Gln His His Trp Arg Thr Val Asp  
                   65                                  70                                  75                                  80  
 His Leu Ser Ala Ala Ala Cys Gly Cys  
                                   85

<210> 17  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Ala Phe Asp Asp Asp  
                   1                                  5

<210> 18  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Ala Tyr Glu Asp Glu  
                   1                                  5

<210> 19  
 <211> 4  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 19

Arg Tyr Glu Ala

1

&lt;210&gt; 20

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

Tyr His Ile Leu Arg Lys His

1

5

&lt;210&gt; 21

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

Tyr His Thr Val His Glu Leu

1

5

&lt;210&gt; 22

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

Trp Arg Thr Val Asp Arg Leu

1

5

&lt;210&gt; 23

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly

1

5

10

15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys

20

25

30

Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln

35

40

45

Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Ala Phe

50

55

60

Asp Asp Asp Val Ala Phe Leu Asp Asp Arg His Arg Tyr His Ile Leu

65

70

75

80

Arg Lys His Ser Ala Ala Ala Cys Gly Cys

85

90

&lt;210&gt; 24

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Ala Tyr  
 50 55 60  
 Glu Asp Glu Val Ala Phe Leu Asp Asp Arg His Arg Tyr His Thr Val  
 65 70 75 80  
 His Glu Leu Ser Ala Ala Ala Cys Gly Cys  
 85 90

<210> 25  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<400> 25  
 Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr  
 50 55 60  
 Glu Ala Val Ala Phe Leu Asp Asp Arg His Arg Trp Arg Thr Val Asp  
 65 70 75 80  
 Arg Leu Ser Ala Ala Ala Cys Gly Cys  
 85

<210> 26  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
 1 5 10 15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
 20 25 30  
 Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
 35 40 45  
 Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
 50 55 60  
 Arg Pro Thr Ala Phe Asp Asp Asp Val Ala Phe Leu Asp Asp Arg His  
 65 70 75 80

Arg Tyr His Ile Leu Arg Lys His Ser Ala Ala Ala Cys Gly Cys Gly  
85 90 95

Gly

<210> 27

<211> 97

<212> PRT

<213> Homo sapiens

<400> 27

Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
1 5 10 15

Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
20 25 30

Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
35 40 45

Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
50 55 60

Arg Pro Thr Ala Tyr Glu Asp Glu Val Ala Phe Leu Asp Asp Arg His  
65 70 75 80

Arg Tyr His Thr Val His Glu Leu Ser Ala Ala Ala Cys Gly Cys Gly  
85 90 95

Gly

<210> 28

<211> 96

&lt;212&gt; PRT

<213> Homo sapiens

<400> 28

Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
1 5 10 15

Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
20 25 30

Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
35 40 45

Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
50 55 60

Arg Pro Thr Arg Tyr Glu Ala Val Ala Phe Leu Asp Asp Arg His Arg  
65 70 75 80

Trp Arg Thr Val Asp Arg Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
85 90 95

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/047946 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 5/10, A61K 38/18, C07K 14/475
- (74) Agents: GENDLOFF, Elie, H. et al.; Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105-1817 (US).
- (21) International Application Number: PCT/US00/34852
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date:  
21 December 2000 (21.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (30) Priority Data:  
09/473,551 28 December 1999 (28.12.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/473,551 (CON)  
Filed on 28 December 1999 (28.12.1999)
- Published:  
— with international search report
- (71) Applicant (*for all designated States except US*): WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).
- (88) Date of publication of the international search report:  
6 February 2003
- (72) Inventors; and
- (15) Information about Correction:  
Previous Correction:  
see PCT Gazette No. 21/2002 of 23 May 2002, Section II
- (75) Inventors/Applicants (*for US only*): MILBRANDT, Jeffrey, D. [US/US]; 75 Aberdeen Place, St. Louis, MO 63105 (US). BALOH, Robert, H. [US/US]; 964 Tuxedo Boulevard, St. Louis, MO 63119 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GFR $\alpha$ 1-RET SPECIFIC AGONISTS AND METHODS THEREFOR

(57) Abstract: Chimeric GDNF family ligands which activate a GFR $\alpha$ /RET are disclosed. Included are chimeras which activate GFR $\alpha$ 1/RET but do not activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The chimeras are useful in providing trophic support to a mammalian cell or in producing differentiation of a mammalian cell, or both, particularly when the cell is in a patient suffering from various diseases, in particular Parkinson's Disease.



WO 01/047946 A3

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/34852**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :C12N 5/10; A61K 38/18; C07K 14/475

US CL :435/325; 514/12; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325; 514/12; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
~~searched~~  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- A	WO 97/33911 A1 (WASHINGTON UNIVERSITY) 18 September 1997, abstract, pages 6, 49-54, and 57-59.	1-2, 9, 21-28 ----- 5

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 SEPTEMBER 2002

Date of mailing of the international search report

05 NOV 2002

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

STEPHEN GUCKER

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/34852

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 3-4 and 6-8  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
multiple sequences and/or non-contiguous segments of multiple sequences that comprise a separate sequence are not searched by the USPTO.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-2, 5 (SEQ ID NO:11), 9 and 21-28

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/34852

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

USPATFULL, MEDLINE, BIOSIS, SCISEARCH, EMBASE, CAPLUS, LIFESCI, CONFSCI

search terms: persephin, neurturin, artemin, GDNF, RET

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-9 and 21-28, drawn to growth factors and method of treatment using growth factors.

Group II, claims 10-20, drawn to encoding nucleic acids, vectors, and host cells for growth factors.

Group III, claim 29, drawn to a growth factor different from the growth factor of Group I.

Group IV, claim 30, drawn to an encoding nucleic acid for a growth factor different from the growth factor of Group I.

Group V, claims 31-32, drawn to a method of treatment using growth factors different from the growth factor of Group I.

Group VI, claim 33, drawn to a growth factor different from the growth factors of Group I or Group III.

Group VII, claim 34, drawn to an encoding nucleic acid for a growth factor different from the growth factors of Group I or Group III.

Group VIII, claims 35-36, drawn to a method of treatment using growth factors different from the growth factors of Group I or Group III.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is a growth factor which activates GFR alpha1-RET, but does not activate GFR alpha2-RET or GFR alpha3-RET. This special technical feature is not shared by the other growth factors of Group III or Group VI or the methods of using such other growth factors (Group V and Group VIII, respectively). Additionally, the growth factors of Group I are polypeptides and do not share any special technical features with the nucleic acids of Group II or Group IV or Group VII.

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/47946 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K**
- (21) International Application Number: PCT/US00/34852
- (22) International Filing Date:  
21 December 2000 (21.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/473,551 28 December 1999 (28.12.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/473,551 (CON)  
Filed on 28 December 1999 (28.12.1999)
- (71) Applicant (for all designated States except US): **WASHINGTON UNIVERSITY** [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **MILBRANDT, Jeffrey, D.** [US/US]; 75 Aberdeen Place, St. Louis, MO 63105 (US). **BALOH, Robert, H.** [US/US]; 964 Tuxedo Boulevard, St. Louis, MO 63119 (US).
- (74) Agents: **GENDLOFF, Elie, H.** et al.; Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105-1817 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- (48) Date of publication of this corrected version:  
23 May 2002
- (15) Information about Correction:  
see PCT Gazette No. 21/2002 of 23 May 2002, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GFR $\alpha$ 1-RET SPECIFIC AGONISTS AND METHODS THEREFOR

(57) Abstract: Chimeric GDNF family ligands which activate a GFR $\alpha$ /RET are disclosed. Included are chimeras which activate GFR $\alpha$ 1/RET but do not activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The chimeras are useful in providing trophic support to a mammalian cell or in producing differentiation of a mammalian cell, or both, particularly when the cell is in a patient suffering from various diseases, in particular Parkinson's Disease.

WO 01/47946 A2

GFR $\alpha$ 1-RET SPECIFIC AGONISTS AND METHODS THEREFORBackground of the Invention

This invention was made with Government support under National Institutes of Health/ National Institute on Aging Grant No. 5R01-AG13730. The Government has certain rights in the invention.

## 5 (1) Field of the Invention

This invention relates generally to trophic or growth factors and, more particularly, to chimeric GDNF family growth factors which activate GFR $\alpha$ 1-RET but do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, growth factors derived therefrom and methods therefor.

## 10 (2) Description of the Related Art

The development and maintenance of tissues in complex organisms requires precise control over the processes of cell proliferation, differentiation, survival and function. A major mechanism whereby these processes are controlled is through the actions of polypeptides known as "growth factors". These structurally diverse molecules act through specific cell surface receptors to produce these actions.

Growth factors termed "neurotrophic factors" promote differentiation, maintain a mature phenotype and provide trophic support, promoting growth, function and survival of neurons. Neurotrophic factors reside in the nervous system or in innervated tissues. Nerve growth factor (NGF) was the first neurotrophic factor to be identified and characterized (Levi-Montalcini et al., *J. Exp. Zool.* 116: 321, 1951). NGF exists as a non-covalently bound homodimer that promotes the survival and growth of sympathetic,

neural crest-derived sensory, and basal forebrain cholinergic neurons. Other effects of NGF, including effects on non-neuronal cells of the endocrine and immune systems (including inflammatory cells) are disclosed in, e.g., Levi-Montalcini and Booker, *Proc Nat'l Acad Sci* 46: 384-391, 1960; Johnson et al. *Science* 210: 916-918, 1980; Crowley et al., *Cell* 76: 1001-12, 1994; Snider and Johnson, *Ann Neurol* 26: 489-506, 1989; Hefti, *J Neurobiol* 25: 1418-35, 1994; Scully and Otten, *Cell Biol Int* 19: 459-469, 1995; Otten and Gadiant, *Int. J. Devl Neurosci* 13: 147-151, 1995; and Horigome et al. *J Biol Chem* 269: 2695-2707, 1994.

In recent years it has become apparent that growth factors fall into classes, i.e. families or superfamilies based upon the similarities in their amino acid sequences. These families include, for example, the fibroblast growth factor family, the neurotrophin family and the transforming growth factor-beta (TGF- $\beta$ ) family. As an example of family member sequence similarities, TGF- $\beta$  family members have 7 canonical framework cysteine residues which identify members of this superfamily.

The NGF family is the prototype of such a family of growth factors. Brain-derived neurotrophic factor, the second member of this family to be discovered, was shown to be related to NGF by virtue of the conservation of all six cysteines that form the three internal disulfides of the NGF monomer (Barde, *Prog Growth Factor Res* 2: 237-248, 1990 and Liebrock et al. *Nature* 341: 149-152, 1989). By utilizing the information provided by brain-derived neurotrophic factor of the highly conserved portions of two factors, additional members (NT-3, NT-4/5) of this neurotrophin family were rapidly found by several groups (Klein, *FASEB J* 8: 738-44, 1994).

Recently, a new family of neurotrophic factors has been identified whose members are not structurally related to NGF and other neurotrophins but are structurally similar to TGF- $\beta$ . As described in U.S. Patent No. 5,739,307, and U.S. patent applications 08/931,858 and 09/220,531, the known members of this subfamily of the TGF- $\beta$  superfamily include glial cell line-derived neurotrophic factor (GDNF), neurturin, persephin, and artemin. The placement of GDNF, neurturin, persephin, and artemin into the same growth factor family, also referred to as the GDNF ligand family, is based on the similarities of their physical structures and biological activities. For example, human persephin has about 40% sequence identity and

about 43% sequence conservation with human GDNF; about 49% sequence identity and about 50% sequence conservation with human neurturin; and about 45% sequence identity and about 48% sequence conservation with human artemin. In addition, these four proteins have the seven  
5 cysteine residues typical of TGF- $\beta$  family members.

The GDNF family ligands support the survival of dopaminergic ventral midbrain neurons cultured from the embryo. Additionally, GDNF, neurturin, and persephin support the survival of spinal and facial motor neurons in both *in vitro* survival and *in vivo* injury  
10 paradigms, identifying these ligands as potential therapeutic agents in the treatment of neurodegenerative diseases (Henderson et al., *Science* 266: 1062-1064, 1994; Horger et al., *J Neurosci.* 18: 4929-37, 1998; Klein et al., *Nature* 387: 717-721, 1997; Lin et al., *Science* 260: 1130-1132, 1993; Milbrandt et al., *Neuron* 20: 245-53, 1998;  
15 Oppenheim et al., *Nature* 373: 344-346, 1995), reviewed by Grondin and Gash, *J Neurol.* 245(11 Suppl 3): 35-42, 1998). However, whereas GDNF and neurturin both support the survival of peripheral sympathetic, parasympathetic, sensory, and enteric neurons (Buj-Bello et al., *Neuron* 15: 821-828, 1995; Ebendal et al., *J Neurosci Res* 40: 276-284,  
20 1995; Heuckeroth et al., *Dev Biol* 200: 116-29, 1998; Kotzbauer et al., *Nature* 384: 467-470, 1996; Trupp et al., *J of Cell Biology* 130: 137-148, 1995), persephin does not support survival in any peripheral neurons tested to date (Milbrandt et al. *supra*).

The GDNF family ligands share receptors and signal transduction  
25 pathways (Creedon et al., *Proc. Natl. Acad. Sci. USA* 94: 7018-7023, 1997; Durbec et al., *Nature* 381: 789-793, 1996; Trupp et al., *Nature* 381: 785-789, 1996; Baloh et al., *Neuron* 18: 793-802, 1997). These proteins act through a multicomponent receptor complex in which a transmembrane signal transducing component, the Ret protein-tyrosine  
30 kinase (RET), is activated upon the binding of a growth factor of the GDNF family with a member of a family of closely related co-receptors named GFR $\alpha$ . A characteristic feature of the GFR $\alpha$  co-receptor family is that its members have no transmembrane domain and are attached to the cell surface via a glycosyl-phosphatidylinositol (GPI) linkage  
35 (Durbec et al., *Nature* 381: 789-793, 1996; Jing et al., *Cell* 85: 1113-1124, 1996; Treanor et al., *Nature* 382: 80-83, 1996; Trupp et al., *Nature* 381: 785-789, 1996; Baloh et al., 1997, *supra*). The members of the GFR $\alpha$  family include GFR $\alpha$ 1 (previously known as GDNFR $\alpha$ , TrnR1 and RetL1), GFR $\alpha$ 2 (previously TrnR2, NTN $\alpha$  and RetL2), GFR $\alpha$ 3

(previously TrnR3) (GFR $\alpha$  Nomenclature Committee, *Neuron* 19: 485, 1997) and possibly GFR $\alpha$ 4, a receptor currently only identified in the chicken (cGFR $\alpha$ 4) (Enokido et al., *Current Biology* 8: 1019-1022, 1998).

5           Results from extensive *in vitro* and *in vivo* experimentation has established that for each GDNF family ligand there is a preferred GFR $\alpha$  receptor, to which the GDNF family ligand binds with highest affinity and most potently activates RET. These preferred interactions are GDNF-GFR $\alpha$ 1, neurturin-GFR $\alpha$ 2, and artemin-GFR $\alpha$ 3  
10 (Baloh et al., 1997, *supra*; Baloh et al., *Proc. Natl. Acad. Sci., USA* 95: 5801-5806, 1998; Jing et al., 1996, *supra*; Jing et al., *J Biol. Chem.* 272: 33111-33117, 1997; Klein et al., *Nature* 387: 717-721, 1997; Treanor et al., 1996, *supra*). Persephin does not bind or activate any of the known mammalian GFR $\alpha$ 's but does bind to chicken GFR $\alpha$ 4  
15 (Milbrandt et al., *supra*; Baloh et al., 1998, *supra*, Enokido et al. *supra*). However, despite these preferred interactions, there is also clear cross-talk between the different ligand-receptor pairs. The known alternative interactions are neurturin-GFR $\alpha$ 1, artemin-GFR $\alpha$ 1, and GDNF-GFR $\alpha$ 2 (Baloh et al., 1998, *supra*; Sanicola et al., *Proc. Natl. Acad. Sci., USA* 94: 6238-6243, 1997; Suvanto et al., *Hum. Molec. Genet.* 6: 1267-1273, 1997). Thus, there is no known naturally occurring GFR $\alpha$ 1-RET activating GDNF family ligand which does not also activate another GFR $\alpha$ -RET complex.

          Some information is available about the roles of each GFR $\alpha$   
25 receptor. Recent analysis of GFR $\alpha$ 1-deficient mice indicated that GFR $\alpha$ 1 is the only physiologically critical GDNF receptor in kidney organogenesis and enteric nervous system development (Cacalano et al., *Neuron* 21: 53-62, 1998; Enomoto et al., *Neuron* 21: 317-324, 1998). However, GDNF-deficient mice have greater losses in peripheral  
30 ganglia than GFR $\alpha$ 1-deficient mice, suggesting that GDNF can utilize other receptors to support survival of peripheral neurons, likely GFR $\alpha$ 2-RET (Cacalano et al., *supra*; Enomoto et al., *supra*). Nevertheless, several lines of evidence argue that the effects of GDNF, neurturin and artemin on dopaminergic ventral midbrain neurons  
35 are mediated through the GFR $\alpha$ 1-RET receptor system. First, since GFR $\alpha$ 3 is not expressed in the ventral midbrain, and artemin cannot utilize GFR $\alpha$ 2, survival promotion of these neurons by artemin is likely through its ability to activate GFR $\alpha$ 1-RET (Baloh et al.,

*supra*). Second, GFR $\alpha$ 2 expression is diffuse and weak in the pars compacta region of the substantia nigra, and does not colocalize with tyrosine hydroxylase staining (TH) neurons, in contrast to the significantly stronger expression of GFR $\alpha$ 1, which does colocalize with TH staining neurons (Horger et al., *J. Neurosci.* 18: 4929-4937, 1998). Finally, the ability of both GDNF and neurturin to support the survival of dopaminergic ventral midbrain neurons is lost in GFR $\alpha$ 1 knockout mice, indicating that at least in the embryo the survival promotion of dopaminergic ventral midbrain neurons is only through GFR $\alpha$ 1-RET signaling (Cacalano et al., 1998).

While the *in vitro* interactions between the different GDNF family ligands and GFR $\alpha$ 's is now relatively well understood, the molecular basis of this specificity and cross-talk has been heretofore unknown. The crystal structure of GDNF reveals that it is a disulfide-bonded dimer that is significantly similar to the structure of TGF- $\beta$ 2, as predicted by the cysteine spacing of its primary sequence (Daopin et al., *Science* 257: 369-373, 1992; Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997; Schlungger and Grutter, *Nature* 358: 430-434, 1992). However, the structure itself yields only speculative information regarding receptor-binding surfaces. Furthermore, analogy to other TGF- $\beta$  superfamily members regarding receptor-binding surfaces would likely be unfounded as the receptors used by GDNF and the TGF- $\beta$ 's are drastically different and likely to have little, if any, structural similarity.

It is now generally believed that neurotrophic factors regulate many aspects of neuronal function, including survival and development in fetal life, and structural integrity, function and plasticity in adulthood. Since both acute nervous system injuries as well as chronic neurodegenerative diseases are characterized by structural damage and, possibly, by disease-induced apoptosis, it is likely that neurotrophic factors play some role in these afflictions. Indeed, a considerable body of evidence suggests that neurotrophic factors may be valuable therapeutic agents for treatment of these neurodegenerative conditions, which are perhaps the most socially and economically destructive diseases now afflicting our society. For example, GDNF has been shown to relieve disease symptoms in several animal models of Parkinson's disease (reviewed by Grondin and Gash, *supra*). Nevertheless, because there is clear cross-talk between the different ligands and receptors, it would be desirable to have growth

factors of the GDNF family which are selective for particular receptors. In particular, because there are several central and peripheral sites of GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET expression which could lead to side effects as a result of treatment of central nervous system injury or neurodegenerative diseases with GDNF, neurturin or artemin, there is a need for GDNF family ligand members which are more specific in activating GFR $\alpha$ 1-RET. The identification of a GDNF family ligand which only activates GFR $\alpha$ 1-RET, would also lead to a further elucidation of the relative roles of each GFR $\alpha$  receptor.

#### 10 Summary of the Invention

Accordingly, the inventors have succeeded in discovering that certain growth factors can be constructed which activate GFR $\alpha$ 1-RET but which do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Reference to the term "substantially" is intended to mean that the growth factor is selective for GFR $\alpha$ 1-RET and does not activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET to an extent greater than that of persephin, which is considered to be ineffective in binding to or activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, and/or preferably, no more than 50%, more preferably, no more than 40%, still more preferably, no more than 30% and, most preferably, no more than 20% as effective as GDNF in activating GFR $\alpha$ 2-RET or artemin in activating GFR $\alpha$ 3-RET.

Thus, in one embodiment, the present invention is directed to growth factors which activate GFR $\alpha$ 1-RET but do not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Such growth factors can be chimeric GDNF family ligands or derivatives thereof. The derivatives can be peptidyl derivatives or non-peptidyl derivatives. Preferred peptidyl derivatives are GDNF family growth factors having conservative amino acid substitutions. In certain aspects of this embodiment, the growth factor can be based upon persephin which does not act upon GFR $\alpha$ 1-RET. The chimeric growth factor, thus, preferably comprises a substituted persephin having different amino acids in the F2a and/or F2c regions than those in a naturally occurring persephin. F2 represents the finger 2 stretch of amino acids as determined for GDNF (Eigenbrot and Gerber, 1997, *supra*) and the F2a and F2c regions are portions of finger 2 as shown in Figure 1.

The F2a region of the substituted persephin preferably comprises from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, i.e. from one to eight amino acids can be the same and in the same position in the F2a region of the



substituted persephin as in the F2a region of GDNF, neurturin or artemin. Alternatively, the amino acid in a particular position in the F2a region of the substituted persephin can be a conservative amino acid substitution for the amino acid in that position in the F2a region of GDNF, neurturin or artemin. Persephin lacks an amino acid between position 71 and 72 which is present in the aligned F2a regions of GDNF and neurturin and, hence, reference to amino acid substitutions in the F2a region of persephin is intended to include an insertion between positions 71 and 72 with an amino acid in that aligned position from GDNF, neurturin or artemin or a conservative amino acid substitution therefor.

Additionally, the F2c region of the substituted persephin of this embodiment preferably comprises from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, i.e. from one to eight amino acids can be the same and in the same position in the F2c region of the substituted persephin as in the F2c region of GDNF, neurturin or artemin. Alternatively, the amino acid in a particular position in the F2c region of the substituted persephin can be a conservative amino acid substitution for the amino acid in that position in the F2c region of GDNF, neurturin or artemin.

Preferably, the growth factor of the present invention comprises a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having substitutions in the F2a and/or F2c regions. The persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted persephin sequences have amino acids substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), mouse artemin (SEQ ID NO:10). Preferably, the growth factor of the present invention comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or human artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

The present invention also includes compositions comprising a pharmaceutically acceptable preparation of the GFR $\alpha$ 1-RET selective growth factors of the present invention.

In another embodiment, the present invention is directed to a  
5 nucleic acid comprising a polynucleotide encoding a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The encoded growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The encoded chimeric growth factor, preferably, comprises a  
10 persephin having the F2a and/or F2c region substituted with from one to eight amino acids identical to and in the same position as the amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the encoded F2a region or F2c region amino acid substitutions can comprise a conservative amino  
15 acid substitution for the amino acid in that position in the F2a region or F2c region of GDNF, neurturin or artemin. Preferably, the encoded, substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions.  
20 The encoded persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the encoded chimeric persephin sequences have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF  
25 (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the encoded sequence comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding sequences of human GDNF,  
30 human neurturin or human artemin. More preferably, the encoded sequence comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred encoded growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

In another embodiment, the present invention comprises a vector  
35 which comprises expression regulatory elements operably linked to a polynucleotide which encodes a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET and which is, preferably, a chimeric GDNF family ligand. The present

invention also encompasses a host cell which is transformed with the vector.

In an additional embodiment, the present invention provides chimeric GDNF family ligands with an altered N-terminus. The N-terminus can be eliminated, truncated, or substituted with the N-terminus of another GDNF family member or another protein such as a member of another TGF- $\beta$  superfamily member. These chimeras retain the GFR $\alpha$ -RET activating ability of the GDNF family ligand.

The growth factors of the present invention can be used to provide trophic support or produce differentiation in a mammalian cell. Thus, in another embodiment, the present invention comprises a method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or both. The method comprises treating the cell with an effective amount of a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The chimeric growth factor, preferably, comprises a persephin having the F2a region and/or F2c region substituted with from one to eight amino acids identical to and in the same position as that amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the F2a region or F2c region amino acid substitutions can comprise a conservative amino acid substitution for the amino acid in that position in the F2a region or F2c region of a GDNF, neurturin or artemin. Preferably, the substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions. The persephin sequence can also include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted or chimeric persephin sequences preferably have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the growth factor of the present invention comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or

human artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28. The mammalian cell can be any cell which contains GFR $\alpha$ 1-RET, preferably,  
5 a neuronal cell, a hematopoietic cell or a cardiac muscle cell. The treatment can further comprise administering to the cell a GFR $\alpha$ 1 polypeptide.

In a variation of this embodiment, the cell can be treated with a nucleic acid comprising a polynucleotide which encodes for  
10 expression, a growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The encoded growth factor is preferably a chimeric GDNF family ligand or a conservatively substituted derivative thereof. In addition the cell can also be treated with a GFR $\alpha$ 1 polypeptide or a polynucleotide  
15 encoding a GFR $\alpha$ 1 polypeptide.

In one aspect of this embodiment, the cell can be in an patient and the treatment comprises administering the growth factor to the patient. The method also encompasses administering a polynucleotide encoding the growth factor to the patient or implanting into the  
20 patient a cell which expresses the growth factor. The cell can be a neuronal cell in a patient suffering from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, a nervous system tumor such  
25 as neuroblastoma, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers. The cell can also be a non-neuronal cell such as, for example, in a patient suffering from small  
30 cell lung carcinoma. The cell can also be a hematopoietic cell in a patient suffering from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemia, thrombocytopenia, or stem-cell insufficiency or a cardiac muscle cell in a patient suffering from cardiomyopathy or congestive heart failure.

35 In another embodiment, the present invention comprises a method for preventing or treating cellular degeneration or insufficiency in an individual. The method comprises administering to the individual a therapeutically effective amount of a growth factor which activates

GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. The growth factor is preferably, a chimeric GDNF family ligand or a conservatively substituted derivative thereof. The chimeric growth factor, preferably, comprises a persephin having the F2a region  
5 and/or F2c regions independently substituted with from one to eight amino acids identical to and in the same position as that amino acid in the F2a region or F2c region, respectively, of GDNF, neurturin or artemin. Alternatively, the F2a region or F2c region amino acid substitutions can comprise a conservative amino acid substitution for  
10 the amino acid in that position in the F2a region or F2c region of GDNF, neurturin or artemin. Preferably, the substituted persephin is a substituted human persephin (SEQ ID NO:1), mouse persephin (SEQ ID NO:2) or rat persephin (SEQ ID NO:3) having amino acid substitutions in the F2a and/or F2c regions. The persephin sequence can also  
15 include variations of these persephin sequences, having conservative amino acid substitutions outside of the F2a and F2c regions. The F2a and F2c regions in the substituted or chimeric persephin sequences preferably have amino acid substitutions from the F2a and F2c regions of human GDNF (SEQ ID NO:4), mouse GDNF (SEQ ID NO:5), rat GDNF (SEQ  
20 ID NO:6), human neurturin (SEQ ID NO:7), mouse neurturin (SEQ ID NO:8), human artemin (SEQ ID NO:9), or mouse artemin (SEQ ID NO:10). Preferably, the growth factor comprises a substituted human persephin having F2a and F2c region substitutions independently selected from corresponding regions of human GDNF, human neurturin or human  
25 artemin. More preferably, the growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25; the most preferred growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28. The mammalian cell can be any cell which contains GFR $\alpha$ 1-RET, preferably, a neuronal cell, a hematopoietic cell or a cardiac muscle cell. The  
30 treatment can further comprise administering to the individual a GFR $\alpha$ 1 polypeptide.

In a variation of this method, a polynucleotide encoding the growth factor can be administered to the individual. Moreover, a cell which expresses the growth factor can be implanted into the  
35 individual. In addition, the treatment with the growth factor can be facilitated by also administering to the individual a GFR $\alpha$ 1 polypeptide or a polynucleotide encoding a GFR $\alpha$ 1 polypeptide or a cell which expresses a GFR $\alpha$ 1 polypeptide can be implanted into the individual.

The growth factor or polynucleotide encoding the growth factor can be administered to an individual suffering from (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, chemotherapy side effects, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, (b) from small cell lung carcinoma, (c) from hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemia, thrombocytopenia, or stem-cell insufficiencies therefor, or (d) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

In an additional embodiment, mimics of neurturin are provided which activate GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET but do not substantially activate GFR $\alpha$ 3-RET. These mimics comprise persephin having amino acid substitutions in regions Ha, F2a and F2c from neurturin, or conservative amino acid substitutions therefor. Nucleic acids comprising polynucleotides encoding these mimics are also provided. These mimics can substitute for neurturin, for example in methods for providing trophic support to a mammalian cell or producing differentiation of a mammalian cell, or in methods for preventing or treating cellular degeneration or insufficiency in an individual. Similarly, mimics of artemin are also provided which activate GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET but do not substantially activate GFR $\alpha$ 2-RET. These mimics comprise persephin having amino acid substitutions in regions Ha, F2a and F2c from artemin, or conservative amino acid substitutions therefor. Nucleic acids comprising polynucleotides encoding these mimics are also provided. These mimics can substitute for artemin, for example in methods for providing trophic support to a mammalian cell or producing differentiation of a mammalian cell, or in methods for preventing or treating cellular degeneration or insufficiency in an individual.

Among the several advantages achieved by the present invention, therefore, may be noted the provision of chimeric GDNF family ligands, which can be used to prevent the atrophy, degeneration or death of certain cells, in particular, neurons in need of trophic

support; the provision of polynucleotides encoding chimeric GDNF family ligands for use in gene therapy; the provision of methods for obtaining chimeric GDNF family ligands by recombinant techniques; the provision of methods for providing trophic support to target cells, particularly neurons; and the provision of methods for treating disease conditions involving cellular degeneration, and in particular, neuronal dysfunction and degeneration.

#### Brief Description of the Drawings

Figure 1 illustrates the amino acid sequence alignment of rat GDNF (comprising SEQ ID NO:6); mouse neurturin (comprising SEQ ID NO:8); mouse artemin (comprising SEQ ID NO:10); and mouse persephin (comprising SEQ ID NO:2), where the sequences include the region N-terminal to the first canonical cysteine and C-terminal to the seventh canonical cysteine, where the canonical cysteines are indicated by a thick outline, and where secondary structure elements (' $\alpha$ ' for  $\alpha$ -helix, ' $\beta$ ' for  $\beta$ -strand and '3' for  $3_{10}$ -helix) as determined for GDNF (Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997) are indicated above the alignment and the regions delineated for homologue-scanning mutagenesis are in gray blocks, with the name of the region (Fla-Flb for finger 1, Ha-Hd for heel, F2a-F2d for finger 2) is below the given region;

Figure 2A depicts a schematic diagram of wild-type and tagged GDNF constructs, where the site of proprotein convertase cleavage of GDNF is indicated by the arrow (SS - signal sequence, PRO - pro domain, MATURE - mature processed monomer), where GDNF with a 6-histidine and FLAG<sup>®</sup> tag inserted two residues after the RXXR cleavage site is designated "G-hf-GDNF" and where GDNF with the histidine and FLAG<sup>®</sup> tag wherein the GDNF pro sequence is substituted with the neurturin pro sequence is designated "N-hf-GDNF";

Figure 2B is an image of a FLAG<sup>®</sup> immunoblot demonstrating the production of tagged GDNF proteins in COS cells, where the immunoblot indicates that N-hf-GDNF produces GDNF with the 40 amino acid N-terminal extension replaced by two amino acids and the tandem His-FLAG tags;

Figure 2C is a graph showing the ability of tagged full-length and truncated GDNF to activate the GFR $\alpha$ 1-RET receptor and the inability of tagged persephin with its own (P-hf-PSPN) or neurturin's pro region (N-hf-PSPN) to activate GFR $\alpha$ 1-RET;

Figure 3A is a schematic representation of the mature region from GDNF, persephin and the homologue-scanning mutants, where GPG signifies a chimera comprising primarily GDNF (open portions of figures) but having the portion of GDNF indicated by shading replaced by a homologous portion of persephin; further where mutant GPG-Hc is a deletion of amino acids 88-92 of mature GDNF to correspond with the lack of these residues in PSPN, and where the sequence of the replacements in these mutants are shown in Figure 1;

Figure 3B is a photograph of an anti-FLAG<sup>®</sup> immunoblot of homologue scanning mutants from transfected COS cell lysates, where the two major bands indicated by arrows represent the unprocessed (top) and mature (bottom) forms of the mutants, since the lower band corresponds in size to the secreted product as shown in Figure 2B;

Figure 4A is a graph showing relative GFR $\alpha$ 1-RET receptor activation by homologue-scanning GDNF mutants, where values are represented as a percentage of reporter activation by GDNF and the mean and standard deviation of triplicate measurements from a representative experiment are shown, along with arbitrary boundary lines at 33% and 66% of wild-type GDNF activation;

Figure 4B depicts a space-filling model of the GDNF crystal structure, where the upper representation is a side-view of the GDNF dimer, and the lower representation is from a viewpoint below the dimer, showing putative critical GFR $\alpha$ 1-RET interaction domains Hb, F2a, and F2c;

Figure 4C is a graph showing relative GFR $\alpha$ 2-RET receptor activation by homologue-scanning GDNF mutants, where values are represented as a percentage of reporter activation by GDNF and the mean and standard deviation of duplicate measurements from a representative experiment are shown, along with arbitrary boundary lines at 33% and 66% of wild-type GDNF activation;

Figure 4D depicts a space-filling model of the GDNF crystal structure, where the upper representation is a side-view of the GDNF dimer, and the lower representation is from a viewpoint below the dimer, showing putative critical GFR $\alpha$ 2-RET interaction domains Ha, F2a, and F2c;

Figure 5A is a schematic representation of G-hf-GDNF, P-hf-PSPN, and GDNF/persephin replacement chimeras (PGP) for gain-of-function analysis, where the persephin amino acid sequence in



parentheses below the schematics was replaced by the GDNF sequence shown above;

Figure 5B is a graph showing the ability of PGP-F2ac to activate the GFR $\alpha$ 1-RET receptor and the inability of other PGP  
5 chimeras and P-hf-PSPN to activate GFR $\alpha$ 1-RET;

Figure 5C is an image of a RET immunoblot of anti-FLAG<sup>®</sup>-immunoprecipitated lysate from neuro2a cells either untransfected (RET) or transfected with FLAG<sup>®</sup>-tagged GFR $\alpha$ 1 (RET + GFR $\alpha$ 1) treated with the indicated factor at 25 ng/mL, where a fraction of the total  
10 lysate shows a RET doublet, with the upper band corresponding to the mature cell-surface form;

Figure 5D is a histogram of BrdU incorporation by NBL-S neuroblastoma cells in the presence of the indicated factors purified from conditioned medium of transiently transfected COS cells, showing  
15 that mutant PGP-F2ac stimulates proliferation of NBL-S cells at a similar level to GDNF at all doses tested;

Figure 5E are photographs of SH-SY5Y neuroblastoma cells cultured in the presence of no factor (CTRL), retinoic acid (RA; 10 $\mu$ M) or conditioned medium from COS cells expressing the indicated  
20 construct, showing that GDNF and PGP-F2ac stimulates neurite outgrowth in these cells, whereas persephin does not;

Figure 6A is a schematic diagram depicting the structures of N-hf-GDNF, P-hf-PSPN, PGP-F2ac, PNP-F2ac, and PAP-F2ac;

Figure 6B is two graphs showing the ability or inability of the  
25 five molecules depicted in Figure 6A to activate GFR $\alpha$ 1-RET (left side) and GFR $\alpha$ 2-RET (right side);

Figure 7A is a schematic diagram depicting the structures of G-hf-GDNF, P-hf-PSPN, PGP-F2ac, PNP-F2ac, PNP-Ha/F2ac, and PNP-Ha;

Figure 7B is a graph showing the ability or inability of the  
30 six molecules depicted in Figure 7A to activate GFR $\alpha$ 2-RET;

Figure 7C is a schematic diagram depicting the structures of N-hf-GDNF, N-hf-artemin, PAP-F2ac, PAP-Ha/F2ac, and P-hf-PSPN;

Figure 7D is a graph showing the ability or inability of the  
five molecules depicted in Figure 7C to activate GFR $\alpha$ 3-RET;

Figure 8A is a graph showing survival of cerebellar granule  
35 cells transfected with the indicated receptor components and cultured for 3 days in the presence of high-potassium plus serum (K25+S), low potassium (K5), or low potassium plus GDNF (GDNF);

Figure 8B is a graph showing survival of cerebellar granule cells transfected with GFR $\alpha$ 1-RET or GFR $\alpha$ 2-RET cultured in the presence of the indicated factors.

Description of the Preferred Embodiments

5       The present invention is directed to growth factors which selectively activate GFR $\alpha$ 1-RET without substantially activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET. Such growth factors are, preferably, chimeric GDNF family ligand growth factors which have the ability to activate a GFR $\alpha$ 1-RET complex, and are thus useful for promoting the  
10 survival of peripheral and central neuronal populations *in vivo* or *in vitro*.

      In one embodiment, the present invention provides novel chimeras which vary from the previously known naturally occurring GDNF ligand family members GDNF, artemin, neurturin, and persephin by  
15 their ability to activate mammalian GFR $\alpha$ 1-RET without substantially activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET complexes. Examples of these novel chimeras are PGP-F2ac (e.g., SEQ ID NOS:12, 23, and 26), PNP-F2ac (e.g., SEQ ID NOS:14, 24, and 27), and PAP-F2ac (e.g., SEQ ID NOS:16, 25, and 28), in which the sequences are identical to human persephin  
20 (e.g., SEQ ID NO:1), mouse persephin (SEQ ID NO:2), or rat persephin (SEQ ID NO:3) except that amino acids 63-66 in the F2a region and/or amino acids 76-82 in the F2c region (corresponding to amino acids 68-71 and 81-87 of full length persephin, as depicted in Figure 1) are replaced with the corresponding amino acids from a GDNF in PGP-F2ac,  
25 a neurturin in PNP-F2ac, or an artemin in PAP-F2ac. Although persephin sequences do not bind to or activate GFR $\alpha$ 1-RET, GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, the replacement of these amino acids of persephin with amino acids in the same aligned positions from GDNF, neurturin, or artemin, confers upon the chimeric molecule the ability to bind to  
30 and activate GFR $\alpha$ 1-RET. However, even though the persephin amino acids 63-66 and 76-82 are substituted with regions from growth factors which can also activate GFR $\alpha$ 2-RET (neurturin and GDNF) and GFR $\alpha$ 3-RET (artemin), the chimeras do not activate those receptors.

      As used herein, the ability to substantially activate a GFR $\alpha$ -  
35 RET complex by a GDNF family ligand is defined as the ability of that ligand to activate the MAP kinase pathway at a level preferably at least about 40%, more preferably at least about 50%, and most preferably at least about 80% of the ability of GDNF to activate that pathway through GFR $\alpha$ 1-RET activation. This can be measured, e.g., by

measuring luciferase activity after activating RET-expressing cells transformed with expression plasmids encoding the individual GFR $\alpha$  receptor together with the Gal4-Elk/Gal4-Luc reporter system as previously described with GDNF (Worby et al., *J Biol Chem* 273: 3502-3508, 1998; Worby et al., *J. Biol. Chem.* 271:23619-23622, 1996).

As used herein, regions in other GDNF family ligands which are "corresponding" or "analogous" to persephin amino acids 65-71 (also known as the F2a region - Figure 1) and 81-87 (the F2c region), starting at the first canonical cysteine, are meant to encompass the regions of those growth factors which are aligned with those persephin regions by commonly used alignment methods which are designed to align regions according to similar predicted tertiary structures. An example is the Clustal method (Higgins et al, *Cabios* 8:189-191, 1992) of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI). In this method, multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment = 10; gap length penalty for multiple alignment = 10; k-tuple value in pairwise alignment = 1; gap penalty in pairwise alignment = 3; window value in pairwise alignment = 5; diagonals saved in pairwise alignment = 5. The residue weight table used for that alignment program is PAM250 (Dayhoff et al., in *Atlas of Protein Sequence and Structure*, Dayhoff, Ed., NBRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

When the GDNF family ligands are aligned using the Clustal method (see, e.g., Figure 1), the F2a and F2c regions consist of amino acids 60-66 and 76-83 of persephin, starting at the first canonical cysteine residue (as set forth in SEQ ID NOS:1-3). When numbered from the N-terminus of persephin, as depicted in Figure 1, these regions correspond to amino acids 65-71 and 81-88, respectively. When persephin is aligned by the Clustal method with

GDNF, the F2a and F2c regions correspond to amino acids 63-71 and 80-87, respectively, of GDNF as set forth in SEQ ID NOS:4-6 and amino acids 103-110 and 120-127, respectively, of full length GDNF (Figure 1), and have the sequences RPIAFDDD and YHILRKHS, respectively, in human GDNF (SEQ ID NO:4). In neurturin, F2a and F2c are amino acids 64-71 and 81-88, respectively, in SEQ ID NOS:7 and 8, and amino acids 69-76 and 86-93, respectively, of full length neurturin (Figure 1), and have the sequences RPTAYEDE and YHTVHELK in human neurturin (SEQ ID NO:7). In artemin, F2a and F2c are amino acids 67-73 and 83-90, respectively, in SEQ ID NOS:9 and 10, and amino acids 82-88 and 98-105, respectively, of full length artemin (Figure 1), and have the sequences RPTRYEA and WRTVDRLS in human artemin (SEQ ID NO:9).

The seven amino acids 60-66 of the persephin F2a region correspond to the eight amino acids 63-70 of GDNF or 64-71 of neurturin because Clustal analysis creates a gap between amino acid 66 and 67 in persephin when aligned with GDNF or neurturin (see, e.g., Figure 1). Thus, the eighth amino acid in this region from GDNF or neurturin is not present in persephin (and artemin).

As it is believed that the replacement of amino acids 60-66 and 76-83 of any persephin (as numbered in SEQ ID NOS:1-3), now known or unknown, with analogous regions from any GFR $\alpha$ 1-RET activating GDNF family ligand (now known or unknown) would create a growth factor which activates GFR $\alpha$ 1-RET without activating GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, the scope of this embodiment is not meant to be limited to the GDNF family members disclosed herein, but is meant to encompass any GDNF family member. The invention also encompasses chimeras wherein the persephin is from one species and each substituting amino acid within 60-66 and 76-83 can be that of the same or different species.

It is also believed that the chimeras need not comprise the exact amino acid sequence of the GDNF family ligand from which they were derived in order to retain the ability to activate GFR $\alpha$ 1-RET. Rather, conservative substitutions in the chimeras are within the scope of the present invention. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. Conservatively substituted amino acids can be grouped according to the chemical properties of their side chains. For example, one grouping of amino acids includes those amino acids have neutral and hydrophobic side chains (A, V, L, I, P, W, F, and M); another grouping is those amino acids having neutral and polar

side chains (G, S, T, Y, C, N, and Q); another grouping is those amino acids having basic side chains (K, R, and H); another grouping is those amino acids having acidic side chains (D and E); another grouping is those amino acids having aliphatic side chains (G, A, V, L, and I); another grouping is those amino acids having aliphatic-hydroxyl side chains (S and T); another grouping is those amino acids having amine-containing side chains (N, Q, K, R, and H); another grouping is those amino acids having aromatic side chains (F, Y, and W); and another grouping is those amino acids having sulfur-containing side chains (C and M). Preferred conservative amino acid substitutions groups are: R-K; E-D, Y-F, L-M; V-I, and Q-H.

As used herein, the chimeras of the present invention can also include modifications of the sequences identified herein, including sequences in which one or more amino acids have been inserted, deleted or replaced with a different amino acid or a modified or unusual amino acid, as well as modifications such as glycosylation or phosphorylation of one or more amino acids so long as the chimera containing the modified sequence retains the ability to activate GFR $\alpha$ 1-RET. Amino acid(s) can be added to or removed from the N-terminus, C-terminus or within the amino acid sequence, provided the structural Cys residues are retained, which are believed to be required for GFR $\alpha$ -RET activating activity. Thus, the sequences set forth in SEQ ID NOS:1-10, which are sequences only between the first and seventh canonical cysteines of the GDNF family members, are believed to be the minimum length required for activity of these growth factors.

It is also known that the substitution of persephin amino acids with amino acids from a GFR $\alpha$ 1-RET activating growth factor need not encompass all of amino acids 60-66 and 76-83 (numbering of SEQ ID NOS:1-3). For example, the GFR $\alpha$ 1-RET activating chimeras PGP-F2ac, PNP-F2ac, and PAP-F2ac all comprise only the substitution of F2a amino acid residues 63-66 and F2c amino acid residues 76-82 (residue 83 is an S in all known GDNF family members). Additionally, a comparison of the GDNF, neurturin, and artemin amino acids in these regions with the corresponding amino acids of persephin reveals that the only GDNF, neurturin, and artemin amino acids which do not also occur in persephin are those at position 65, 77, 78, 80, and 81, as well as the amino acid which is "missing" between amino acid 66 and 67 in persephin. The "missing" amino acid between 66 and 67 is a D

in known GDNF sequences and an E in known neurturin, which are both acidic amino acids. However, this amino acid is also missing in artemin which activates GFR $\alpha$ 1. Therefore the provision of that missing amino acid in a persephin chimera is unlikely to influence the ability of the chimera to activate GFR $\alpha$ 1. At position 65, the known persephins have an A or a T, which are both uncharged at physiological pH, whereas the GFR $\alpha$ 1-activating growth factors have an E or a D, which are both acidic. At position 77, the persephins have a Q, which is uncharged and polar, whereas known GFR $\alpha$ 1-RET activating growth factors have an R or an H, which are basic. At position 78, the persephins have a Q (uncharged and polar) or an R (basic), whereas the GFR $\alpha$ 1-RET activating growth factors have a T (uncharged and polar) or an I (nonpolar). At position 80, the persephins have P (nonpolar), whereas the GFR $\alpha$ 1-RET activating growth factors have D, H, (both acidic), R (basic), and Q (uncharged and polar). Finally, at position 81, the persephins have a Q (uncharged and polar), whereas the GFR $\alpha$ 1-RET activating growth factors have an H (basic), an E (acidic), or a K (basic). Based on this analysis, only the substitutions at residues 65 and 77 represent an unequivocal change to a particular charge or polarity from the "nonfunctional" (i.e., does not activate GFR $\alpha$ 1-RET) persephin to the "functional" (GFR $\alpha$ 1-RET activating) GDNF family ligands. Therefore, these "hot spots" may be particularly important for GFR $\alpha$ 1-RET activation. Thus, it is believed that GFR $\alpha$ 1-RET activation can be achieved with a persephin wherein (a) from 1 to 4 of amino acids 63-66 are substituted with the corresponding amino acids of a GFR $\alpha$ 1-RET activating GDNF family ligand, or a conservatively substituted variant thereof, including at least the substitution of amino acid 65 with an acidic amino acid; and (b) from 1 to 7 of amino acids 76-82 are substituted with the corresponding amino acids of a GFR $\alpha$ 1-RET activating GDNF family ligand, or a conservatively substituted variant thereof, including the substitution of amino acid 77 with a basic amino acid. Preferred substitutions at position 65 are E and D. Preferred substitutions at position 77 are K, R, or H; most preferred are R and H.

In another embodiment, the present invention provides chimeric GDNF family ligands comprising a persephin wherein all three of the F2a, the F2c, and the Ha regions are substituted with the equivalent regions of a GFR $\alpha$ -RET activating GDNF family ligand. The Ha region encompasses amino acids 33-41 of persephin SEQ ID NOS:1-3 (equivalent

to amino acids 38-46 of full length persephin - Figure 1) and equivalent regions (as determined by Clustal analysis) of other GDNF family ligands (figure 1). The addition of the Ha region provides the ability to activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET, depending on the source of the Ha region. If the Ha region (along with F2a and F2c) is derived from neurturin (e.g., PNP-Ha/F2ac - figure 7A), the chimera will activate GFR $\alpha$ 2-RET; if the Ha region (along with F2a and F2c) is derived from artemin (e.g., PAP-Ha/F2ac - figure 7C) the chimera will activate GFR $\alpha$ 3-RET. It has been found that the activation of GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET by these chimeras is generally about 70% of the activation of that GFR $\alpha$ -RET by the natural (e.g., neurturin or artemin) ligand (see, e.g., figure 7). Because neurturin does not substantially bind to or activate GFR $\alpha$ 3, chimeras such as PNP-Ha/F2ac would be expected to activate only GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET and not GFR $\alpha$ 3-RET or other GFR $\alpha$ -RET complexes having similar additional binding and activation requirements. Similarly, because artemin does not substantially bind to or activate GFR $\alpha$ 2-RET, chimeras such as PAP-Ha/2ac would be expected to activate only GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET and not GFR $\alpha$ 2-RET or other GFR $\alpha$ -RET complexes having similar additional binding and activation requirements.

PNP-Ha/F2ac and PAP-Ha/F2ac thus represent mimics of neurturin and artemin, respectively. As used herein, a mimic of a GDNF family ligand is a chimera which activates the same GFR $\alpha$ -RET receptor as the GDNF family ligand but which primarily comprises a different GDNF family ligand. Because mimics such as PNP-Ha/F2ac and PAP-Ha/F2ac activate the same GFR $\alpha$ -RET receptors as neurturin and artemin, respectively, it is believed that they can substitute for those GDNF family ligands in any treatment regime, such as described in U.S. Patent No. 5,843,914 for neurturin, or U.S. Patent Application No. 09/218,698 for artemin, both of which are hereby incorporated by reference.

As with the persephin chimeras having only the F2a and F2c regions from GFR $\alpha$ 1-RET activating ligands, the persephin chimeras with the F2a, F2c, and Ha chimeric regions can encompass conservatively substituted and modified amino acids. The chimeric regions from the GFR $\alpha$ 1-RET activating ligands can also comprise only partial substitutions, as previously discussed.

In an additional embodiment, the present invention provides chimeric GDNF family ligands with an altered N-terminal region. It

has been discovered that the region N-terminal to the first cysteine residue is not necessary to activate a GFR $\alpha$ /RET (see Example 1). Thus, any GDNF family ligand with an N-terminal region from any other GDNF family ligand, or with any other sequence of about 100 amino acids or less (including a lack of an N-terminal region) would be expected to activate the GFR $\alpha$ -RET which the wild-type ligand activates. Thus, this embodiment comprises a GDNF family member with from zero to 100 amino acids N-terminal to the first cysteine residue. This N-terminal region can comprise a functional sequence, such as a signal sequence or a prepro region comprising a signal sequence. It is well known in the art that many proteins are synthesized within a cell with a signal sequence at the N-terminus of the mature protein sequence and the protein carrying such a leader sequence is referred to as a preprotein. The pre region can serve as a signal peptide which directs transport of the protein to subcellular organelles or outside of the cell. The pre- portion of the protein is cleaved during cellular processing of the protein. In addition to a pre-leader sequence, many proteins contain a distinct pro sequence that describes a region on a protein that is a stable precursor of the mature protein. In view of the processing events known to occur with other TGF- $\beta$  family members, the inventors believe that the form of the GDNF family ligands which are synthesized within a cell is the pre-pro-ligand. The GDNF family ligand pre- region is thus generally followed by a pro- domain which is believed to preferably terminate with an RXXR consensus site immediately before the N-terminal amino acid of the mature ligand. Proteins synthesized with both pre- and pro- regions are referred to as preproproteins.

Thus, within the scope of the present invention are GDNF family ligands containing a pre-pro- region from another GDNF family ligand or another protein, as well as polynucleotides encoding such polypeptides. The polypeptides can generate a mature ligand upon cleavage of the pre-pro- region and the polynucleotides can be used in an expression system to produce the polypeptide which upon cleavage of the non-artemin pre-pro- region yields mature artemin. Such non-GDNF family ligand pre-pro- region polypeptides and encoding polynucleotides are well known in the art.

Thus, chimeras of the GDNF family ligand can comprise an N-terminal region from any protein, pro-protein, or pre-pro-protein. This can be utilized, for example, to target the protein to a



particular cellular region, or outside of the cell. Alternatively, GFR $\alpha$ -RET activating, truncated GDNF family members (including chimeras) containing only a portion of, or entirely lacking an N-terminal region can be made.

5           Although it is not intended that the inventors herein be bound by any theory, it is thought that the chimeric GDNF family ligands identified herein may exist as dimers in their biologically active form in a manner consistent with what is known for other factors of the TGF- $\beta$  superfamily. The chimeras may be used in homodimers or  
10 heterodimers. It is believed that monomers of the chimeras will associate under physiological conditions into homodimers.

          A preferred chimera according to the present invention is prepared in pure form by recombinant DNA technology. By "pure form" or "purified form" or "substantially purified form" it is meant that  
15 a chimera composition is substantially free of other proteins which are not the chimera. Preferably, a substantially purified chimera composition comprises at least about 50 percent chimera on a molar basis compared to total proteins or other macromolecular species present. More preferably, a substantially purified chimera  
20 composition will comprise at least about 80 to about 90 mole percent of the total protein or other macromolecular species present and still more preferably, at least about 95 mole percent or greater.

          A recombinant chimera may be made by expressing a DNA sequence encoding the chimera in a suitable transformed host cell. Using  
25 methods well known in the art, the DNA encoding the chimera may be linked to an expression vector and transformed into a host cell, and conditions established that are suitable for expression of the chimera by the transformed cell.

          Any suitable expression vector may be employed to produce a  
30 recombinant chimera such as, for example, the mammalian expression vector pCB6 (Brewer, *Meth Cell Biol* 43: 233-245, 1994) or the *E. coli* pET expression vectors, specifically, pET-30a (Studier et al., *Methods Enzymol* 185: 60-89, 1990). Other suitable expression vectors for expression in mammalian and bacterial cells are known in the art  
35 as are expression vectors for use in yeast or insect cells. Baculovirus expression systems can also be employed.

          A number of cell types may be suitable as host cells for expression of a recombinant chimera. Mammalian host cells include, but are not limited to, monkey COS cells, Chinese Hamster Ovary (CHO)

cells, human kidney 293 cells, human epidermal A431 cells, human Colo 205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK and Jurkat cells. Yeast strains that may act as suitable host cells include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, and any other yeast strain capable of expressing heterologous proteins. Host bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium* and any other bacterial strain capable of expressing heterologous proteins. If the polypeptide is made in yeast or bacteria, it may be necessary to modify the polypeptide, for example, by phosphorylation or glycosylation of the appropriate sites using known chemical or enzymatic methods, to obtain a biologically active polypeptide.

The chimeras of the present invention can also be expressed in transgenic plants (see, for example, U.S. Patent No. 5,679,880) or transgenic animals such as, for example, cows, goats, pigs, or sheep whose somatic or germ cells contain a nucleotide sequence encoding the chimera.

The expressed chimera can be purified using known purification procedures, such as gel filtration and ion exchange chromatography. Purification may also include affinity chromatography using an agent that will specifically bind the chimeric polypeptide, such as a polyclonal or monoclonal antibody raised against the mature chimera or fragment thereof. Other affinity resins typically used in protein purification may also be used such as concanavalin A-agarose, HEPARIN-TOYOPEARL® or CIBACROM BLUE 3GA SEPHAROSE®. Purification of the chimera can also include one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether.

It is also contemplated that the chimera may be expressed as a fusion protein to facilitate purification. Such fusion proteins, for example, include the chimera amino acid sequence fused to a histidine tag, as well as the chimera amino acid sequence fused to the amino acid sequence of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Similarly, the invention chimera can be tagged with a heterologous epitope, such as a FLAG® epitope, and subsequently purified by immunoaffinity chromatography

using an antibody that specifically binds the epitope. Kits for expression and purification of such fusion proteins and tagged proteins are commercially available. A preferred fusion protein is one containing both a histidine tag and a FLAG® tag, e.g. as described in Example 1.

The recombinant chimeras may also be expressed as monomeric units or such monomeric form may be produced by preparation under reducing conditions. In such instances refolding and renaturation can be accomplished using one of the agents noted above that is known to promote dissociation/association of proteins. For example, the monomeric form can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.

The chimeras of the present invention may also be produced by chemical synthesis using methods known to those skilled in the art.

The present invention also encompasses isolated polynucleotides comprising nucleotide sequences that encode any of the chimeras described herein. As used herein, a polynucleotide includes DNA and/or RNA and thus the nucleotide sequences recited in the Sequence Listing as DNA sequences also include the identical RNA sequences with uracil substituted for thymine residues.

The present invention also encompasses vectors comprising an expression regulatory element operably linked to any of the chimera-encoding nucleotide sequences included within the scope of the invention. This invention also includes host cells, of any variety, that have been transformed with such vectors.

In yet another embodiment, a polynucleotide which specifically hybridizes to a chimera-encoding polynucleotide or to its complement is provided. Specific hybridization is defined herein as the formation of hybrids between a polynucleotide, including oligonucleotides, and a specific reference polynucleotide (e.g., a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence encoding a chimera) wherein the polynucleotide preferentially hybridizes to the specific chimera over other GDNF family ligands. Specific hybridization is preferably done under high stringency conditions which, as well understood by those skilled in the art, can readily be determined by adjusting several factors during hybridization and during the washing procedure, including temperature, ionic strength, length of hybridization or washing

times, and concentration of formamide (see for example, Sambrook, Fritsch and Maniatis., *Molecular Cloning: a Laboratory Manual*, 2d Ed., Vols. 1-3, Cold Spring Harbor Laboratory Press, Plainview N.Y. 11803, 1989)

5           The chimeras of the present invention would be expected to promote the survival and growth of neuronal as well as non-neuronal cells (see, e.g., Examples 2 and 4 herein). As discussed above, GDNF, neurturin, artemin and persephin influence a broad spectrum of neuronal populations in the peripheral and central nervous systems  
10           and the invention chimeras would be expected to also have such an effect. Moreover, all other growth factors isolated to date have been shown to act on many different cell types (for example see Scully and Otten, *Cell Biol Int* 19: 459-469, 1005; Hefti, *Neurotrophic Factor Therapy* 25: 1418-1435, 1994 which are  
15           incorporated by reference). As an example of the actions of neurotrophic factors on non-neuronal tissues, the prototypical neurotrophic factor, NGF, also acts upon mast cells to increase their number when injected into newborn rats (Aloe, *J Neuroimmunol* 18: 1-12, 1988). In addition, mast cells express the trk receptor and  
20           respond to NGF such that NGF is a mast cell secretagogue and survival promoting factor (Horigome et al., *J Biol Chem* 269: 2695-2707, 1994). Moreover, members of the TGF- $\beta$  superfamily act on many cell types of different function and embryologic origin. For example, GDNF activation of GFR $\alpha$ 1 is apparently critical in kidney organogenesis.  
25           Thus, it is likely that the invention chimeras will have trophic activity on a variety of different neuronal cells, both peripheral and central, as well as on non-neuronal cells.

          The present invention also includes therapeutic or pharmaceutical compositions comprising a chimera of the present  
30           invention in an effective amount for providing trophic support to cells in patients with cellular degeneration or dysfunction and a method comprising administering a therapeutically effective amount of the chimera to a cell *ex vivo* or *in vivo*. The term "trophic support" is used herein to mean that a growth factor such as the invention  
35           chimeras provides sufficient nourishment to a cell such that the cell maintains or recovers at least one or more of its normal functions.

          The compositions and methods of the present invention are useful for treating a number of degenerative diseases and anaplastic diseases. Where the cellular degeneration, dysfunction or anaplasia

involves neurons, the diseases include, but are not limited to peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal cord injury, nervous system tumors such as neuroblastomas, multiple sclerosis, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal dysfunctions and damage caused by infectious agents or chemotherapy. In addition, compositions of the invention chimeras can be used to treat enteric diseases such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers. If the cellular degeneration or dysfunction involves nonneuronal cells such as bone marrow cells, a chimera may be useful in treating diseases including, but not limited to disorders of insufficient blood cells such as, for example, leukopenias including eosinopenia and/or basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia as well as an insufficiency of stem cells for any of the above. The cellular degeneration or dysfunction can also involve myocardial muscle cells in diseases such as cardiomyopathy and congestive heart failure. In addition small cell lung carcinoma can be treated with polypeptide or polynucleotide compositions of the invention chimeras.

Treatment of enteric diseases with the chimeras includes the treatment of enteric neuropathies. The enteric nervous system is a complex collection of nerves that control the function of the gastrointestinal system, including gastrointestinal motility. Initial clinical studies with the NT-3, have shown that this neurotrophic factor increases gastrointestinal motility in normal volunteers and in patients suffering from peripheral neuropathies. Heuckeroth et al., *Dev Biol* 200: 116-29, 1998. Similarly, it is believed that the invention chimeras as well as the other GDNF family ligands will show activity on enteric neurons. As a result, it is believed that the chimeras will be useful in treating enteric neuropathies such as in patients suffering from severe idiopathic constipation as well as patients suffering from constipation associated with Parkinson's disease, spinal cord injury, use of opiate pain-killers, and the like.

Whether the invention chimeras would be effective in the treatment of a particular cell type or tissues can be readily

determined by one skilled in the art using any of a variety of assays known in the art. For example, with respect to providing trophic support for cells, trophic factors can produce beneficial biochemical and morphological effects and, under some circumstances, will promote cell survival. With respect to neurons, it is known in the art that depriving a neuron of trophic support results in a decrease in metabolic activity, i.e., glucose uptake, RNA synthesis and protein synthesis, required for normal function and growth. Deckwerth and Johnson, *J. Cell Biol.* 123: 1207-1222, 1993. Removal of trophic support also results in a reduction in size of the cell body of the neuron. Presumably as a consequence of the loss of the metabolic effects of trophic factors, trophic factor deprivation results in a decrease or cessation of process outgrowth and may result in retraction of neuronal processes. In addition to the requirement of trophic factor for these aspects of neuronal biology, the neuron may require the neurotrophic factor to maintain survival. Thus, survival assays are a frequently used means to detect or quantitate the actions of a neurotrophic factor. However, trophic support can also be manifest as morphological, biochemical, and/or functional changes independent of neuronal number or any effect on survival.

As discussed above, growth factors can produce a cell differentiation in addition to providing trophic support for cells. Thus, it is believed that the invention chimeras and polynucleotides encoding them can be beneficially used to produce a differentiation of anaplastic cells such as cancer cells. In particular, the chimeras can be used to treat nervous system tumors such as neuroblastomas. In addition, small cell lung carcinomas are known to express RET. Hence, it is believed that the chimeras can also be used to treat small cell lung carcinomas.

It is also contemplated that the eliciting of trophic support and/or differentiation can be achieved by administering a chimera along with a GFR $\alpha$ 1 polypeptide (and/or GFR $\alpha$ 2 or GFR $\alpha$ 3, for the neurturin or artemin mimics, respectively) or by administering a polynucleotide encoding the chimera and the appropriate GFR $\alpha$  polynucleotide using the methods previously described with GDNF in Treanor et al., *Nature* 382: 80-83, 1996. Sequences for GFR $\alpha$ 1 are known in the art. See, e.g., Genbank Accession numbers NP\_005255 for a human polypeptide sequence and NM\_005264 for a polynucleotide sequence encoding human GFR $\alpha$ 1.

The invention chimeras are believed to bind to GFR $\alpha$ 1 (and GFR $\alpha$ 2 or GFR $\alpha$ 3 in the case of the neurturin or artemin mimics, respectively) in the absence of RET and it is believed that the resulting ligand/coreceptor complex is capable of binding to and activating RET receptors expressed by a target cell. Thus, treatment with a chimera and the appropriate GFR $\alpha$  would be expected to increase the sensitivity of cells normally responsive to the chimera and would also be expected to provide trophic support to cells that express RET but that are not normally responsive to the chimera. Preferably, the chimera and GFR $\alpha$  polypeptides are from the same species, i.e., human. It is also preferred that the GFR $\alpha$  polypeptide be in soluble form, i.e., that it lack the GPI linkage to avoid potential undesirable interactions with cell membranes. As used herein a GFR $\alpha$  polypeptide is intended to include the mature protein with or without the GPI anchor, as well as GFR $\alpha$  fragments, particularly soluble fragments lacking a GPI anchor, that are capable of binding to both the invention chimeras and RET with such binding leading to the activation of RET.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of a slow release formulation. For treating tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that an invention chimera be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the chimera across the blood-brain barrier.

The invention chimeras can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, a chimera can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection (See for example, Friden et al., *Science* 259:373-377, 1993). Furthermore, a chimera can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other

pharmaceutically advantageous properties. (See for example Davis et al. *Enzyme Eng* 4: 169-73, 1978; Burnham, *Am J Hosp Pharm* 51: 210-218, 1994).

5 Preferably, a chimera of the present invention is administered with a carrier such as liposomes or polymers containing a targeting moiety to limit delivery of the chimera to targeted cells. Examples of targeting moieties include but are not limited to antibodies, ligands or receptors to specific cell surface molecules.

10 For nonparenteral administration, the compositions can also include absorption enhancers which increase the pore size of the mucosal membrane. Such absorption enhancers include sodium deoxycholate, sodium glycocholate, dimethyl- $\beta$ -cyclodextrin, lauroyl-1-lysophosphatidylcholine and other substances having structural similarities to the phospholipid domains of the mucosal membrane.

15 The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as  
20 physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition  
25 of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. The invention chimeras can also be incorporated into a solid or semi-solid biologically compatible matrix which can be implanted into tissues requiring treatment.

30 The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or  
35 maintaining release or absorption or penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct



infusion into the cerebrospinal fluid by continuous or periodic infusion.

Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

It is also contemplated that certain formulations containing a chimera are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art based on the activity of the chimera for a particular cell type *in vitro*. The activity of invention chimeras on various peripheral and central neurons in culture is described below and its activity on a particular target cell type can be determined by routine experimentation. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and

response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

In one embodiment of this invention, an invention chimera may be therapeutically administered by implanting into patients vectors  
5 or cells capable of producing a biologically-active form of the chimera or a precursor of the chimera, i.e. a molecule that can be readily converted to a biological-active form of the chimera by the body. In one approach cells that secrete the chimera may be encapsulated into semipermeable membranes for implantation into a  
10 patient. In some embodiments, the cells are transformed to express and secrete both the chimera and the appropriate GFR $\alpha$ , preferably in a soluble form. It is preferred that the cell be of human origin and that the chimera be derived from human GDNF family ligands when the patient is human. However, the formulations and methods herein can  
15 be used for veterinary as well as human applications and the term "patient" as used herein is intended to include human and veterinary patients.

Cells can be grown *ex vivo* for use in transplantation or engraftment into patients (Muench et al., *Leuk & Lymph* 16: 1-11,  
20 1994). In another embodiment of the present invention, an invention chimera can be used to promote the *ex vivo* survival or expansion of cells for transplantation or engraftment. Current methods have used bioreactor culture systems containing factors such as erythropoietin, colony stimulating factors, stem cell factor, and interleukins to  
25 expand hematopoietic progenitor cells for erythrocytes, monocytes, neutrophils, and lymphocytes (Verfaillie, *Stem Cells* 12: 466-476, 1994). These stem cells can be isolated from the marrow of human donors, from human peripheral blood, or from umbilical cord blood cells. The expanded blood cells are used to treat patients who lack  
30 these cells as a result of specific disease conditions or as a result of high dose chemotherapy for treatment of malignancy (George, *Stem Cells* 12(Suppl 1): 249-255, 1994). In the case of cell transplant after chemotherapy, autologous transplants can be performed by removing bone marrow cells before chemotherapy, expanding the cells  
35 *ex vivo* using methods that also function to purge malignant cells, and transplanting the expanded cells back into the patient following chemotherapy (for review see Rummel and Van Zant, *J Hematotherapy* 3: 213-218, 1994).

It is also believed that an invention chimera with or without the appropriate GFR $\alpha$  can be used for the ex vivo expansion of precursor cells in the nervous system. Transplant or engraftment of cells is currently being explored as a therapy for diseases in which certain populations of neurons are lost due to degeneration such as, for example, in Parkinson's disease (Bjorklund, *Curr Opin Neurobiol* 2: 683-689, 1992) and spinal cord injury. Neuronal precursor cells can be obtained from animal or human donors or from human fetal tissue and then expanded in culture using a chimera of the present invention. These cells can then be engrafted into patients where they would function to replace some of the cells lost due to degeneration. Because neurotrophins have been shown to be capable of stimulating the survival and proliferation of neuronal precursor cells such as, for example, NT-3 stimulation of sympathetic neuroblast cells (Birren et al., *Develop* 119: 597-610, 1993), the chimera could also function in similar ways during the development of the nervous system and could be useful in the ex vivo expansion of neuronal cells.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

The procedures disclosed herein which involve the molecular manipulation of nucleic acids are known to those skilled in the art. See generally Fredrick M. Ausubel et al. (1995), "Short Protocols in Molecular Biology", John Wiley and Sons, and Joseph Sambrook et al. (1989), "Molecular Cloning, A Laboratory Manual", second ed., Cold Spring Harbor Laboratory Press, which are both incorporated by reference.

#### Example 1

This example illustrates that the N-terminal extension of GDNF is not required for activity.

An alignment of the mature rat GDNF with mouse neurturin, artemin and persephin is shown in Figure 1. This amino acid sequence comparison and alignment was performed using the MegAlign program of

the DNASTAR software package. Rat GDNF was the basis for all mutagenesis in this example because its structure has been determined (Eigenbrot and Gerber, *Nat. Struct. Biol.* 4: 435-438, 1997). For this and all other examples, the amino acid sequence of rat GDNF (SEQ ID NO:12) and mouse neurturin (SEQ ID NO:14) and persephin (SEQ ID NO:2), and human artemin (SEQ ID NO:15) were used for all constructs. The largest notable difference between the GDNF family ligands is the N-terminal extension before the first structural cysteine, which varies from 40 amino acids in GDNF (SEQ ID NO:18) to only 5 amino acids in neurturin (SEQ ID NO:18) and persephin (amino acids 1-5 of SEQ ID NOs 1-3), and shows little similarity between the different family members. Furthermore GDNF, neurturin and artemin have multiple RXXR consensus subtilisin-like proprotein convertase (SPC) cleavage sites (Molloy et al., *J. Biol. Chem.* 267: 16396-16402, 1992), and therefore multiple isoforms of these extensions are possible. The ones shown are consistent with N-terminal sequencing of GDNF and neurturin (Kotzbauer et al., *Nature* 384: 467-470, 1996), the single cleavage site in PSPN (Milbrandt et al., *supra*), and a cleavage site conserved between mouse and human artemin (Baloh et al., *supra*).

To determine if the large N-terminal extension of GDNF is required for its activity, the differential processing of GDNF and neurturin by mammalian cells was utilized. Chimeric constructs with the pre-pro region from neurturin attached to GDNF were generated, and both their processing and their ability to activate the GFR $\alpha$ 1-RET receptor complex was assessed (Figure 2). Tandem 6X Histidine and FLAG<sup>®</sup> tags were inserted after the RXXR cleavage site of GDNF or neurturin to allow purification and tracking of the proteins (Figure 2A). For mutant G-hf-GDNF the 6His-FLAG<sup>®</sup> tag was inserted between the third and fourth residue of mature GDNF, making the sequence N-...RLKR<sub>Δ</sub>SPD-HHHHHHDYKDDDDK-QAAALPRRERNRQAAAASPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCEAAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDDDLFLDDSLVYHILRKHSKRGCIGCI. For mutant P-hf-PSPN, the tag was inserted between the third and fourth residue of mature PSPN, resulting in N-...RLPR<sub>Δ</sub>ALA-HHHHHHDYKDDDDK-GSCRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTSYADVTFLDDQHHWQQLPQLSAAACGCGG. All mutants were produced by fusion PCR mutagenesis. PCR products were directly cloned into the MluI and XbaI sites of plasmid pCB6 (Brewer, *Meth Cell Biol.* 43: 233-245,

1994) and the inserts sequenced entirely. For mutant N-hf-GDNF, residues 1-38 were truncated from mature GDNF, and attached to the pre-pro region of NRTN. The resulting sequence was N-...RRAR<sub>A</sub>PGA-HHHHHHDYKDDDDK-

5 RGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCEAAETMYDKILKNLSRSRRLTSDKVGQACCRPVAF  
DDDL<sub>S</sub>FLDDSLVYHILRKHS<sub>A</sub>KRCGCI.

The mutant proteins were produced in COS cells as follows. For mutant protein production in COS cells, expression plasmids were transfected using the DEAE-dextran/Chloroquine method (Seed and  
10 Aruffo, *Proc. Natl. Acad. Sci. U.S.A.* 84: 3365-3369, 1987). COS cells were plated onto 10 cm or 15 cm dishes, transfected, and switched to Delbecco's Modified Eagle's Media containing 1% fetal calf serum. After 4-5 days, conditioned medium was collected, cleared, and either concentrated using Centriprep-10 concentrators  
15 (Amicon) or purified by nickel chromatography (Qiagen). Proteins were visualized by immunoblotting with anti-FLAG<sup>®</sup> M2 monoclonal antibody (Sigma). Relative quantities of FLAG<sup>®</sup>-tagged proteins were determined by an ELISA also using the anti-FLAG<sup>®</sup> M2 antibody. The absolute concentration of GDNF in purified and conditioned medium  
20 samples was determined for the G-hf-GDNF construct using the GDNF E-MAX ELISA kit following the manufacturer's instructions (Promega). As shown in Figure 2B, monomeric G-hf-GDNF ran at ~25 kD, and N-hf-GDNF at ~21.5 kD, consistent with processing at the predicted RXXR cleavage sites from GDNF and neurturin. Therefore N-hf-GDNF produces  
25 GDNF with the 40 amino acid N-terminal extension replaced by two amino acids and the tandem His-FLAG<sup>®</sup> tags. When expressed in COS cells, similar quantities of tagged GDNF with its own pro-region (G-hf-GDNF) or the neurturin pro-region (N-hf-GDNF) could be purified from conditioned medium using nickel chromatography (Figure 2B).  
30 Only species corresponding to the expected processing events were observed, indicating that the pro-domains of neurturin and GDNF are sufficient to direct proper processing of their different N-terminal extensions.

To assess the ability of these proteins to activate the high-  
35 affinity GDNF receptor, GFR $\alpha$ 1-RET, the Gal4-Elk1/Gal4-luciferase reporter system was used as described previously (Baloh et al., *supra*). This system monitors the level of RET activation of the MAP kinase pathway, which induces the Gal4-Elk1 fusion protein to activate the Gal4-luciferase reporter, giving a facile measure of

receptor activation (Worby et al., *J Biol Chem* 273: 3502-3508, 1998; York et al., *Nature* 392: 622-626, 1988). RET-3T3 cells were plated at 85,000 cells/well in 12-well plates, and transfected using Superfect (Qiagen) with the reporter plasmids (250 ng/well Gal4-Luc, 50 ng/well Gal4-Elk), CMV-lacZ (50 ng/well) for transfection normalization, CMV-GFR $\alpha$ 1 (250 ng/well) expression plasmid, the mutant GFL construct (250 ng/well) and 650 ng/well pBluescript as carrier for a total of 1.5  $\mu$ g DNA/well. Cells were switched to 0.5% serum-containing medium the morning after transfection and harvested 36 hours later. The average luciferase activity of duplicate or triplicate samples were normalized to  $\beta$ -galactosidase activity of the cotransfected lacZ reporter. As shown in Figure 2C, wild-type GDNF, G-hf-GDNF and N-hf-GDNF all showed comparable activation of GFR $\alpha$ 1-RET in this assay, whereas tagged PSPN constructs with either the PSPN or neurturin pro-region did not activate the receptor. These results are consistent with previous receptor activation and binding experiments indicating that GDNF, but not PSPN, can bind and activate RET through GFR $\alpha$ 1 (Baloh et al., *supra*; Milbrandt et al., *supra*). Furthermore, these data indicate that the N-terminal extension of GDNF is not required for its ability to activate the GFR $\alpha$ 1-RET receptor complex, and the location of the epitope tag does not interfere with the function of GDNF.

The N-terminal extension before the first structural cysteine-knot cysteine is highly variable amongst the TGF- $\beta$  superfamily members. In the case of TGF- $\beta$ 2, it exists as a short  $\alpha$ -helix and is stabilized by an additional disulfide bond relative to other members of the superfamily (Daopin et al., *supra*; Schlunegger and Grutter, *Nature* 358: 430-434, 1992). However, in GDNF and OP-1, the only other members of the TGF- $\beta$  superfamily that have been crystallized, the 35-37 residue N-terminal extension was unresolved and therefore does not adopt a consistent conformation in solution (Eigenbrot and Gerber, *supra*; Griffith et al., *Proc. Natl. Acad. Sci. U.S.A.* 93: 878-883, 1996). Truncating the N-terminal extension did not affect GDNF's ability to activate its receptors. This is consistent with experiments characterizing monoclonal antibodies against GDNF that also suggested the N-terminal extension is not required for receptor binding or bioactivity (Xu et al., *J. Neurochem.* 70: 1383-1393, 1998).

## Example 2

This example illustrates the use of homologue scanning to identify critical GDNF regions for activation of GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET.

5        Although the crystal structure of GDNF is known, the molecular determinants for GDNF-GFR $\alpha$  receptor binding and specificity are currently undefined. To identify regions of GDNF that are required for its ability to activate the GFR $\alpha$ 1-RET receptor complex, homologue-scanning mutagenesis was utilized together with the  
10        receptor activation assay described in Example 1. Ten GDNF mutants (termed "GPG" mutants) were generated by replacing blocks of non-conserved sequence from PSPN into GDNF (Figure 3; see Figure 1 for sequence changes). This method allows comprehensive mutagenesis of sites responsible for the difference in the ability of GDNF and PSPN  
15        to activate GFR $\alpha$ 1-RET, and is highly likely to maintain structural integrity of the mutants because the replacements are from a homologous (and likely structurally similar) protein. Expression plasmids for these mutants were produced as described in Example 1 using fusion PCR, and all were based on the N-hf-GDNF construct. All  
20        mutants were produced at similar quantities when transfected into COS cells, and processing of each appeared normal (Figure 3B).

Comparison of the GPG mutants with GDNF revealed that although many mutants showed slightly decreased activity, only one (GPG-F2a) completely lost the ability to activate the GFR $\alpha$ 1-RET receptor  
25        (Figure 4A). This region was identified in a molecular model of GDNF. Molecular modeling and analysis was done using the SwissPDB viewer (Guex and Peitsch, *Electrophoresis* 18: 2714-2723, 1997), and models were rendered using Mole software (Applied Thermodynamics). The GDNF structure was modeled after entry 1AGQ (Eigenbrot and  
30        Gerber, *supra*) of the Protein Data Bank. The 'C/D' dimer from 1AGQ is shown, with the missing segment of monomer 'C' built as determined for monomer 'D'. The F2a region maps to the bottom of the GDNF molecule along the second finger (Figure 4B; Eigenbrot and Gerber, *supra*). The only other notable mutant that consistently showed  
35        activity 60% or lower than full-length GDNF was GPG-F2c, which maps to the strand adjacent to region F2a along the bottom of the molecule.

It is well established that GDNF is also capable of activating the GFR $\alpha$ 2-RET receptor, albeit with a lower affinity than neurturin

(Baloh et al., *Neuron* 18: 793-802, 1997 Sanicola et al., *Proc. Natl. Acad. Sci., USA* 94: 6238-6243, 1997; Suvanto et al., *Hum. Molec. Genet.* 6: 1267-1273, 1997), whereas persephin cannot (Baloh et al., 1998, *supra*; Milbrandt et al., 1998, *supra*). Therefore, to compare the molecular determinants of GDNF required for GFR $\alpha$ 1 vs. GFR $\alpha$ 2 interaction, we tested the ability of this same panel of mutants to activate the GFR $\alpha$ 2-RET receptor complex. Several of the GPG mutants were significantly more attenuated in their ability to activate RET through GFR $\alpha$ 2 than they were through GFR $\alpha$ 1 (Figure 4C). As before, mutant GPG-F2a was unable to activate the receptor. Interestingly, mutant GPG-F2c, which was the second most affected mutant in activating GFR $\alpha$ 1-RET, showed essentially no activation of GFR $\alpha$ 2-RET. Finally, the mutant that showed the most contrast in its ability to activate GFR $\alpha$ 1-RET vs. GFR $\alpha$ 2-RET was mutant GPG-Ha, which was severely affected only in its ability to activate GFR $\alpha$ 2-RET. Interestingly, mapping these three regions to the GDNF crystal structure reveals that they form a continuous surface, with residues from F2a and F2c from one monomer directly adjacent to region Ha from the heel of the other monomer, suggesting a possible receptor-ligand interaction surface (Figure 4D).

To summarize, the above mutagenesis data suggest that two adjacent regions of GDNF located along the second finger are necessary for interaction with both GFR $\alpha$ 1 and GFR $\alpha$ 2 (regions F2a and F2c), and that additional regions appear required for GDNF interaction with GFR $\alpha$ 2.

### Example 3

This example illustrates that regions F2a and F2c from GDNF, neurturin, or artemin are sufficient for activating GFR $\alpha$ 1-RET.

The homologue-scanning screen disclosed in Example 2 suggests several regions that are necessary for the full ability of GDNF to activate the GFR $\alpha$ 1-RET receptor. However, using only loss of function analysis it is difficult to assess whether critical receptor-contact residues are being altered directly, or if the mutations induce structural changes that alter receptor contact surfaces elsewhere on the molecule. To identify if any of the critical regions identified above (either alone or in combination) are sufficient to allow binding and activation of the GFR $\alpha$ 1-RET receptor complex, persephin mutants were generated with the putative critical regions from GDNF replacing the corresponding regions of



persephin. It was then determined if these "PGP" mutants had gained the ability to activate the GFR $\alpha$ 1-RET receptor complex (Figure 5).

Two candidate regions, F2a and F2c, were initially evaluated along the second finger of GDNF, because mutant GPG-F2a was entirely  
5 inactive, and mutant GPG-F2c was the only other mutant that consistently showed decreased activation of GFR $\alpha$ 1-RET. Replacement of either region F2a or F2c alone from GDNF into persephin was not sufficient to allow the resulting mutants (PGP-F2a or PGP-F2c) to activate GFR $\alpha$ 1-RET. However, when both regions were placed into  
10 persephin the resulting mutant (PGP-F2ac) gained the ability to activate the GFR $\alpha$ 1-RET receptor at a level comparable to full-length GDNF (Figure 5B).

GFR $\alpha$ 1-transfected Neuro2a cells (which endogenously express RET) were then treated with either GDNF or mutant PGP-F2ac as  
15 follows. Neuro2a cells were transiently transfected using Superfect with an expression plasmid for rat GFR $\alpha$ 1 with a FLAG<sup>®</sup> tag inserted by PCR mutagenesis at after the signal sequence. Cells were treated with 25 ng/mL of the indicated factor for 6 hours, the cells were washed once with cold PBS, lysed, and immunoprecipitated using an  
20 anti-FLAG<sup>®</sup> M2 monoclonal antibody conjugated to agarose (Sigma). After washing, the immunoprecipitated samples were visualized by immunoblotting with an anti-RET antibody (C-9; Santa Cruz). Both GDNF and PGP-F2ac induced comparable receptor complex formation, demonstrating that PGP-F2ac had gained the ability to bind and induce  
25 GFR $\alpha$ 1-RET complex formation (Figure 5C).

To determine if mutant PGP-F2ac was also able to elicit biological responses comparable to GDNF, its ability to induce proliferation in the NBL-S neuroblastoma cell line was determined. This cell line expresses GFR $\alpha$ 1 and RET and responds to GFR $\alpha$ 1-RET  
30 agonists (GDNF, neurturin, artemin) by proliferation. The NBL-S proliferation assay was performed as described in Baloh et al., 1998, *supra*. Mutant PGP-F2ac purified from transiently transfected COS cell conditioned medium induced robust proliferation of NBL-S cells, similar to GDNF at all doses, whereas persephin did not (Figure 5D).  
35 Furthermore, PGP-F2ac was also able to induce neurite outgrowth in the GFR $\alpha$ 1-RET expressing neuroblastoma line SH-SY5Y (as evaluated according to the method of Baloh et al., 1998, *supra*) similar to GDNF (Figure 5E).

Neurturin and artemin are also able to activate GFR $\alpha$ 1-RET (Baloh et al., 1998, *supra*; Creedon et al., *Proc. Natl. Acad. Sci. US* 94: 7018-7023, 1997), and therefore it was determined if the same regions (F2a and F2c) from these two additional GFR $\alpha$ 1 agonists are also sufficient to activate the GFR $\alpha$ 1-RET receptor (Figure 6). Interestingly, the corresponding persephin mutants with regions F2a and F2c from neurturin and artemin were also capable of activating the GFR $\alpha$ 1-RET receptor complex, at levels comparable to GDNF and PGP-F2ac (Figure 6B). This indicates that elements of regions F2a and F2c from all the known GFR $\alpha$ 1 agonists are sufficient to activate GFR $\alpha$ 1-RET when placed in the context of persephin. Furthermore, these regions appear to be sufficient only for GFR $\alpha$ 1-RET activation, as the same mutants did not activate GFR $\alpha$ 2-RET comparably to GDNF (Figure 6C). Mutants PNP-F2ac and PGP-F2ac did elicit low-level activation (less than 30% of GDNF) of GFR $\alpha$ 2-RET, whereas PAP-F2ac did not. This is consistent with the ability of GDNF and neurturin, but not artemin to activate GFR $\alpha$ 2-RET, and indicates that regions F2a and F2c are also involved in binding and activating GFR $\alpha$ 2-RET, but that additional regions are required for full activation.

The mutagenesis reported here indicates that critical residues for GFR $\alpha$  receptor interaction and specificity are located in the second finger region of the GDNF molecule. However, while the use of homologue-scanning mutagenesis is ideally suited for identifying sites involved in differential receptor specificity, it cannot delineate all residues involved in receptor binding, as some of these are identical in GDNF and persephin. The fact that residues from region F2a and F2c are sufficient when placed in the context of persephin to activate GFR $\alpha$ 1-RET indicates that residues in these regions are likely to be directly involved in binding to GFR $\alpha$ 's.

Although it is possible that the GDNF family ligands also contact RET in the active receptor complex, the fact that all members of the GDNF family ligands, including persephin, appear to signal through RET makes it doubtful that the regions identified by this mutagenesis scheme are involved in RET-interaction directly. However, because this analysis focused on functional activation of the GFR $\alpha$ -RET receptor complex rather than receptor binding assays, the possibility cannot be excluded that some of the non-functional mutants produced here may still be capable of binding to the GFR $\alpha$  coreceptors, and potentially even function as receptor antagonists.

Current evidence suggests that the stoichiometry of the active receptor complex for GDNF is  $(\text{GDNF})_1(\text{GFR}\alpha)_2(\text{RET})_2$  (Jing et al., *Cell* 85: 1113-1124, 1996). Residues from regions F2a and F2c project essentially from the bottom the GDNF structure, and form symmetric sites on both monomers of the molecule (see Figure 4B). Interestingly, residues from region Ha (which is critical for GDNF-GFR $\alpha$ 2, and ARTN-GFR $\alpha$ 3 interaction) lie directly adjacent to regions F2a and F2c from the finger 2 region of the opposing monomer, and form continuous surfaces along the side and bottom of the molecule (see Figure 4C). Because these regions are all critical for GFR $\alpha$  specificity, it appears that the molecular surface formed by the heel of one monomer and the second finger of the adjacent monomer form GFR $\alpha$  binding surfaces on GDNF.

Comparison of structure/function studies from other TGF- $\beta$  and cystine-knot superfamily members reveals common themes in the location of receptor binding surfaces. The best characterized of these is the binding of vascular endothelial growth factor (VEGF) with its receptors KDR and Flt-1, where extensive mutagenesis and co-crystallization have been performed (Muller et al., *Proc. Natl. Acad. Sci. U.S.A.* 94: 7192-7197, 1997; Wiesmann et al., *Cell* 91: 695-704, 1997). Mutagenesis of VEGF identified a cluster of residues critical for KDR binding, several of which were along the adjacent  $\beta$ -strands of the second finger, similar to regions F2a and F2c identified here for GDNF. Furthermore, even though the orientation of the monomers in the VEGF dimer is different from GDNF, the receptor binding site on VEGF involves residues from finger 2 and the analogous heel region of the opposing monomer. Finally, mutagenesis of TGF- $\beta$  indicates that the binding affinity of the different TGF- $\beta$  isoforms for the TGF- $\beta$  type II receptor is also determined by residues along the second finger of the molecule, analogous in location to region F2c (Burmester et al., *Growth Factors* 15: 231-242, 1998; Qian et al., *J. Biol. Chem.* 271: 30656-30662, 1996). Therefore it is possible that although the receptor systems and dimerization modes are strikingly different for these different cystine-knot superfamily proteins, the location of their receptor interaction surfaces may be quite similar.

#### Example 4

This example illustrates that additional determinants are critical for neurturin to activate GFR $\alpha$ 2-RET and artemin to activate GFR $\alpha$ 3-RET.

The observation that mutants PGP-F2ac and PNP-F2ac cannot activate GFR $\alpha$ 2-RET is consistent with the homologue-scanning mutagenesis in Example 2 (Figure 4), which suggested that regions in addition to F2a and F2c are required for GDNF to activate GFR $\alpha$ 2-RET.

5 In particular, mutant PGP-Ha was significantly attenuated in its ability to activate GFR $\alpha$ 2-RET (~27%), whereas it showed a minor loss in the ability to activate GFR $\alpha$ 1-RET (~80%; Figure 4). To address whether region Ha contains additional molecular determinants required for activating GFR $\alpha$ 2-RET, a persephin mutant was generated with

10 regions F2a, F2c and Ha replaced by the corresponding regions from neurturin, the highest affinity GFR $\alpha$ 2 agonist (PNP-Ha/F2ac; Figure 7A). While mutant PNP-F2ac elicited only a minor increase in GFR $\alpha$ 2-RET activation as before, mutant PNP-Ha/F2ac was significantly better at activating GFR $\alpha$ 2-RET, however it did not restore full activity

15 (usually 70-80% of GDNF; Figure 7B). Therefore, consistent with the homologue-scanning mutagenesis above, these data indicate that regions F2a and F2c of GDNF and NRTN are only sufficient to activate GFR $\alpha$ 1-RET, and additional regions are required for full activation of GFR $\alpha$ 2-RET (region Ha and perhaps others).

20 Artemin is a recently identified member of the GDNF family ligands that can activate GFR $\alpha$ 1-RET, and the only member of the family that can activate GFR $\alpha$ 3-RET. As shown in example 3, regions F2a and F2c from artemin are sufficient to activate GFR $\alpha$ 1-RET. In an

25 initial attempt to characterize the molecular determinants of the artemin-GFR $\alpha$ 3 interaction, the ability of persephin-artemin chimeras to activate the GFR $\alpha$ 3-RET receptor complex was examined (Figure 7C and D). To this end, the chimera N-hf-ARTN was prepared by the fusion PCR mutagenesis procedure as in example 1, where residues 1-13 were truncated from mature human ARTN and attached to the pre-pro

30 region of NRTN, with the resulting sequence (N-...RRAR<sub>A</sub>PGA-HHHHHHDYKDDDDK-RGCR...-C). As expected, N-hf-ARTN gave robust activation of GFR $\alpha$ 3-RET, whereas N-hf-GDNF showed no activity. Mutant PAP-F2ac, which is capable of activating GFR $\alpha$ 1-RET (see Figure 6), was also unable to activate GFR $\alpha$ 3-RET, indicating that like the

35 neurturin-GFR $\alpha$ 2 interaction, the artemin-GFR $\alpha$ 3 interaction requires regions in addition to F2a and F2c. To determine if region Ha was also involved in the artemin-GFR $\alpha$ 3 interaction, a persephin mutant was generated with regions Ha, F2a and F2c from artemin (Figure 7C). Interestingly, whereas mutant PAP-F2ac was entirely inactive, mutant

PAP-Ha/F2ac regained significant activity (ca. 70-80% of full length artemin; Figure 7D). Therefore, similar to the neurturin-GFR $\alpha$ 2 interaction, the artemin-GFR $\alpha$ 3 interaction requires molecular determinants from both the heel and finger 2 regions of the molecule, whereas interaction of GDNF, neurturin or artemin with GFR $\alpha$ 1 only requires regions F2a and F2c from finger 2.

In this analysis, it was observed that regions F2a and F2c were minimal requirements for interaction with GFR $\alpha$ 1-RET, but that additional regions (including region Ha) were required for activating GFR $\alpha$ 2-RET. GFR $\alpha$ 1-RET is the most promiscuous of the GFL receptors, able to interact with three of the four known ligands. This is consistent with GFR $\alpha$ 1-RET having the most minimal requirements for being activated (regions F2a and F2c), and additional regions being required for activating GFR $\alpha$ 2-RET and GFR $\alpha$ 3-RET. Although region Ha is critical for the neurturin-GFR $\alpha$ 2 and artemin-GFR $\alpha$ 3 interactions, persephin mutants containing regions Ha, F2a and F2c were not fully active, suggesting either additional regions are necessary, or the binding determinants from neurturin and artemin are not presented properly in the context of the persephin molecule.

#### Example 5

This example illustrates that persephin chimeras which activate GFR $\alpha$ 1-RET function as GFR $\alpha$ 1-specific agonists *in vitro*.

The homologue-scanning mutagenesis and gain of function experiments in previous examples demonstrate that for the GFR $\alpha$ 1-RET agonists (GDNF, neurturin and artemin), regions F2a and F2c are sufficient for interaction with GFR $\alpha$ 1, but that additional regions are required for interaction with GFR $\alpha$ 2 and GFR $\alpha$ 3 (Figures 6 and 7). This suggests that the persephin mutants containing only regions F2a and F2c from GDNF, neurturin or artemin may function as GFR $\alpha$ 1-RET specific agonists.

To test the above idea, a cell survival assay using rat cerebellar granule cells in culture was developed. These cells do not express endogenous RET or GFR $\alpha$  coreceptors and can be transfected efficiently, therefore providing a model system of cell survival with defined receptor components. Rat cerebellar granule cell dissection and culture was performed as described previously Miller and Johnson, *J. Neurosci.* 16: 7487-7495, 1996. Timed-pregnant Sprague-Dawley rats were purchased from Harlan Sprague-Dawley (Indianapolis, IN). At postnatal day 7 (P7), cerebella were dissected, cut into 1 mm pieces,

and incubated for 15 min in 0.3 g/ml trypsin (Worthington, Freehold, NJ) at 37°C. The pieces were triturated with a fire-polished Pasteur pipette in the presence of trypsin and the resulting cell suspension was passed through a Nitex filter (size 3-20/14; Tetko, Elmsford, NY). Cells were plated at a density of  $2.3 \times 10^5$  cells/cm<sup>2</sup> in four-well dishes (Nunc) coated with 0.1 mg/ml poly-L-lysine. Plating medium (K25 +S) consisted of Basal Medium Eagle (Life Tech, Gaithersburg, MD) containing 10% dialyzed fetal bovine serum, 20 mM KCl, 100 U/ml penicillin and 100 ug/ml streptomycin. To reduce the number of non-neuronal cells, 3.3 ug/ml aphidocholine was added to the medium 24 hrs after plating.

Granule cell transfections were performed using a modified calcium phosphate protocol as described previously (Moulder et al., *J. Neurosci.* 19: 705-715, 1999). Expression plasmids for GFR $\alpha$ 1, GFR $\alpha$ 2 and RET are described elsewhere (Baloh et al., 1997, *supra*). At 5 days in vitro (DIV), medium was replaced with Dulbecco's Modified Eagle's Medium (Life Tech) for 1 hr. During this time, an equal volume of solution containing 0.25M CaCl and 67 ug/ml DNA was added to a 2XHEPES-buffered saline [274 mM NaCl, 10 mM KCl, 1.4 mM Na<sub>2</sub>HPO<sub>4</sub>-7H<sub>2</sub>O (Fisher Scientific, Houston, TX), 15 mM dextrose, and 42 mM HEPES (free acid), pH 7.07] and incubated in the dark at room temperature for 25 min. 30 uL of the precipitate (1 ug DNA) were added to each of a four-well dish and incubated at 37°C for 1 hr. Cells were washed twice with Dulbecco's Modified Eagle's Medium and then returned to plating medium. Transfection efficiency was approximately 0.2-0.5%.

To quantify transfection results, the number of initial EGFP-positive cells in a defined area (minimum of 150 cells) of two to four wells (of a four-well dish) per condition were counted 24 hrs after transfection, then rinsed the cultures twice in Dulbecco's Modified Eagle's Medium and switched them to high-potassium/serum (K25+S); low potassium/no serum (K5-S) medium alone; or K5-S supplemented with the indicated factors for 48 hrs. After this period, the number of EGFP-positive cells remaining in the originally defined area of the well was counted again to obtain the percentage neuronal survival.

Cerebellar granule cells transfected with RET or GFR $\alpha$ 1 alone do not survive in the absence of high potassium or in the presence of GDNF, however cells cotransfected with GFR $\alpha$ 1 and RET survive in the

presence of GDNF at levels comparable to the control condition of high potassium plus serum (Figure 8A; Miller and Johnson, *supra*). Consistent with other assays, cerebellar granule cells transfected with GFR $\alpha$ 1-RET or GFR $\alpha$ 2-RET survive in the presence of either GDNF or neurturin, but not persephin (Figure 8B). However, mutant PGP-F2ac was only capable of supporting the survival of GFR $\alpha$ 1-RET transfected, but not GFR $\alpha$ 2-RET transfected cells. This is consistent with its minimal ability to activate the GFR $\alpha$ 2-RET receptor in fibroblasts (Figure 6C), and indicates that unlike GDNF and neurturin, mutant PGP-F2ac functions as a GFR $\alpha$ 1-RET specific agonist in this in vitro cell survival paradigm.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification, including patents and patent applications, are hereby incorporated by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

Summary of SEQ ID NOS

SEQ ID NO:1 - Human Persephin - C1-C7

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRYTDVAF  
LDDRHRWQRLPQLSAAACGC

SEQ ID NO:2 - Mouse Persephin - C1-C7

CRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSVLRLRGRGRAHGRPCCQPTSYADVTF  
LDDQHHWQQLPQLSAAACGC

SEQ ID NO:3 - Rat Persephin - C1-C7

CRLWSLTLPVAELGLGYASEEKIIFRYCAGSCPQEVRTQHSVLRLRGQGRAHGRPCCQPTSYADVTF  
LDDHHHWQQLPQLSAAACGC

SEQ ID NO:4 - Human GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFDD  
DLSFLDDNLVYHILRKHSAKRCGC

5

SEQ ID NO:5 - Mouse GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCESAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDD  
DLSFLDDNLVYHILRKHSAKRCGC

10

SEQ ID NO:6 - Rat GDNF - C1-C7

CVLTAIHLNVTDLGLGYETKEELIFRYCSGSCEAAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDD  
DLSFLDDSLVYHILRKHSAKRCGC

SEQ ID NO:7 - Human Neurturin - C1-C7

15

CGLRELEVRVSELGLGYASDETVLFRYCSGACEAAARVYDLGLRRLRQRRRLRRERVRAQPCCRPTAYE  
DEVSFDAHSRYHTVHELARECAC

SEQ ID NO:8 - Mouse Neurturin - C1-C7

20

CGLRELEVRVSELGLGYTSDETVLFYCSGACEAAIRIYDLGLRRLRQRRRVRRERARAHPPCCRPTAYE  
DEVSFDDVHSRYHTLQELARECAC

SEQ ID NO:9 - Human Artemin - C1-C7

25

CRLRSQVLPVRAALGLGHRSEDLVRFRFCSGSCRRARSPHDLASLLGAGALRPPPGSRPVSQPCCRPT  
RYEAVSFMDVNSTWRTVDRLSATAACGC

SEQ ID NO:10 - Mouse Artemin - C1-C7

CRLRSQVLPVSALGLGHSSDELIRFRFCSGSCRRARSQHDLSLASLLGAGALRSPPGSRPISQPCCRPT  
RYEAVSFMDVNSTWRTVDHLSATAACGC

30

SEQ ID NO:11 - His-Flag®-PGP-F2ac (from mouse persephin and rat GDNF): GDNF sequences are underlined

ALAHHHHHHDYKDDDDKGSCLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
GRAHGRPCCQPTAFDDDDVTFLDDQH<sup>Y</sup>HILRKHSAAACGC

35

SEQ ID NO:12 - PGP-F2ac (from mouse persephin and rat GDNF) C1-C7: GDNF sequences are underlined

CRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTAFDDDDVT  
FLDDQH<sup>Y</sup>HILRKHSAAACGC



- 5     SEQ ID NO:13 - His-Flag®-PNP-F2ac (from mouse sequences): Neurturin  
          sequences are underlined  
          ALAHHHHHHDYKDDDDKGSCRLWSLTLPAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
          GRAHGRPCCQPTAYEDEVTFLLDDQHHYHTLQELSAACGC
- 10    SEQ ID NO:14 - PNP-F2ac (from mouse sequences) C1-C7: Neurturin  
          sequences are underlined  
          CRLWSLTLPAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTAYEDEVTF  
          LLDDQHHYHTLQELSAACGC
- 15    SEQ ID NO:15 - His-Flag®-PAP-F2ac (from mouse sequences): Artemin  
          sequences are underlined  
          ALAHHHHHHDYKDDDDKGSCRLWSLTLPAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGR  
          GRAHGRPCCQPTRYEAVTFLLDDQHHWRTVDHLSAACGC
- 20    SEQ ID NO:16 - PAP-F2ac (from mouse sequences) C1-C7: Artemin  
          sequences are underlined  
          CRLWSLTLPAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTRYEAVTF  
          LDDQHHWRTVDHLSAACGC
- 25    SEQ ID NO:17 - human GDNF F2a 5-mer  
          AFDDD
- SEQ ID NO:18 - human neurturin F2a 5-mer  
          AYEDE
- SEQ ID NO:19 - human artemin F2a 4-mer  
          RYEA
- 30    SEQ ID NO:20 - human GDNF F2c 7-mer  
          YHILRKH
- SEQ ID NO:21 - human neurturin F2c 7-mer  
          YHTVHEL
- 35    SEQ ID NO:22 - human artemin F2c 7-mer  
          WRTVDRL

SEQ ID NO:23 - PGP-F2ac (from human sequences) C1-C7: GDNF sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAFDDDDVA  
FLDDRHRHYHILRKHSAAACGC

5

SEQ ID NO:24 - PNP-F2ac (from human sequences) C1-C7: Neurturin sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAYEDEVA  
FLDDRHRHYHTVHELSSAAACGC

10

SEQ ID NO:25 - PAP-F2ac (from human sequences) C1-C7: Artemin sequences are underlined

CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRYEAVAF  
LDDRHRWRTVDRLSAAACGC

15

SEQ ID NO:26 - full length PGP-F2ac (from human sequences): GDNF sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAF  
DDDDVAFLDDRHRHYHILRKHSAAACGCGG

20

SEQ ID NO:27 - full length PNP-F2ac (from human sequences): Neurturin sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTAY  
EDEVAFLDDRHRHYHTVHELSSAAACGCGG

25

SEQ ID NO:28 - full length PAP-F2ac (from human sequences): Artemin sequences are underlined

ALSGPCQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCRPTRY  
EAVAFLLDDRHRWRTVDRLSAAACGCGG

30

What is claimed is:

1. A growth factor which activates GFR $\alpha$ 1-RET but does not substantially activate GFR $\alpha$ 2-RET or GFR $\alpha$ 3-RET.
2. The growth factor of claim 1, comprising a chimeric GDNF family ligand or a derivative thereof.
3. The growth factor of claim 2, comprising a persephin having substitutions in regions F2a and F2c wherein the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, or conservative amino acid  
5 substitutions therefor, and wherein the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor.
4. The growth factor of claim 3, wherein the substituted persephin comprises persephin as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 with substitutions in regions F2a and F2c independently selected from corresponding regions of SEQ ID NO:4, SEQ  
5 ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
5. The growth factor of claim 4, comprising SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.
6. The growth factor of claim 4, wherein the substituted persephin comprises a human persephin as set forth in SEQ ID NO:1 with substitutions for amino acid residues 63-66 selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, and  
5 substitutions for amino acid residues 76-82 selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.
7. The growth factor of claim 6, comprising SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25.
8. The growth factor of claim 6, consisting of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.
9. A composition comprising the growth factor of claim 1 in a pharmaceutically acceptable preparation.
10. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 1.
11. The nucleic acid of claim 10, wherein the encoded growth factor is a chimeric GDNF family ligand or a conservatively substituted derivative thereof.

12. The nucleic acid of claim 11, wherein the encoded growth factor comprises a persephin having substitutions in regions F2a and F2c wherein the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor, and wherein the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of GDNF, neurturin or artemin, or conservative amino acid substitutions therefor.

13. The nucleic acid of claim 12, wherein the encoded substituted persephin comprises persephin as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 with substitutions in regions F2a and F2c independently selected from corresponding regions of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

14. The nucleic acid of claim 13, wherein the encoded growth factor comprises SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.

15. The nucleic acid of claim 13, wherein the encoded growth factor comprises a human persephin as set forth in SEQ ID NO: 1 with substitutions for amino acid residues 63-66 selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19, and substitutions for amino acid residues 76-82 selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.

16. The nucleic acid of claim 15, wherein the encoded growth factor comprises SEQ ID NO:23, SEQ ID NO:24 or SEQ ID NO:25.

17. The nucleic acid of claim 15, wherein the encoded growth factor consists of SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.

18. A vector comprising expression regulatory elements operably linked to the polynucleotide of claim 10.

19. A host cell comprising the vector of claim 18.

20. The host cell of claim 19 which is a bacterial cell, a yeast cell, a plant cell, an insect cell or a mammalian cell.

21. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the growth factor of claim 1 or a polynucleotide which encodes for expression of the growth factor.

22. The method of claim 21, wherein the treating step further comprises administering to the cell a GFR $\alpha$ 1 polypeptide.

23. The method of claim 21, wherein the cell is in a patient and the treating comprises administering the growth factor to the patient.

24. The method of claim 23, wherein the administering comprises implanting into the patient a cell which expresses the growth factor.

25. The method of claim 24, wherein the cell is a neuronal cell in a patient suffering from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal chord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, or the cell is a non-neuronal cell in a patient suffering from small cell lung carcinoma.

26. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 1 or a polynucleotide encodes for expression of the growth factor.

27. The method of claim 26 wherein the administering comprises implanting into the individual a cell which expresses the growth factor.

28. The method of claim 25 wherein the individual suffers from (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, AIDS, ischemic stroke, acute brain injury, acute spinal chord injury, a nervous system tumor such as neuroblastomas, multiple sclerosis, infection, side effects of chemotherapy, or an enteric disease such as idiopathic constipation or constipation associated with Parkinson's disease, spinal cord injury or use of opiate pain-killers, (b) from small cell lung carcinoma, (c) from hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia, or stem-cell insufficiencies therefor, or (d) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

29. A growth factor which activates GFR $\alpha$ 1-RET and GFR $\alpha$ 2-RET but does not substantially activate GFR $\alpha$ 3-RET comprising a persephin having substitutions in regions Ha, F2a and F2c wherein:

5 (a) the substitutions in region Ha comprise from one to nine amino acids identical to region Ha of neurturin, or conservative amino acid substitutions therefor;

(b) the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of neurturin, or conservative amino acid substitutions therefor; and

10 (c) the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of neurturin.

30. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 29.

31. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the growth factor of claim 29 or a polynucleotide which encodes for  
5 expression of the growth factor.

32. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 29 or a polynucleotide which encodes for expression of the  
5 growth factor.

33. A growth factor which activates GFR $\alpha$ 1-RET and GFR $\alpha$ 3-RET but does not substantially activate GFR $\alpha$ 2-RET comprising a persephin having substitutions in regions Ha, F2a and F2c wherein:

5 (a) the substitutions in region Ha comprise from one to nine amino acids identical to region Ha of artemin, or conservative amino acid substitutions therefor;

(b) the substitutions in region F2a comprise from one to eight amino acids identical to region F2a of artemin, or conservative amino acid substitutions therefor; and

10 (c) the substitutions in region F2c comprise from one to eight amino acids identical to region F2c of artemin.

34. A nucleic acid comprising a polynucleotide encoding the growth factor of claim 33.

35. A method for providing trophic support to a mammalian cell or for producing differentiation of a mammalian cell or for both, the method comprising treating the cell with an effective amount of the

growth factor of claim 33 or a polynucleotide which encodes for  
5 expression of the growth factor.

36. A method for preventing or treating cellular degeneration  
or insufficiency in an individual comprising administering to the  
individual a therapeutically effective amount of the growth factor of  
claim 33 or a polynucleotide which encodes for expression of the  
5 growth factor.

rGDNF	S	P	D	K	Q	A	A	L	P	R	R	E	R	N	R	Q	A	A	A	S	P	E	N	S	R	G	K	G	R	R	G	Q	R	G	K	N	R	G	40									
mNRTN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	P	G	A	R	P	5						
mARTN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	D	A	R	G	15			
mPSPN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A	L	A	G	S	5

rGDNF	C	V	L	T	A	I	H	L	N	V	T	D	L	G	L	G	Y	E	T	K	E	E	L	I	F	R	Y	C	S	G	S	C	E	A	A	E	-	T	M	Y	79
mNRTN	C	G	L	R	E	L	E	V	R	V	S	E	L	G	L	G	Y	T	S	D	E	T	V	L	F	R	Y	C	A	G	A	C	E	A	A	I	R	I	-	Y	44
mARTN	C	R	L	R	S	Q	L	V	P	V	S	A	L	G	L	G	H	S	S	D	E	L	I	R	F	R	F	C	S	G	S	C	R	R	-	A	R	S	Q	H	54
mPSPN	C	R	L	W	S	L	T	L	P	V	A	E	L	G	L	G	Y	A	S	E	E	K	V	I	F	R	Y	C	A	G	S	C	P	Q	E	A	R	T	Q	H	45

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115	
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81	
mARTN	D	L	S	L	A	S	L	L	G	A	G	A	L	R	S	P	P	G	S	R	P	I	S	Q	P	C	C	R	P	T	R	Y	E	A	-	V	S	F	M	D	93		
mPSPN	S	L	V	L	A	R	L	R	-	-	-	-	-	-	-	-	-	-	G	R	G	R	A	H	G	R	P	C	C	Q	P	T	S	Y	A	D	-	V	T	F	L	D	76

rGDNF	D	S	L	V	Y	H	I	L	R	K	H	S	A	K	R	C	G	G	I																							
mNRTN	V	H	S	R	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V																							
mARTN	V	N	S	T	W	R	T	V	D	H	L	S	A	T	A	C	G	C	L	G																						
mPSPN	D	Q	H	H	W	Q	Q	L	P	Q	L	S	A	A	A	C	G	C	G	G																						

rGDNF	D	K	I	L	K	N	L	S	R	S	R	R	L	-	-	-	-	-	T	S	D	K	V	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	115
mNRTN	D	L	G	L	R	R	L	R	Q	R	R	R	V	R	R	-	-	-	-	E	R	A	R	A	H	F	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	81
mARTN	D	L	S	L	A	S	L	L	G	A	G	A																														

FIGURE 1



2/24




FIGURE 2A

3/24

G-hf-GDNF

N-hf-GDNF

46.0 —

30.0 —

21.5 —

14.3 —



**FIGURE 2B**

4/24






FIGURE 2C

5/24

**FIGURE 3A**

6/24

**FIGURE 3B**

7/24





FIGURE 4A

8/24



**FIGURE 4B**

9/24





FIGURE 4C



10/24



**FIGURE 4D**

11/24





FIGURE 5A

12/24

**FIGURE 5B**

13/24




FIGURE 5C

14/24





FIGURE 5D

15/24



**FIGURE 5E**

16/24




FIGURE 6A

17/24




FIGURE 6B1



18/24




FIGURE 6B2




FIGURE 7A

20/24




FIGURE 7B

21/24




FIGURE 7C

22/24




FIGURE 7D

23/24




FIGURE 8A

24/24




FIGURE 8B

## SEQUENCE LISTING

<110> MILBRANDT, Jeffrey D.  
BALOH, Robert H.

<120> GFR-alpha-1-RET Specific Agonists and Methods Therefor

<130> 6029-6940

<140>

<141>

<150> 09/473,551

<151> 28 December 1999

<160> 28

<170> PatentIn Ver. 2.0

<210> 1

<211> 89

<212> PRT

<213> Homo sapiens

<400> 1

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
1 5 10 15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30

Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
35 40 45

Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr  
50 55 60

Thr	Asp	Val	Ala	Phe	Leu	Asp	Asp	Arg	His	Arg	Trp	Gln	Arg	Leu	Pro
65					70					75					80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 2

<211> 89

<212> PRT

<213> Mouse

<400> 2

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
1 5 10 15

Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30

Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
35 40 45

Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
50 55 60

Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu Pro  
65 70 75 80



Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 3  
<211> 89  
<212> PRT  
<213> RAT

<400> 3  
Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
1 5 10 15  
Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30  
Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
35 40 45  
Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
50 55 60  
Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro  
65 70 75 80  
Gln Leu Ser Ala Ala Ala Cys Gly Cys  
85

<210> 4  
<211> 93  
<212> PRT  
<213> Homo sapiens

<400> 4  
Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
1 5 10 15  
Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
20 25 30  
Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
35 40 45  
Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
50 55 60  
Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
65 70 75 80  
His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
85 90

<210> 5  
<211> 93  
<212> PRT  
<213> Mouse

<400> 5  
Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
1 5 10 15  
Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
20 25 30

Glu Ser Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
                   35                  40                  45  
 Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
           50                  55                  60  
 Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
       65                  70                  75                  80  
 His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
                   85                  90

<210> 6  
 <211> 93  
 <212> PRT  
 <213> RAT

<400> 6  
 Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
       1                  5                  10                  15  
 Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
           20                  25                  30  
 Glu Ala Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
           35                  40                  45  
 Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
       50                  55                  60  
 Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Ser Leu Val Tyr  
       65                  70                  75                  80  
 His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
                   85                  90

<210> 7  
 <211> 94  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly  
       1                  5                  10                  15  
 Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
           20                  25                  30  
 Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
           35                  40                  45  
 Arg Arg Arg Leu Arg Arg Glu Arg Val Arg Ala Gln Pro Cys Cys Arg  
       50                  55                  60  
 Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Ala His Ser Arg  
       65                  70                  75                  80  
 Tyr His Thr Val His Glu Leu Ser Ala Arg Glu Cys Ala Cys  
                   85                  90

<210> 8  
 <211> 94  
 <212> PRT

&lt;213&gt; Mouse

&lt;400&gt; 8

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
 20 25 30  
 Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
 35 40 45  
 Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His Pro Cys Cys Arg  
 50 55 60  
 Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg  
 65 70 75 80  
 Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys  
 85 90

&lt;210&gt; 9

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

Cys Arg Leu Arg Ser Gln Leu Val Pro Val Arg Ala Leu Gly Leu Gly  
 1 5 10 15  
 His Arg Ser Asp Glu Leu Val Arg Phe Arg Phe Cys Ser Gly Ser Cys  
 20 25 30  
 Arg Arg Ala Arg Ser Pro His Asp Leu Ser Leu Ala Ser Leu Leu Gly  
 35 40 45  
 Ala Gly Ala Leu Arg Pro Pro Pro Gly Ser Arg Pro Val Ser Gln Pro  
 50 55 60  
 Cys Cys Arg Pro Thr Arg Tyr Glu Ala Val Ser Phe Met Asp Val Asn  
 65 70 75 80  
 Ser Thr Trp Arg Thr Val Asp Arg Leu Ser Ala Thr Ala Cys Gly Cys  
 85 90 95

&lt;210&gt; 10

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Mouse

&lt;400&gt; 10

Cys Arg Leu Arg Ser Gln Leu Val Pro Val Ser Ala Leu Gly Leu Gly  
 1 5 10 15  
 His Ser Ser Asp Glu Leu Ile Arg Phe Arg Phe Cys Ser Gly Ser Cys  
 20 25 30  
 Arg Arg Ala Arg Ser Gln His Asp Leu Ser Leu Ala Ser Leu Leu Gly  
 35 40 45

Ala	Gly	Ala	Leu	Arg	Ser	Pro	Pro	Gly	Ser	Arg	Pro	Ile	Ser	Gln	Pro
	50					55					60				
Cys	Cys	Arg	Pro	Thr	Arg	Tyr	Glu	Ala	Val	Ser	Phe	Met	Asp	Val	Asn
65					70					75					80
Ser	Thr	Trp	Arg	Thr	Val	Asp	His	Leu	Ser	Ala	Thr	Ala	Cys	Gly	Cys
				85					90					95	

```
<210> 11
<211> 109
<212> PRT
<213> MURINE
```

```

<400> 11
Ala Leu Ala His His His His His His Asp Tyr Lys Asp Asp Asp Asp
  1                    5                      10                15

Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu
      20                      25                30

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala
      35                      40                45

Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala
      50                      55                60

Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro
  65                      70                75                80

Thr Ala Phe Asp Asp Asp Val Thr Phe Leu Asp Asp Gln His His Tyr
      85                      90                95

His Ile Leu Arg Lys His Ser Ala Ala Ala Cys Gly Cys
      100                      105

```

<210> 12  
<211> 90  
<212> PRT  
<213> MURINE

```

<400> 12
Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly
  1           5           10           15
Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys
          20           25           30
Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg
      35           40           45
Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ala Phe
  50           55           60
Asp Asp Asp Val Thr Phe Leu Asp Asp Gln His His Tyr His Ile Leu
  65           70           75           80
Arg Lys His Ser Ala Ala Ala Cys Gly Cys
          85           90

```

<210> 13  
 <211> 109  
 <212> PRT  
 <213> Mouse

<400> 13  
 Ala Leu Ala His His His His His Asp Tyr Lys Asp Asp Asp Asp  
   1                  5                  10                  15  
 Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
                   20                  25                  30  
 Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
                   35                  40                  45  
 Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
                   50                  55                  60  
 Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
   65                  70                  75                  80  
 Thr Ala Tyr Glu Asp Glu Val Thr Phe Leu Asp Asp Gln His His Tyr  
                   85                  90                  95  
 His Thr Leu Gln Glu Leu Ser Ala Ala Ala Cys Gly Cys  
                   100                  105

<210> 14  
 <211> 90  
 <212> PRT  
 <213> Mouse

<400> 14  
 Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
   1                  5                  10                  15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
                   20                  25                  30  
 Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
                   35                  40                  45  
 Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ala Tyr  
                   50                  55                  60  
 Glu Asp Glu Val Thr Phe Leu Asp Asp Gln His His Tyr His Thr Leu  
   65                  70                  75                  80  
 Gln Glu Leu Ser Ala Ala Ala Cys Gly Cys  
                   85                  90

<210> 15  
 <211> 108  
 <212> PRT  
 <213> Mouse

<400> 15  
 Ala Leu Ala His His His His His Asp Tyr Lys Asp Asp Asp Asp  
   1                  5                  10                  15  
 Lys Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
                   20                  25                  30

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
                   35                                  40                                  45  
 Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
                   50                                  55                                  60  
 Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
                   65                                  70                                  75                                  80  
 Thr Arg Tyr Glu Ala Val Thr Phe Leu Asp Asp Gln His His Trp Arg  
                                   85                                  90                                  95  
 Thr Val Asp His Leu Ser Ala Ala Ala Cys Gly Cys  
                   100                                  105

<210> 16  
 <211> 89  
 <212> PRT  
 <213> Mouse

<400> 16  
 Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
           1                                  5                                  10                                  15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
                   20                                  25                                  30  
 Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
                   35                                  40                                  45  
 Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Arg Tyr  
                   50                                  55                                  60  
 Glu Ala Val Thr Phe Leu Asp Asp Gln His His Trp Arg Thr Val Asp  
                   65                                  70                                  75                                  80  
 His Leu Ser Ala Ala Ala Cys Gly Cys  
                                   85

<210> 17  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Ala Phe Asp Asp Asp  
           1                                  5

<210> 18  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Ala Tyr Glu Asp Glu  
           1                                  5

<210> 19  
 <211> 4  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 19

Arg Tyr Glu Ala  
1

&lt;210&gt; 20

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

Tyr His Ile Leu Arg Lys His  
1 5

&lt;210&gt; 21

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

Tyr His Thr Val His Glu Leu  
1 5

&lt;210&gt; 22

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

Trp Arg Thr Val Asp Arg Leu  
1 5

&lt;210&gt; 23

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
1 5 10 15Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
20 25 30Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
35 40 45Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Ala Phe  
50 55 60Asp Asp Asp Val Ala Phe Leu Asp Asp Arg His Arg Tyr His Ile Leu  
65 70 75 80Arg Lys His Ser Ala Ala Ala Cys Gly Cys  
85 90

&lt;210&gt; 24

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Ala Tyr  
 50 55 60  
 Glu Asp Glu Val Ala Phe Leu Asp Asp Arg His Arg Tyr His Thr Val  
 65 70 75 80  
 His Glu Leu Ser Ala Ala Ala Cys Gly Cys  
 85 90

<210> 25  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<400> 25  
 Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr  
 50 55 60  
 Glu Ala Val Ala Phe Leu Asp Asp Arg His Arg Trp Arg Thr Val Asp  
 65 70 75 80  
 Arg Leu Ser Ala Ala Ala Cys Gly Cys  
 85

<210> 26  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
 1 5 10 15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
 20 25 30  
 Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
 35 40 45  
 Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
 50 55 60  
 Arg Pro Thr Ala Phe Asp Asp Asp Val Ala Phe Leu Asp Asp Arg His  
 65 70 75 80



Arg Tyr His Ile Leu Arg Lys His Ser Ala Ala Ala Cys Gly Cys Gly  
                                     85                                    90                                    95

Gly

<210> 27  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 27  
 Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
   1                                    5                                    10                                    15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
                                     20                                    25                                    30  
 Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
                                     35                                    40                                    45  
 Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
                                     50                                    55                                    60  
 Arg Pro Thr Ala Tyr Glu Asp Glu Val Ala Phe Leu Asp Asp Arg His  
   65                                    70                                    75                                    80  
 Arg Tyr His Thr Val His Glu Leu Ser Ala Ala Ala Cys Gly Cys Gly  
                                     85                                    90                                    95

Gly

<210> 28  
 <211> 96  
 <212> PRT  
 <213> Homo sapiens

<400> 28  
 Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
   1                                    5                                    10                                    15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
                                     20                                    25                                    30  
 Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
                                     35                                    40                                    45  
 Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
                                     50                                    55                                    60  
 Arg Pro Thr Arg Tyr Glu Ala Val Ala Phe Leu Asp Asp Arg His Arg  
   65                                    70                                    75                                    80  
 Trp Arg Thr Val Asp Arg Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
                                     85                                    90                                    95